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 Gene therapy offers an alternative therapeutic approach for a variety of diseases 
and genetic disorders that conventional therapies currently manage.  In order to clinically 
advance this therapeutic alternative, more safe and efficient gene delivery vehicles must 
be continuously developed.  To date, the development of safe and efficient gene delivery 
reagents for clinical application is hampered by undefined design and formulation 
requirements. In an attempt to further elucidate these requirements for improved gene 
delivery reagents, research labs often engineer and study many putative products that 
possess subtle physiochemical differences that may influence carrier function and 
biological activity. The synthesis of many putative gene delivery reagents, however, 
requires multiple optimization cycles for each product, is time-intensive, laborious and 
costly.  
 As such, the intent of this dissertation is to implement a method that facilitates 
evaluation ease of novel, modified gene delivery reagents by avoiding the synthesis of 
many putative products for the identification of optimal candidates and reagent 
properties.  This method uses mixtures of a promising nonviral gene delivery reagent and 
its modified counterpart, whereby the relative amount of each species in the formulation 
mixture is easily controlled, and thus, physiochemical differences and their influence on 
biological activity can be studied to identify optimal reagent candidates.  
 The initial part of this dissertation focuses on the chemical modification of a 
previously published and flourishing non-viral, polycationic gene delivery vehicle, 
poly(triethylenetetramine/cystamine bisacrylamide) (p(TETA/CBA)) with poly(ethylene 
glycol) (PEG) to derive poly(triethylenetetramine/cystamine bisacrylamide)-g-
poly(ethylene glycol) (p(TETA/CBA)-g-PEG) with physiochemical properties different 
form p(TETA/CBA) alone.  Subsequent studies focused on improving the synthetic ease 
of p(TETA/CBA)-g-PEG as well as improving its tissue specificity for oncogenic cells 
and their associated vasculature via modification using a tumor specific peptide.  As a 
result, design and formulation requirements for safe and efficient gene delivery carriers is 
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1.1 General Introduction 
 Due to significant research breakthroughs in molecular biology and genetic 
engineering, nucleic acid-based therapeutics have become plausible candidates for the 
treatment of genetic diseases that conventional therapies strive to manage. Gene therapy 
offers the distinct advantage of correcting a genetic defect by delivering nucleic acid 
cargo in the form of circular DNA (pDNA) or RNA interference (RNAi) sequences to 
redirect protein translation and establish appropriate cellular function or homeostasis (1).  
Encouraging results have been produced for the treatment of traditional genetic diseases 
such as cystic fibrosis and muscular dystrophy as well as cardiovascular disease and 
cancer (2-5).  Infectious diseases such as Human Immunodeficiency Virus (HIV), have 
also been impacted by advances in gene therapy (6). 
 While promising gene therapy results have been produced by many research labs, 
its clinical success is hampered by undefined design and formulation requirements to 
engineer a safe and efficient gene delivery vehicle.  Problems including adverse 
immunological responses, oncogenesis and limited cargo encapsulation are associated 
with viral gene carriers. Conversely, if nonviral polymeric gene carriers are designed 
prudently, they are nonimmunogenic and they can encapsulate relatively large amounts of 
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therapeutic nucleic acid; however, transcellular cargo delivery of these carriers must be 
improved for their clinical success (7-9).   
 Because design and formulation requirements are largely undefined for improved 
nonviral gene delivery reagents, research labs often engineer and study many putative 
products that possess subtle physiochemical differences that may influence carrier 
function and biological activity in an attempt to better understand pertinent requirements 
for improved gene delivery carriers and identify clinically acceptable candidates. The 
synthesis of many putative reagents, however, requires multiple optimization cycles for 
each product, is time-intensive, laborious and costly.   
 The purpose of this study was to improve a promising and flourishing non-viral, 
polymeric gene carrier for in vitro and in vivo use by modifying the gene carrier with 
poly(ethylene glycol) (PEG) or PEG-ligand chemical conjugation.  Moreover, the studies 
herein employ a unique method that that promotes evaluation ease of these developed 
gene carriers by avoiding the synthesis of many putative products in order to identify 
optimal candidate and reagent properties.  Specifically, this method uses mixtures of the 
existing, flourishing nonviral gene delivery reagent and its modified counterpart(s), 
whereby the relative amount of each species in the formulation mixture is easily 
controlled, and thus, physiochemical differences and their influence on biological activity 
can be empirically studied to identify optimal reagent properties and candidates.   
 In order to evaluate this unique method, several co-polymeric gene carriers are 
developed in this work using the disulfide-containing, bioreducible gene carrier, 
poly(triethylenetetramine/cystamine-bis-acrylamide) (p(TETA/CBA)) as the backbone 
polycation.  p(TETA/CBA) was previously developed as a bioreducible analog of the 
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efficient, though often toxic, poly(ethylene imine) (PEI) carriers.  Researchers have 
extensively studied various forms of PEI as potential nucleic acid delivery vehicles and 
its class has become a standard in the nonviral gene delivery field.  PEI carriers can 
condense and protect nucleic acid very easily and provide relatively high cellular 
transgene expression in vitro and in vivo, which is largely due to its high charge density 
and buffer capacity (10-12).  The major problem associated with PEI systems is that 
because of their high charge density, as the molecular weight of these carriers increases, 
so does its cellular toxicity and thus are not a viable option for clinical use (13-16).  The 
bioreducible PEI analog, p(TETA/CBA), maintains an advantageous high charge density 
all-the-while avoids cellular toxicity that is imposed by high molecular weight 
polycations through exploiting the intracellular reductive potential maintained by 
glutathione and other co-enzymes that trigger its cytosolic degradation (17).   Despite this 
advantage, p(TETA/CBA) and other bioreducible gene carriers require further 
modification to improve their efficacy in vitro and in vivo to advance gene therapy 
applications.  This is especially true for their use as systemic gene delivery vehicles that 
can be used to combat metastatic cancers. 
 Modification of bioreducible polycations for systemic application is required to 
improve their circulation half-life and avoid rapid clearance by the immune system.   
Insufficient circulation times are due to several factors.  One apparent factor is their 
cationic nature.  Often polycation/nucleic acid complexes (polyplexes), if net-positively 
charged, interact with net-negatively charged serum proteins that lead to particle 
aggregation, destabilization and often complement system activation.  Complement 
activation facilitates the innate immune response and promotes polyplex sequestration by 
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the reticuloendothelial system (RES), thereby mitigating polyplex circulation time and 
putative efficacy (18, 19).   Research has also shown that significant thiol concentrations 
exist in the mammalian bloodstream due to the presence of cysteine, homocysteine and 
glutathione (20).  These thiols can participate with disulfide-containing bioreducible gene 
carriers in thiol-disulfide exchange, which leads to premature and uncontrolled carrier 
degradation and particle instability.  In order to avoid the interaction of polycationic 
carriers with serum proteins, neutrally charged and hydrophilic polymers such as 
poly(ethylene glycol) (PEG) have been conjugated to polycationic systems to reduce 
polyplex surface charge and prevent the adsorption of serum proteins to carrier surfaces 
(21). While potentially advantageous, PEG conjugation to polycations has also been 
shown to adversely affect nucleic acid condensation and carrier function, which is 
especially true if the polycation has a low molecular weight (22, 23).  These results taken 
together reveal the delicate influence of gene carrier chemical properties on their 
performance and suggest the need to easily alter and study carrier properties following 
PEG modification in order to optimize carrier function and ensure clinical advancement. 
 Following this brief introduction chapter, the dissertation herein commences with 
a literature review that encompasses the use of various nonviral gene delivery systems. 
Systems discussed will range from initial prototype gene carriers to more advanced 
systems that have proven to increase payload delivery to solid tumors using targeting 
moieties, which results in improved therapeutic efficacy and reduced off-target effects.  
The review will recognize current in vitro and in vivo limitations inherent to nonviral 
gene delivery systems and how gene carriers can be modified to enhance nucleic acid 
delivery to cancer-related cells.   
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 Chapter 3 describes the synthesis and characterization of a bioreducible polymer 
and corresponding copolymer for gene delivery and provides evidence that these two 
species can be used in conjunction to alter gene carrier properties and study the effects on 
their bioactivity to optimize and improve gene carrier formulation reagents. The 
physiochemical characteristics and bioactivity of these products are evaluated using a 
facile appraisal method of a panel of putative gene delivery reagents and the use of 
empirical studies to identify improved gene carriers (24).  Chapter 4 focuses on the 
synthesis of a copolymer that has the same chemical functionality to that developed in 
Chapter 3; however, it is generated by a less labor intensive method and has a 
significantly different molecular weight and degree of modification.  
 The studies described in Chapter 4 utilize the evaluation method developed in 
Chapter 3 to derive a panel of putative gene delivery reagents of varying composition to 
study the characteristics and bioactivity of the reagents, and it provide evidence that the 
facile evaluation method can be used to identify optimal formulations despite changes in 
physiochemical properties like molecular weight and degree of modification.  This 
chapter provides evidence to support this claim and suggests that the facile evaluation can 
be applied to additional gene carriers.  The studies maintain in vitro evaluation and 
extend the use of gene carrier mixtures to in vivo studies where the biodistribution of 
different carrier formulations is assessed following systemic injection.   
 Chapter 5 extends the previous studies to engineer a nucleic acid carrier that can 
enhance payload delivery using a targeted gene carrier that recognizes a cell surface 
receptor overexpressed on many cancer-related cell types.  The study demonstrates that 
the aforementioned formulation method of mixing multiple delivery reagents can be used 
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to derive a panel of targeted gene delivery reagents. Targeting of this gene carrier relies 
on the overexpression of the !V"3 integrin, which is characteristic of many solid tumors 
and the surrounding vasculature, which can be exploited to improve tissue-specific 
delivery of therapeutic payload and avoid off-target effects (22, 23).  This is 
accomplished by modifying the gene carrier with a peptide moiety that contains the 
following amino acid sequence: Arginine-Glycine-Aspartic acid (RGD) that can 
specifically interact with the !V"3 integrin and promote cellular internalization of the 
gene carrier.   The data presented in this chapter demonstrate that targeted gene carrier 
mixtures can alter carrier properties and be used in vitro to enhance transgene delivery to 
known !V"3 integrin expressing cells compared to carriers devoid of the targeting 
peptide.  Studies also show cell specificity of the RGD-targeted nucleic acid delivery 
reagent.  The studies provide a foundation for further investigation to determine 
therapeutic applicability and efficacy in vivo of the RGD-targeted gene delivery reagents. 
 
1.2 Rational for the Study 
 The full potential of nonviral gene delivery has not been met.  PEI systems 
continue to be the nonviral gene carrier standard because of their ability to facilitate 
significantly greater transgene delivery and expression compared to other carrier systems.  
In recent years, however, biodegradable gene carriers have gained tremendous 
recognition as potentially superior candidates because they are nontoxic and have proven 
to maintain equal or greater transgene delivery compared to PEI carriers.  Despite the 
ability of biodegradable systems to provide high levels of transgene delivery to a wide 
range of cell types, their application in vivo is often limited to local administration due to 
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their degradation and rapid clearance in the blood stream.  Modification of these systems 
with PEG to prevent rapid clearance provides a promising next step towards clinical 
application.  However, if PEG and ligand modification is not thoroughly investigated, 
optimal carrier performance may not be achieved.  Therefore, new methods should be 
developed that allow PEG and ligand modification of gene carriers that accommodate 
easy manipulation of the relative amount of PEG or ligand incorporated in gene carrier 
formulations so that improved gene delivery reagents are more easily developed for in 
vitro or in vivo use. 
 
1.3 Specific Aims 
 Provided the aforementioned rationale, the overlying hypothesis is that mixtures 
of a polycation and PEG-polycation can be used to alter the relative amount of each 
species in a gene carrier formulation and thus influence carrier properties.  Easy 
manipulation over gene carrier properties and function will allow rapid, facile evaluation 
and identification of optimal gene carrier reagents when used with nucleic acid. It is also 
expected that this method can be used for a targeted gene carrier with a PEG spacer to 
generate an optimal candidate for improved nucleic acid delivery to targetable cell types.  
The first specific aim was to develop a novel gene carrier comprised of an efficient and 
nontoxic bioreducible polycation in conjunction with its PEGylated counterpart to 
improve cellular transgene delivery compared to the polycation itself in serum-
conditioned media.  By using a feasible and facile approach to tailor the relative amount 
of PEG to polycation in a gene carrier formulation and derive a panel of putative 
reagents, the time and costly synthesis of multiple candidate copolymers for use in gene 
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delivery is avoided.  By doing so researchers may study the influence of subtle 
physiochemical differences on gene carriers properties and bioactivity in order to identify 
optimal candidates for gene delivery. 
 The second specific aim is to synthesize a copolymer with the same chemical 
functionality to that developed in aim one, but with a different molecular weight and 
degree of PEG conjugation that can be used in conjunction with the bioreducible 
polycation and substantiate the validity of using mixture formulations for optimization 
irrespective of synthesis methods and product differences.  In vivo biodistribution studies 
are also employed to evaluate formulation application in a murine adenocarcinoma 
model. 
 The third specific aim is to synthesize a targeted copolymer to enhance nucleic 
acid delivery to oncogenic cell types as well as angiogenic endothelial cells that surround 
tumor masses. In vitro studies investigate the potential of this targeted copolymer using 
formulation methods applied in the first two specific aims to verify their use in a targeted 
gene carrier system and provides a foundation for further studies in vivo.  The gene 
carrier is designed using a nontoxic bioreducible polycation in conjunction with a peptide 
moiety, cyclic Arginine-Glycine-Aspartic Acid-(D)-Phenylalanine-Cysteine (c(RGDfC)), 
that that confers specificity toward !V"3 integrins, which are often overexpressed in the 
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NONVIRAL GENE DELIVERY SYSTEMS AND CANCER  
GENE THERAPY: LITERATURE REVIEW 
 
2.1 Introduction 
 Despite extensive progress in the field of gene therapy, the most prominent 
obstacles that hinder its clinical success are the development of a safe and efficient 
delivery system for nucleic acids.  Research has produced many different gene carriers 
that have promising attributes, however carrier-mediated toxicity and/or low transgene 
expression continue to plague their therapeutic approval.  There are two distinct classes 
of gene carriers: viral and nonviral (1-4).  Viral gene therapy employs attenuated viruses 
that are derived using genetic engineering techniques.  The most common viruses used 
are retroviruses, adenoviruses and adeno-associated viruses (5).  These viral delivery 
systems often show more effective transgene delivery than nonviral carriers; however, 
there are significant problems that limit their clinical success (1).  These problems 
include oncogenesis that results from chromosomal insertion of genetic payload in the 
host organism, immunogenicity, limited nucleic acid encapsulation, quality control issues 
and exorbitantly high production costs (4, 6, 7).  Therefore, the use of nonviral nucleic 
acid delivery systems is desirable.  Nonviral delivery systems can be designed to avoid 
immunogenicity, appease quality control mandates, maintain relatively low production 
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cost, and they are easily modified to possess multifunctional properties that are often 
advantageous (8).  Examples of nonviral delivery systems include: physical methods for 
unprotected (naked) nucleic acid, amphiphilic lipids and polymers.  The delivery of 
nucleic acid using these systems will be examined thoroughly, herein, with emphasis on 
polymeric systems and how they can be used for cancer gene therapy.  
 
2.2 Nonviral Nucleic Acid Delivery Systems 
2.2.1 Delivery of Naked Nucleic Acid 
 The delivery of unprotected nucleic acid is the most rudimentary method for 
delivering genetic material to cells.  Naked nucleic acid has been delivered to the heart, 
skeletal muscle, liver, brain, thyroid, skin and to tumors (9-21).  While transcellular 
delivery of unprotected nucleic acid has been achieved, its efficiency is limited due to the 
relatively high molecular weight and negative charge conferred in the phosphodiester 
backbone of these molecules.  Thus, efficient cellular uptake is limited by the charge-
charge repulsion between nucleic acid and the negatively charged cell membrane.  In 
order to enhance the cellular delivery of naked nucleic acid, physical methods have been 
developed.  These methods include electroporation, gene gun injection, the use of lasers, 
hydrodynamic pressure and ultrasound (22, 23).   
 Electroporation relies on a controlled electric field that is applied to cells or tissue 
in order to enhance cell permeability and uptake of genetic material.  This method is 
useful, however, if the electric fields are not carefully controlled they can impose 
significant cell mortality and tissue damage (24).  Ultrasound waves are also used to 
increase cell permeability and enhance delivery of naked nucleic acid.  This method has 
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advantages because it can use microbubbles loaded with genetic material that when 
subjected to ultrasonic irradiation release their cargo in a specific location (25, 26).  
Ballistic, or gene gun applications involve shooting genetic payload that coats tungsten or 
gold nanoparticles into the cytoplasm and the nucleus of cells (27).  Research presented 
in the literature has shown that the aforementioned methods can be used to enhance 
transgene delivery to cells or tissue; however, these methods have limited accessibility to 
internal organs so as long as minimally invasive applications are maintained.  Thus, 
additional delivery systems are required to circumvent this shortcoming and ensure 
strong patient compliance. 
 
2.2.2 Cationic Lipids 
 Minimally invasive delivery methods via systemic administration require the 
encapsulation and protection of nucleic acid cargo from serum proteins, as nucleic acids 
are extremely susceptible to nuclease degradation in the extracellular environment.  
Cationic amphiphiles or lipids can be used for nucleic acid protection and to drive 
cellular uptake for therapeutic application.  Cationic lipids are composed of three basic 
domains: a positively charged and hydrophilic head group, a hydrophobic chain(s) and a 
linker group that joins the non-polar and polar regions of the amphiphile.  The use of 
cationic lipids for cellular delivery of nucleic acid was first reported by Felgner and 
colleagues, who used N-(1-2,3-dioleyloxy)propyl-N,N,N-trimethylammonium chloride 
(DOTMA) (Figure 2.1) (28).  Since then, there have been numerous lipids and lipid 
combinations developed for nucleic acid delivery.  Many of them have shown promise in 
vitro and in vivo, and in fact, some of them have even been used in the clinic (29-31).  
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When cationic lipids are used in conjunction with nucleic acid cargo they form cationic 
lipid/nucleic acid complexes (lipoplexes) formed spontaneously via electrostatic and 
hydrophobic interactions.  Lipoplexes maintain condensed nucleic acid cores that are 
devoid of water (32, 33).  These systems can interact and fuse with the plasmid 
membrane of cells to facilitate their uptake and are believed to release nucleic acid 
payload in the cytoplasm by disruption of the endosomal compartment membrane.  
Membrane disruption occurs via electrostatic interaction between the cationic lipids of 
the lipoplex and the anionic phospholipids of the endosomal compartment. The 
dissociation of nucleic acid payload from the lipoplex occurs simultaneously with 
endosomal escape (34).  
 Research has shown that lipid structure and functionality can greatly influence 
their amphiphilicty, shape, size and pKa, which in turn profoundly affect their 
performance as nucleic acid carriers.  Thus, these parameters must be rigorously studied 
(35, 36).  Unfortunately, many of these lipid-mediated carriers have exhibited toxic side 
effects in cultured cells and in animals.  Moreover, their colloidal stability and 
immunogenic concerns limit their clinical application, thus requiring the development of 
additional nucleic acid carriers (29, 37-40). 
 
2.2.3 Cationic Polymers 
 There are numerous polycations that have been used as nucleic acid carriers; both 
natural and synthetic. Naturally occurring polycations include proteins such as histones 
and human serum albumin that has been cationized by conjugating 
hexamethylenediamine to its carboxylic acid groups. Aminopolysaccharides such as 
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chitosan are also naturally occurring polycations that have been used (41-44).  Common 
synthetic polycations include polyamines such as poly(ethylene imine) (PEI), poly-L-
lysine, poly(amido amine) (PAMAM) dendrimers and cyclodextrins, among many others 
(45-49). 
 For quite sometime, poly(ethylene imine)s have been considered the ‘gold 
standard’ of nonviral polymeric gene delivery.  This class is subdivided into two major 
types: hyperbranched poly(ethylene imine) (BPEI or bPEI) and linear poly(ethylene 
imine) (LPEI or lPEI), respectively (Figure 2.2) (50).  For both classes, the fundamental 
repeat unit contains a protonable amine that allows the polycation to buffer over a wide 
pH range.  The buffering capacity of these systems is particularly useful within the 
endosomal pH 5-7 range, as this attribute facilitates endosomal escape and contributes to 
the delivery efficiency of the carrier.  Endosomal escape of the polycationic carrier 
occurs via ‘the proton sponge effect,’ and the fundamental hypothesis is that the buffering 
capacity of a polycation influences the endosomal acidification process, which leads to an 
exorbitantly high influx of protons and corresponding counterions such as chloride (45).  
The heavy influx of these counter-ions results in osmotic swelling and rupture of the 
endosome therefore releasing its contents into the cytosol (51).  It is also believed that 
these counter-ions destabilize the interaction of polycation with the nucleic acid payload, 
and thus influence transgene delivery (52). 
 The PEI systems were first used for oligonucleotide delivery in 1995 (45).  Since 
then, extensive studies have focused on the biophysical properties of PEI systems, 
including their branching profiles, molecular weight and polydispersity, all of which 
greatly influence their gene delivery properties (53).  In theory, bPEIs maintain a 1:2:1 
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ratio of primary, secondary and tertiary amines, respectively, that contribute to its 
preferable buffer capacity and solubility (54).   However, the high charge density 
maintained by these amines also greatly increases serum protein interaction and cell 
membrane destabilization, which leads to reduced transfection efficiency and cellular 
toxicity (55).  Moreover, PEI molecular weight and branching have shown to correlate 
with transfection efficiency and cell toxicity.  Attempts to circumvent these negative 
issues have spawned PEI modification by introducing degradable linkages and neutral, 
hydrophilic polymers such as poly(ethylene glycol) (PEG) (56-61).  One very successful 
modification of a PEI carrier was the incorporation of cholesteryl chloroformate to bPEI 
1.8 kDa.  This modification proved to increase transfection efficiency of this low 
molecular weight species significantly above bPEI 25 kDa; however, the polymer product 
was relatively nontoxic to cells when compared to bPEI 25 kDa.  This carrier has been 
used for in vivo local applications to combat tumor progression as well as attenuate 
infarct size and cell death following a myocardial infarct.  Both applications have proved 
extremely successful and show clinical promise (62-64).  
 The polycationic backbone of LPEI systems is predominantly comprised of 
secondary amines and is more water soluble than BPEI (65).  Nonetheless, LPEIs have 
shown comparable or greater transfection efficiency compared to their branched 
counterparts but with considerably less cell toxicity (66, 67).   Despite these advantages, 
branched and linear PEIs, alike, still have questionable clinical application due to their 
cellular toxicity and hampered clearance in vivo.  Thus, additional polycationic carriers 
have been developed and characterized in an attempt to overcome these adversities (68).  
 Poly(L-lysine) (PLL) is a peptidomimetic polymer that contains the !-amino group 
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of lysine in each repeat unit, which maintains protonation at physiologic pH and drives its 
electrostatic interaction with nucleic acid (Figure 2.2).  While complexation of PLL with 
nucleic acid occurs, it has relatively low transfection efficiency compared to the PEIs and 
is highly variable between cell types.  Its limited transfection capacity is primarily 
attributed to the high pKa of the !-amines (9.3-9.5), which are almost entirely protonated 
at physiologic pH and thus possess little buffer capacity (69).  In order to improve its 
buffer capacity, modification of PLL with histidine (pka 6.7-7.1) has been performed.  
Moreover, to also improve its ability to escape the endosome, co-delivery of PLL/nucleic 
acid with chloroquine, a known endosomolytic agent, has been investigated.  Both 
attempts have been relatively unsuccessful, as these systems have persistent cell toxicity 
(47, 70-72).   Additional modifications to improve solubility, mitigate toxicity and 
improve transfection via PEG conjugation and/or targeting ligands have also been 
performed (70, 73-75).  Yet, mandates for clinical success have not been met using PLL 
gene carriers and the pursuit of improved polycationic nucleic acid carriers continues. 
 Another large group of polycations that have been developed and rigorously studied 
for gene therapy application are dendrimers.  Dendrimers are highly branched synthetic 
molecules that possess a functional core from which multiple layers can be radially 
synthesized in a sequential manner (76).  Due to their stepwise synthesis, dendrimers are 
characteristically well defined and maintain a high degree of molecular uniformity and 
low polydispersity compared to other synthetic polymers (77).   Provided with their 
relatively high amine content, poly(amido amine) (PAMAM) dedrimers are commonly 
used for nucleic acid delivery  (Figure 2.3) (78-80).  Interestingly, these dendrimers can 
be fractured by heating them in water or butanol, which improves their flexibility and 
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correlates with transgene delivery efficiency (81).  Similar to PEIs, however, polycationic 
dendrimers often exhibit cell toxicity that is influenced by their size, molecular weight 
and charge density.  Moreover, amine terminated dendrimers exhibit a high degree of red 
blood cell hemolysis that is disadvantageous for in vivo applications (82, 83).  Despite 
their advantages, because of their putative toxicity as well as the time consuming nature 
of their step wise iterative synthesis, their clinical use is avoided. 
 In general, the molecular weight and branching profile of polycations correlate 
with transgene expression and cellular toxicity.  That is, high molecular weight and 
branched polycations tend to provide relatively high transgene delivery and expression, 
whereas, low molecular weight and linear counterparts exhibit less cytotoxicty but lower 
efficacy (53, 84).   In lieu of this trend, degradable polycations have been engineered and 
studied for nucleic acid delivery.  As such, degradable polycations can exploit the 
advantages of high molecular weight or branched systems, all the while degrade into 
small molecular weight species to limit their cellular accumulation and toxicity (68, 85-
87).   
 The earliest degradable cationic polymer used as a nucleic acid delivery reagent 
was poly(4-hydroxyl-L-proline ester) (PHP) (Figure 2.4).  Provided with an ester bond, 
PHP, similar to other esters, is susceptible to hydrolysis and the polymer product 
degraded in less than 24 hrs due to ester hydrolysis accentuated by the amine present in 
the backbone polymer (88). While the synthesis of this degradable polymer for nucleic 
acid delivery was novel, its transfection efficiency is relatively low (88, 89).  A PLL 
analogue, poly("-(4-aminobutyl)L-glycolic acid) (PAGA), which degrades rapidly under 
physiologic conditions was developed shortly thereafter and proved to be a more efficient 
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nucleic acid carrier than PHP and PLL (Figure 2.4) (90).  Other degradable polycationic 
esters, deemed poly(ester amine)s ((PAE)s) have been synthesized and extensively 
studied (Figure 2.4).  Large libraries of these compounds currently exist.  However, 
despite screening more than 2,000 putative PAE carriers, only a small number of them 
were able to effectively condense nucleic acid and provide transgene expression 
comparable to PEIs.  Nonetheless, they have proven to be nontoxic irrespective of 
branching and molecular weight characteristics, thus providing promise for degradable 
polycations (85, 91, 92). 
 Polyester systems using PEI have also been developed.  This was achieved using 
1,3-butanediol diacrylate, hexanediol diacrylate or polycaprolactone monomers in 
conjunction with oligoethylenimine or PEIs (11, 93, 94).  The gene carrier synthesized 
using the 1,3-butanediol diacrylate monomer proved to be extremely more efficient (16x 
greater transgene expression) than bPEI 25kDa with significantly less toxicity.  The 
others, however, were nontoxic but provided relatively low transfection efficiency.   Low 
molecular weight PEI has also been crosslinked with bi-functional poly(ethylene glycol) 
(PEG) to produce a polyester type PEI-PEG network (95).  This system proved to be 
significantly less toxic to cells than bPEI 25kDa; however, transfection paled in 
comparison due to rapid degradation and reduced charge density.  Kim and colleagues 
also reported Schiff base formation following reaction between gluteraldehyde and PEI to 
produce an acid-labile PEI counterpart (Figure 2.5).  Again, this system showed very 
little toxicity but similar levels of gene expression compared to its corresponding PEI 
control (56).  These hydrolytically unstable PEI systems, as well as the other poly(ester 
amine)s discussed above, have produced encouraging results in vitro.  However, because 
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of their susceptibility to hydrolytic cleavage, their purification and rapid degradation 
present problems for potential clinical application as nucleic acid delivery reagents. 
 In an attempt to overcome the problems associated with hydrolytically degradable 
nucleic acid carriers, biodegradable polycations that contain reducible disulfide bonds 
have been synthesized and evaluated.  The existence of disulfide bonds in these 
respective carriers provides hydrolytic stability, all the while providing triggered 
intracellular degradation of the polycation in order to mitigate putative cellular toxicity.  
The difference in redox potential between the extracellular and the intracellular space is 
the driving force for triggered degradation (96).  Reduced glutathione (GSH) largely 
participates in the redox cycle of most cells (97). In fact, mammalian cells maintain 
approximately 100x [GSH] compared to [GSSG] inside the cell, depending on the cell 
line and its oxidative stress (96, 98).  GSH concentrations are maintained by various 
enzymes and NADPH via the pentose phosphate pathway (99, 100).  Several classes of 
bioreducible polymers capable of exploiting this pathway have been synthesized, 
including hyperbranched and linear forms (68, 101-105). Low molecular weight PEI has 
also been crosslinked with disulfide-containing monomers to mimic these systems 
(Figure 2.6) (50). The characteristics of these systems such as charge density, rigidity, 
bascity, hydrophilicity/hydrophobicity influenced by their structure, molecular weight 
and amino groups profoundly affect their performance as nucleic acid delivery vehicles.  
Nonetheless, provided with their biodegradable composite, they are relatively non-toxic 
to cells and many of these gene carriers offer comparable or improved transfection to 
bPEI 25kDA (106). Their hydrolytic stability and synthetic ease make them excellent 
candidates for clinical application.  However, to date, their application is limited to in 
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vitro use and in vivo local administration.  To expand their potential for clinical use, 
these carriers should be modified for in vivo systemic application in order to avoid their 
interaction with serum proteins and thus improve their pharmacokinetics.   The following 
section will discuss potential modifications of these systems and polycations alike, which 
improve carrier use for systemic administration and for cancer gene therapy specifically. 
 
2.2.4 Background and Use of Targeted Polycationic Nucleic Acid  
Carriers for Cancer Gene Therapy 
 The success rate for cancer therapy is largely disappointing.  In the year 2008, an 
article in the International Journal of Cancer estimated that more than 12.7 million people 
had developed a malignant tumor and that approximately 7.6 million others died of the 
disease that year (107).  Moreover, cancer is the second leading cause of death in the 
United States and is responsible for more than half a million deaths per year.  The 
financial implications are multifaceted, as the overall cost of cancer in 2004 for the 
United States was $189.8 billion: $69.4 billion for direct medical, $16.9 billion for 
indirect morbidity and $103.5 billion for indirect mortality costs.  Even more 
disconcerting is that as mortality rate of many chronic diseases has decreased 
significantly in the past 50 years, mortality rates of cancer have remained constant (108).  
Clearly there is a need for more safe and effective anti-cancer therapies. 
 Systemic administration of drug and nucleic acid carriers is particularly useful for 
cancer therapy because as malignant tumors grow, oncogenic cells often spread to distant 
tissues or organs from which they initially arise by migrating through the bloodstream 
and depositing elsewhere. This process is defined as tumor metastasis.  By employing 
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systemic administration of nucleic acid delivery reagents, whereby these reagents can 
circulate in the bloodstream, distant and internal organs or tissue(s) including primary 
tumors and metastatic malignancies that rely on vascularization for their growth and 
survival can be reached.  Oncogenic cells arise from abnormal gene function or gene 
expression, thus, provided the genetic basis of this disease, gene therapy is particularly 
useful for overcoming or correcting the responsible genetic defect(s) (109, 110).   The 
therapeutic efficacy of nucleic acid based therapies relies, of course, on the ability of 
therapeutic payload to reach relevant cells or tissue. 
 Polycationic nucleic acid carriers have been modified to improve their in vivo 
pharmacokinetics and enhance their delivery to the tumor site following systemic 
administration(s).  Probably the most widely employed modification of these carriers is 
the covalent coupling of poly(ethylene glycol) (PEG) to them, which can mask their 
surface charge to avoid undesirable, nonspecific interaction with serum proteins that 
often leads to opsonization and removal of the delivery vehicle from the blood stream by 
the reticuloendothelial System (RES) (111-114).  Relatively high levels of nonspecific 
deposition in the lung and liver following systemic administration can also be reduced via 
PEG conjugation of these polycationic carriers by reducing their surface charge and 
mitigating their adsorption to capillaries and tight junctions (115-117).  If non-specific 
deposition and RES uptake of polyplexes are reduced, putative therapeutic efficacy is 
improved. Moreover, polyplexes that maintain a prolonged circulation time beyond 6 hrs 
can exploit the Enhanced Permeability and Retention Effect (EPR) (118). This 
phenomenon is commonly observed when macromolecules or nanocarriers are delivered 
intravenously and with long circulation times tend to deposit to a greater extent at tumor 
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sites than in normal tissues.  The maintained principle behind this effect is the 
characteristic ‘leaky,’ fenestration of the vasculature surrounding tumors and their 
impaired lymphatic drainage.  Abundant evidence suggests that this phenomenon is 
operational in humans (119).  However, the extent to which the EPR effect can be 
exploited by drug/nucleic acid delivery reagents depends largely on tumor types and its 
pathophysiological characteristics that affect tumor vascularization, otherwise known as 
angiogenesis (120).  Nonetheless, within the past decade the significance of this 
vascularization around growing tumors has been widely recognized to have clinical 
utility (121, 122).   
 While PEG modification of polycations can improve their circulation half-life and 
exploit the EPR effect for passive targeting of the carriers, PEG modification often 
decreases transgene delivery and expression compared to un-PEGylated counterparts.  
The delivery capacity of PEGylated polycations can often be recovered with the 
incorporation of targeting moieties that possess binding affinity for transmembrane 
receptors expressed on specific cell types (123).  Upon receptor binding, the nucleic acid 
carriers undergo receptor-mediated endocytosis, which has proven to enhance cellular 
uptake (124).  Sugar residues, vitamins, peptides, proteins, antibodies and antibody 
fragments have all been successfully employed as targeting moieties for drug and gene 
carriers (124-133).  Of particular interest to this discussion are those molecular entities 
that recognize transmembrane receptors specifically overexpressed on primary and 
metastatic cancers or the angiogenic vasculature that surrounds many tumors. 
 The use of relevant targeting molecules for cancer treatment is particularly 
important because despite significant progress in surgical, radio and chemotherapies, long 
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term patient survival is still unmet.  Targeting molecules used in conjunction with 
therapeutic nucleic acid agents provide an alternate means to systemically treat a broad 
range of tumors and associated angiogenesis.  Specific tumor cells have been delineated 
and targeted individually as well. Prostate cancer cells are one specific example.  As 
such, the transmembrane protein known as Prostate Specific Membrane Antigen (PSMA) 
is expressed in virtually all prostate cancer cell despite their heterogeneity, and its 
expression is greatly increased in poorly differentiated, metastatic, and hormone-
refractory carcinomas.  A humanized monoclonal antibody, deemed J591, was developed 
and recognizes the extracellular domain of PSMA.  This targeting agent has been used for 
radioimmunotherapy and confirmed as a prostate cancer targeting agent (134).  J591 has 
not been used for nucleic acid delivery; however, this targeting agent serves as a platform 
for other similar agents that can be used for prostate-specific nucleic acid therapy. Further 
studies are required to elucidate this prospect.  
 Two of the most widely studied and applied targeting agents for cancer gene 
therapy are folate (vitamin B9) and Arginine-Glycine-Aspartic Acid (RGD)-containing 
peptide sequences that possess strong binding affinity for folate receptors and "v#3 
integrins, respectively. Both of these receptors are up-regulated on numerous cancer cells 
and the related tumor vasculature compared to normal, nonpathological tissues (110, 121, 
128, 135-138).    
 The folate receptor (FR) has several isoforms.  These isoforms exhibit differential 
binding affinity for folate, though all of them are members of the 
glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein family. More 
importantly, once bound by folate, these receptors are able to transport folate-bound 
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macromolecules and nanoparticles via receptor-mediated endocytosis (136, 137, 139).   
High affinity FR are specifically over-expressed in ovarian, mammary gland, colon, lung, 
prostate, and leukemic cancers.  Enhanced receptor expression correlates with poor 
prognosis and metastasized cancer cells possess greater amounts of this FR than their 
primary tumors.  Moreover, the only nonpathological tissues that express the FR are 
placenta, lung, choroids plexus, thyroid and kidney (139, 140).  With the exception of the 
kidney, FR expression in these tissues is preserved to the apical side of polarized 
epithelial cells. Thus, folate-targeting of nanoparticles and nucleic acid carriers is 
promising for the treatment of a variety of cancers and their related metastasis (136, 137).  
Also noteworthy, folate-targeted therapeutics have proven to be anti-angiogenic, which 
may provide additive therapeutic affect compared to tumor-targeted eradication alone 
(141).  
 As suggested above, RGD-containing peptides also provide tremendous promise 
as targeting agents for anti-angiogenic therapy as well as metastasis (142).  A variety of 
different RGD peptides have been used to target melanoma, mammary, colon, renal and 
ovarian carcinomas as well as prostate cancer (143).  Fundamental for the growth and 
metastasis of malignant tumors is their ability to perpetrate blood supply through the 
conquest of preexisting vasculature.  This triumph is known as angiogenesis, or is the 
sprouting of new blood vessels from existing ones, which provides nutrients to the 
metabolically active and growing tumor (144, 145).  There is a strong correlation 
between tumor microvessel density and the clinical stage of cancer, which further 
correlates with the disease-specific survival rate of patients (146, 147). 
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 Extensive research on tumor-associated angiogenesis has shown that its induction, 
known as the angiogenic switch, is tightly regulated by the expression of endogenous 
anti-angiogenic and pro-angiogenic molecules (148-153).  The angiogenic switch occurs 
in the early stages of tumor growth as a response to hypoxia and decreased cell pH, 
which increases the expression of hypoxia-inducible factors (HIF) in tumor and stromal 
cells.  Increased HIF production drives the expression of vascular endothelial factor 
(VEGF) and several other pro-angiogenic factors that promote the angiogenic process by 
increasing the destabilization, proliferation and migration of endothelial cells (149, 154, 
155).  As mentioned above, tumor-associated angiogenesis leads to ‘leaky’ and 
fenestrated blood vessel formation due to the immature and irregular shape of the 
endothelial cells that comprise the neovasculature (156).  This vasculature is also 
characterized by an abnormal increase in "v#3 integrin expression compared to non-
pathogenic tissues, which can be exploited for the active targeting of nucleic acid carriers 
to these tissues using ligands that confer specificity for "v#3 integrins (130, 131).   
 Both tumor cells and the angiogenic vasculature can be targeted using RGD-
containing peptide ligands that possess high affinity for the "v#3 integrin receptor.  
Targeting the angiogenic vasculature using these ligands have several advantages over 
targeting tumors specifically. First, endothelial targets are common to all solid tumors. 
Endothelial cells are also immediately accessible to RGD-targeted drug and nucleic acid 
carriers delivered systemically and are therefore more easily targeted than the tumor 
cells.  These endothelial cells also maintain greater genetic stability than oncogenic cells, 
which makes them less likely to develop resistance to cancer therapy. Lastly, because one 
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endothelial cell can support the survival of ~5-50 tumor cells, endothelial cell death can 
lead to the death of many oncogenic cells (157, 158). 
 Since the initial discovery of RGD-containing peptides by Pierschbacher and 
Ruoslahti, many different RGD-containing peptides have been employed as tissue-
specific targeting agents for oncogenic and angiogenic cells (159).   For polymeric 
nucleic acid delivery, probably the most widely used carriers for these targeting purposes 
are the PEIs.  RGD-targeted PEIs used to deliver nucleic acid payload that abrogate 
oncogenic protein function have provided promising results in vivo demonstrating 
reduced tumor growth and vascularization compared to untargeted carriers (130, 131, 
160).   RGD-targeted degradable nucleic acid carriers have also been used as promising 
delivery agents for cancer therapy (161).  These targeted polycations provide an 
opportunity to exploit the active and passive targeting of tumors and provide a platform 
for combination therapy to deliver anti-cancer nucleic acid and chemotherapeutic agents.  
Moreover, they allow potential increased delivery of therapeutic payload to the tumor 
site, reduced off-target effects and if applicable, circumvent multi-drug resistance through 
receptor-mediated uptake at the target site (Figure 2.7).   To date, however, no disulfide-
containing bioreducible nucleic acid carriers have been used in conjunction with RGD-
targeting peptides to evaluate their potential for cancer gene therapy application in vitro 
or in vivo.  Nucleic acid delivery systems in this arena should be developed and studied 









Figure 2.1. Structure of the cationic lipid N-(1-2,3-dioleyloxy)propyl-N,N,N-
trimethylammonium chloride (DOTMA).  A polar head group, hydrophobic tail and ether 










































Figure 2.2.  Chemical structures of classic, synthetic nondegradable polycations linear 
poly(ethylene imine) (LPEI); branched poly(ethylene imine) (BPEI); poly-L-lysine 

























































Figure 2.3.  Structure of G1 (generation 1) poly(amido amine) (PAMAM) dendrimer.  



















































Figure 2.4. Structural examples of degradable nucleic acid carriers; poly(4-hydroxyl-L-



















































Figure 2.6. General structure of disulfide-containing polycations a) crosslinked low 
molecular weight poly(ethylene imine); b) poly(ethylenediamine/cystamine-bis-
































































Figure 2.7.  General scheme for targeted nucleic acid delivery to tumors.  a) Ligand-
conjugated polymeric carrier forms electrostatic complex with nucleic acid.  When 
circulating in the bloodstream following systemic injection, complexes extravasate from 
fenestrated tumor vasculature to access the tumor cells.  b) Once the targeted complex 
binds to the cell surface receptors of tumor and/or vasculature cell, the complex is taken 
up by receptor-mediated endocytosis.  Following uptake, the carrier’s buffering capacity 







(1) Pfeifer, A., and Verma, I. M. (2001) Gene therapy: promises and problems. Annu 
Rev Genomics Hum Genet 2, 177-211. 
(2) Verma, I. M., and Somia, N. (1997) Gene therapy -- promises, problems and 
prospects. Nature 389, 239-42. 
(3) Pack, D. W., Hoffman, A. S., Pun, S., and Stayton, P. S. (2005) Design and 
development of polymers for gene delivery. Nat Rev Drug Discov 4, 581-93. 
(4) Merdan, T., Kopecek, J., and Kissel, T. (2002) Prospects for cationic polymers in 
gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54, 715-58. 
(5) Kootstra, N. A., and Verma, I. M. (2003) Gene therapy with viral vectors. Annu 
Rev Pharmacol Toxicol 43, 413-39. 
(6) Rolland, A. P. (1998) From genes to gene medicines: recent advances in nonviral 
gene delivery. Crit Rev Ther Drug Carrier Syst 15, 143-98. 
(7) Thomas, C. E., Ehrhardt, A., and Kay, M. A. (2003) Progress and problems with 
the use of viral vectors for gene therapy. Nat Rev Genet 4, 346-58. 
(8) Davis, M. E. (2002) Non-viral gene delivery systems. Curr Opin Biotechnol 13, 
128-31. 
(9) Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., and 
Felgner, P. L. (1990) Direct gene transfer into mouse muscle in vivo. Science 247, 
1465-8. 
(10) Hengge, U. R., Dexling, B., and Mirmohammadsadegh, A. (2001) Safety and 
pharmacokinetics of naked plasmid DNA in the skin: studies on dissemination 
and ectopic expression. J Invest Dermatol 116, 979-82. 
(11) Arote, R., Kim, T. H., Kim, Y. K., Hwang, S. K., Jiang, H. L., Song, H. H., Nah, 
J. W., Cho, M. H., and Cho, C. S. (2007) A biodegradable poly(ester amine) 
based on polycaprolactone and polyethylenimine as a gene carrier. Biomaterials 
28, 735-44. 
(12) Wang, C. H., Liang, C. L., Huang, L. T., Liu, J. K., Hung, P. H., Sun, A., and 
Hung, K. S. (2004) Single intravenous injection of naked plasmid DNA encoding 
erythropoietin provides neuroprotection in hypoxia-ischemia rats. Biochem 
Biophys Res Commun 314, 1064-71. 
(13) Heilmann, C. A., Attmann, T., Thiem, A., Haffner, E., Beyersdorf, F., and Lutter, 
G. (2003) Gene therapy in cardiac surgery: intramyocardial injection of naked 




(14) Hickman, M. A., Malone, R. W., Lehmann-Bruinsma, K., Sih, T. R., Knoell, D., 
Szoka, F. C., Walzem, R., Carlson, D. M., and Powell, J. S. (1994) Gene 
expression following direct injection of DNA into liver. Hum Gene Ther 5, 1477-
83. 
(15) Sikes, M. L., O'Malley, B. W., Jr., Finegold, M. J., and Ledley, F. D. (1994) In 
vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. 
Hum Gene Ther 5, 837-44. 
(16) Schwartz, B., Benoist, C., Abdallah, B., Rangara, R., Hassan, A., Scherman, D., 
and Demeneix, B. A. (1996) Gene transfer by naked DNA into adult mouse brain. 
Gene Ther 3, 405-11. 
(17) Ardehali, A., Fyfe, A., Laks, H., Drinkwater, D. C., Jr., Qiao, J. H., and Lusis, A. 
J. (1995) Direct gene transfer into donor hearts at the time of harvest. J Thorac 
Cardiovasc Surg 109, 716-9; discussion 719-20. 
(18) Vogel, J. C., Walker, P. S., and Hengge, U. R. (1996) Gene therapy for skin 
diseases. Adv Dermatol 11, 383-98; discussion 399. 
(19) Hengge, U. R., Walker, P. S., and Vogel, J. C. (1996) Expression of naked DNA 
in human, pig, and mouse skin. J Clin Invest 97, 2911-6. 
(20) Vile, R. G., and Hart, I. R. (1993) In vitro and in vivo targeting of gene 
expression to melanoma cells. Cancer Res 53, 962-7. 
(21) Nomura, T., Yasuda, K., Yamada, T., Okamoto, S., Mahato, R. I., Watanabe, Y., 
Takakura, Y., and Hashida, M. (1999) Gene expression and antitumor effects 
following direct interferon (IFN)-gamma gene transfer with naked plasmid DNA 
and DC-chol liposome complexes in mice. Gene Ther 6, 121-9. 
(22) Wells, D. J. (2004) Gene therapy progress and prospects: electroporation and 
other physical methods. Gene Ther 11, 1363-9. 
(23) Niidome, T., and Huang, L. (2002) Gene therapy progress and prospects: nonviral 
vectors. Gene Ther 9, 1647-52. 
(24) Somiari, S., Glasspool-Malone, J., Drabick, J. J., Gilbert, R. A., Heller, R., 
Jaroszeski, M. J., and Malone, R. W. (2000) Theory and in vivo application of 
electroporative gene delivery. Mol Ther 2, 178-87. 
(25) Yoon, C. S., and Park, J. H. (2010) Ultrasound-mediated gene delivery. Expert 
Opin Drug Deliv 7, 321-30. 
(26) Mayer, C. R., Geis, N. A., Katus, H. A., and Bekeredjian, R. (2008) Ultrasound 
targeted microbubble destruction for drug and gene delivery. Expert Opin Drug 
Deliv 5, 1121-38. 
 
37 
(27) Heiser, W. C. (1994) Gene transfer into mammalian cells by particle 
bombardment. Anal Biochem 217, 185-96. 
(28) Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., 
Northrop, J. P., Ringold, G. M., and Danielsen, M. (1987) Lipofection: a highly 
efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 
84, 7413-7. 
(29) Dass, C. R. (2004) Lipoplex-mediated delivery of nucleic acids: factors affecting 
in vivo transfection. J Mol Med 82, 579-91. 
(30) Karmali, P. P., and Chaudhuri, A. (2007) Cationic liposomes as non-viral carriers 
of gene medicines: resolved issues, open questions, and future promises. Med Res 
Rev 27, 696-722. 
(31) Audouy, S. A., de Leij, L. F., Hoekstra, D., and Molema, G. (2002) In vivo 
characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm 
Res 19, 1599-605. 
(32) Pozharski, E., and MacDonald, R. C. (2003) Lipoplex thermodynamics: 
determination of DNA-cationic lipoid interaction energies. Biophys J 85, 3969-78. 
(33) Matulis, D., Rouzina, I., and Bloomfield, V. A. (2002) Thermodynamics of 
cationic lipid binding to DNA and DNA condensation: roles of electrostatics and 
hydrophobicity. J Am Chem Soc 124, 7331-42. 
(34) Zelphati, O., and Szoka, F. C., Jr. (1996) Mechanism of oligonucleotide release 
from cationic liposomes. Proc Natl Acad Sci U S A 93, 11493-8. 
(35) Zhang, S., Xu, Y., Wang, B., Qiao, W., Liu, D., and Li, Z. (2004) Cationic 
compounds used in lipoplexes and polyplexes for gene delivery. J Control 
Release 100, 165-80. 
(36) Horobin, R. W., and Weissig, V. (2005) A QSAR-modeling perspective on 
cationic transfection lipids. 1. Predicting efficiency and understanding 
mechanisms. J Gene Med 7, 1023-34. 
(37) Zuidam, N. J., and Barenholz, Y. (1998) Electrostatic and structural properties of 
complexes involving plasmid DNA and cationic lipids commonly used for gene 
delivery. Biochim Biophys Acta 1368, 115-28. 
(38) Tousignant, J. D., Gates, A. L., Ingram, L. A., Johnson, C. L., Nietupski, J. B., 
Cheng, S. H., Eastman, S. J., and Scheule, R. K. (2000) Comprehensive analysis 
of the acute toxicities induced by systemic administration of cationic 
lipid:plasmid DNA complexes in mice. Hum Gene Ther 11, 2493-513. 
 
38 
(39) Mui, B., Ahkong, Q. F., Chow, L., and Hope, M. J. (2000) Membrane 
perturbation and the mechanism of lipid-mediated transfer of DNA into cells. 
Biochim Biophys Acta 1467, 281-92. 
(40) Lv, H., Zhang, S., Wang, B., Cui, S., and Yan, J. (2006) Toxicity of cationic 
lipids and cationic polymers in gene delivery. J Control Release 114, 100-9. 
(41) Balicki, D., Reisfeld, R. A., Pertl, U., Beutler, E., and Lode, H. N. (2000) Histone 
H2A-mediated transient cytokine gene delivery induces efficient antitumor 
responses in murine neuroblastoma. Proc Natl Acad Sci U S A 97, 11500-4. 
(42) Esser, D., Amanuma, H., Yoshiki, A., Kusakabe, M., Rudolph, R., and Bohm, G. 
(2000) A hyperthermostable bacterial histone-like protein as an efficient mediator 
for transfection of eukaryotic cells. Nat Biotechnol 18, 1211-3. 
(43) Fischer, D., Bieber, T., Brusselbach, S., Elsasser, H., and Kissel, T. (2001) 
Cationized human serum albumin as a non-viral vector system for gene delivery? 
Characterization of complex formation with plasmid DNA and transfection 
efficiency. Int J Pharm 225, 97-111. 
(44) Borchard, G. (2001) Chitosans for gene delivery. Adv Drug Deliv Rev 52, 145-50. 
(45) Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., 
Demeneix, B., and Behr, J. P. (1995) A versatile vector for gene and 
oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc 
Natl Acad Sci U S A 92, 7297-301. 
(46) Dennig, J., and Duncan, E. (2002) Gene transfer into eukaryotic cells using 
activated polyamidoamine dendrimers. J Biotechnol 90, 339-47. 
(47) Pouton, C. W., Lucas, P., Thomas, B. J., Uduehi, A. N., Milroy, D. A., and Moss, 
S. H. (1998) Polycation-DNA complexes for gene delivery: a comparison of the 
biopharmaceutical properties of cationic polypeptides and cationic lipids. J 
Control Release 53, 289-99. 
(48) Qin, L., Pahud, D. R., Ding, Y., Bielinska, A. U., Kukowska-Latallo, J. F., Baker, 
J. R., Jr., and Bromberg, J. S. (1998) Efficient transfer of genes into murine 
cardiac grafts by Starburst polyamidoamine dendrimers. Hum Gene Ther 9, 553-
60. 
(49) Zinselmeyer, B. H., Mackay, S. P., Schatzlein, A. G., and Uchegbu, I. F. (2002) 
The lower-generation polypropylenimine dendrimers are effective gene-transfer 
agents. Pharm Res 19, 960-7. 
(50) Jeong, J. H., Kim, S. W., and Park, T. G. (2007) Molecular design of functional 
polymers for gene therapy. Progress in Polymer Science 32, 1239-1274. 
 
39 
(51) Behr, J.-P. (1997) The Proton Sponge: a Trick to Enter Cells the Viruses Did Not 
Exploit. CHIMIA International Journal for Chemistry 51, 34-36. 
(52) Kichler, A., Leborgne, C., Coeytaux, E., and Danos, O. (2001) Polyethylenimine-
mediated gene delivery: a mechanistic study. J Gene Med 3, 135-44. 
(53) Fischer, D., Bieber, T., Li, Y., Elsasser, H. P., and Kissel, T. (1999) A novel non-
viral vector for DNA delivery based on low molecular weight, branched 
polyethylenimine: effect of molecular weight on transfection efficiency and 
cytotoxicity. Pharm Res 16, 1273-9. 
(54) Suh, J., Paik, H. J., and Hwang, B. K. (1994) Ionization of Poly(ethylenimine) 
and Poly(allylamine) at Various pH's. Bioorganic Chemistry 22, 318-327. 
(55) Neu, M., Fischer, D., and Kissel, T. (2005) Recent advances in rational gene 
transfer vector design based on poly(ethylene imine) and its derivatives. J Gene 
Med 7, 992-1009. 
(56) Kim, Y. H., Park, J. H., Lee, M., Park, T. G., and Kim, S. W. (2005) 
Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J 
Control Release 103, 209-19. 
(57) Kircheis, R., Wightman, L., and Wagner, E. (2001) Design and gene delivery 
activity of modified polyethylenimines. Advanced Drug Delivery Reviews 53, 
341-358. 
(58) Lee, M., Rentz, J., Han, S. O., Bull, D. A., and Kim, S. W. (2003) Water-soluble 
lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther 
10, 585-93. 
(59) Neu, M., Sitterberg, J., Bakowsky, U., and Kissel, T. (2006) Stabilized 
nanocarriers for plasmids based upon cross-linked poly(ethylene imine). 
Biomacromolecules 7, 3428-38. 
(60) Park, M. R., Han, K. O., Han, I. K., Cho, M. H., Nah, J. W., Choi, Y. J., and Cho, 
C. S. (2005) Degradable polyethylenimine-alt-poly(ethylene glycol) copolymers 
as novel gene carriers. J Control Release 105, 367-80. 
(61) Zhong, Z., Feijen, J., Lok, M. C., Hennink, W. E., Christensen, L. V., Yockman, 
J. W., Kim, Y. H., and Kim, S. W. (2005) Low molecular weight linear 
polyethylenimine-b-poly(ethylene glycol)-b-polyethylenimine triblock 
copolymers: synthesis, characterization, and in vitro gene transfer properties. 
Biomacromolecules 6, 3440-8. 
(62) Han, S., Mahato, R. I., and Kim, S. W. (2001) Water-soluble lipopolymer for 
gene delivery. Bioconjug Chem 12, 337-45. 
 
40 
(63) Janat-Amsbury, M. M., Yockman, J. W., Lee, M., Kern, S., Furgeson, D. Y., 
Bikram, M., and Kim, S. W. (2004) Combination of local, nonviral IL12 gene 
therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol 
Ther 9, 829-36. 
(64) Yockman, J. W., Choi, D., Whitten, M. G., Chang, C. W., Kastenmeier, A., 
Erickson, H., Albanil, A., Lee, M., Kim, S. W., and Bull, D. A. (2009) Polymeric 
gene delivery of ischemia-inducible VEGF significantly attenuates infarct size 
and apoptosis following myocardial infarct. Gene Ther 16, 127-35. 
(65) Furgeson, D. Y., Chan, W. S., Yockman, J. W., and Kim, S. W. (2003) Modified 
linear polyethylenimine-cholesterol conjugates for DNA complexation. Bioconjug 
Chem 14, 840-7. 
(66) Coll, J. L., Chollet, P., Brambilla, E., Desplanques, D., Behr, J. P., and Favrot, M. 
(1999) In vivo delivery to tumors of DNA complexed with linear 
polyethylenimine. Hum Gene Ther 10, 1659-66. 
(67) Wightman, L., Kircheis, R., Rossler, V., Carotta, S., Ruzicka, R., Kursa, M., and 
Wagner, E. (2001) Different behavior of branched and linear polyethylenimine for 
gene delivery in vitro and in vivo. J Gene Med 3, 362-72. 
(68) Christensen, L. V., Chang, C. W., Kim, W. J., Kim, S. W., Zhong, Z., Lin, C., 
Engbersen, J. F., and Feijen, J. (2006) Reducible poly(amido ethylenimine)s 
designed for triggered intracellular gene delivery. Bioconjug Chem 17, 1233-40. 
(69) Osada, K., and Kataoka, K. (2006) Drug and Gene Delivery Based on 
Supramolecular Assembly of PEG-Polypeptide Hybrid Block Copolymers, in 
Peptide Hybrid Polymers (Klok, H.-A., and Schlaad, H., Eds.) pp 113-153, 
Springer Berlin / Heidelberg. 
(70) Bikram, M., Ahn, C.-H., Chae, S. Y., Lee, M., Yockman, J. W., and Kim, S. W. 
(2004) Biodegradable Poly(ethylene glycol)-co-poly(l-lysine)-g-histidine 
Multiblock Copolymers for Nonviral Gene Delivery. Macromolecules 37, 1903-
1916. 
(71) Funhoff, A. M., van Nostrum, C. F., Lok, M. C., Kruijtzer, J. A., Crommelin, D. 
J., and Hennink, W. E. (2005) Cationic polymethacrylates with covalently linked 
membrane destabilizing peptides as gene delivery vectors. J Control Release 101, 
233-46. 
(72) Pack, D. W., Putnam, D., and Langer, R. (2000) Design of imidazole-containing 
endosomolytic biopolymers for gene delivery. Biotechnol Bioeng 67, 217-23. 
(73) Cho, K. C., Kim, S. H., Jeong, J. H., and Park, T. G. (2005) Folate receptor-
mediated gene delivery using folate-poly(ethylene glycol)-poly(L-lysine) 
conjugate. Macromol Biosci 5, 512-9. 
 
41 
(74) Kim, T. G., Kang, S. Y., Kang, J. H., Cho, M. Y., Kim, J. I., Kim, S. H., and Kim, 
J. S. (2004) Gene transfer into human hepatoma cells by receptor-associated 
protein/polylysine conjugates. Bioconjug Chem 15, 326-32. 
(75) Nah, J. W., Yu, L., Han, S. O., Ahn, C. H., and Kim, S. W. (2002) Artery wall 
binding peptide-poly(ethylene glycol)-grafted-poly(L-lysine)-based gene delivery 
to artery wall cells. J Control Release 78, 273-84. 
(76) Esfand, R., and Tomalia, D. A. (2001) Poly(amidoamine) (PAMAM) dendrimers: 
from biomimicry to drug delivery and biomedical applications. Drug Discovery 
Today 6, 427-436. 
(77) Samad, A., Alam, M. I., and Saxena, K. (2009) Dendrimers: a class of polymers 
in the nanotechnology for the delivery of active pharmaceuticals. Curr Pharm Des 
15, 2958-69. 
(78) Choi, J. S., Nam, K., Park, J. Y., Kim, J. B., Lee, J. K., and Park, J. S. (2004) 
Enhanced transfection efficiency of PAMAM dendrimer by surface modification 
with L-arginine. J Control Release 99, 445-56. 
(79) D'Emanuele, A., Attwood, D., and Abu-Rmaileh, R. (2006)  pp 872-890, Informa 
Healthcare. 
(80) McNerny, D. Q., Leroueil, P. R., and Baker, J. R. (2010) Understanding specific 
and nonspecific toxicities: a requirement for the development of dendrimer-based 
pharmaceuticals. Wiley Interdisciplinary Reviews: Nanomedicine and 
Nanobiotechnology 2, 249-259. 
(81) Tang, M. X., Redemann, C. T., and Szoka, F. C., Jr. (1996) In vitro gene delivery 
by degraded polyamidoamine dendrimers. Bioconjug Chem 7, 703-14. 
(82) El-Sayed, M., Rhodes, C. A., Ginski, M., and Ghandehari, H. (2003) Transport 
mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. 
Int J Pharm 265, 151-7. 
(83) Malik, N., Wiwattanapatapee, R., Klopsch, R., Lorenz, K., Frey, H., Weener, J. 
W., Meijer, E. W., Paulus, W., and Duncan, R. (2000) Dendrimers: relationship 
between structure and biocompatibility in vitro, and preliminary studies on the 
biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control 
Release 65, 133-48. 
(84) Banerjee, P., Reichardt, W., Weissleder, R., and Bogdanov, A., Jr. (2004) Novel 
hyperbranched dendron for gene transfer in vitro and in vivo. Bioconjug Chem 15, 
960-8. 
(85) Anderson, D. G., Lynn, D. M., and Langer, R. (2003) Semi-automated synthesis 
and screening of a large library of degradable cationic polymers for gene delivery. 
Angew Chem Int Ed Engl 42, 3153-8. 
 
42 
(86) Lin, C., Zhong, Z., Lok, M. C., Jiang, X., Hennink, W. E., Feijen, J., and 
Engbersen, J. F. (2007) Novel bioreducible poly(amido amine)s for highly 
efficient gene delivery. Bioconjug Chem 18, 138-45. 
(87) Luten, J., van Nostrum, C. F., De Smedt, S. C., and Hennink, W. E. (2008) 
Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J 
Control Release 126, 97-110. 
(88) Lim, Y.-b., Choi, Y. H., and Park, J.-s. (1999) A Self-Destroying Polycationic 
Polymer:‚Äâ Biodegradable Poly(4-hydroxy-l-proline ester). Journal of the 
American Chemical Society 121, 5633-5639. 
(89) Putnam, D., and Langer, R. (1999) Poly(4-hydroxy-l-proline ester): Low-
Temperature Polycondensation and Plasmid DNA Complexation. 
Macromolecules 32, 3658-3662. 
(90) Lim, Y.-B., Han, S.-O., Kong, H.-U., Lee, Y., Park, J.-S., Jeong, B., and Kim, S. 
W. (2000) Biodegradable Polyester, Poly[!-(4-Aminobutyl)-l-Glycolic Acid], as a 
Non-Toxic Gene Carrier. Pharmaceutical Research 17, 811-816. 
(91) Lynn, D. M., Anderson, D. G., Putnam, D., and Langer, R. (2001) Accelerated 
discovery of synthetic transfection vectors: parallel synthesis and screening of a 
degradable polymer library. J Am Chem Soc 123, 8155-6. 
(92) Zhong, Z., Song, Y., Engbersen, J. F., Lok, M. C., Hennink, W. E., and Feijen, J. 
(2005) A versatile family of degradable non-viral gene carriers based on 
hyperbranched poly(ester amine)s. J Control Release 109, 317-29. 
(93) Kloeckner, J., Bruzzano, S., Ogris, M., and Wagner, E. (2006) Gene carriers 
based on hexanediol diacrylate linked oligoethylenimine: effect of chemical 
structure of polymer on biological properties. Bioconjug Chem 17, 1339-45. 
(94) Forrest, M. L., Koerber, J. T., and Pack, D. W. (2003) A degradable 
polyethylenimine derivative with low toxicity for highly efficient gene delivery. 
Bioconjug Chem 14, 934-40. 
(95) Ahn, C. H., Chae, S. Y., Bae, Y. H., and Kim, S. W. (2002) Biodegradable 
poly(ethylenimine) for plasmid DNA delivery. J Control Release 80, 273-82. 
(96) Saito, G., Swanson, J. A., and Lee, K. D. (2003) Drug delivery strategy utilizing 
conjugation via reversible disulfide linkages: role and site of cellular reducing 
activities. Adv Drug Deliv Rev 55, 199-215. 
(97) Ikebuchi, M., Kashiwagi, A., Asahina, T., Tanaka, Y., Takagi, Y., Nishio, Y., 
Hidaka, H., Kikkawa, R., and Shigeta, Y. (1993) Effect of medium pH on 
glutathione redox cycle in cultured human umbilical vein endothelial cells. 
Metabolism 42, 1121-6. 
 
43 
(98) Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., and Turner, N. D. (2004) 
Glutathione metabolism and its implications for health. J Nutr 134, 489-92. 
(99) Meister, A. (1983) Transport and metabolism of glutathione and gamma-glutamyl 
amino acids. Biochem Soc Trans 11, 793-4. 
(100) Meister, A., and Anderson, M. E. (1983) Glutathione. Annu Rev Biochem 52, 711-
60. 
(101) Hill, I. R., Garnett, M. C., Bignotti, F., and Davis, S. S. (1999) In vitro 
cytotoxicity of poly(amidoamine)s: relevance to DNA delivery. Biochim Biophys 
Acta 1427, 161-74. 
(102) Lin, C., Blaauboer, C. J., Timoneda, M. M., Lok, M. C., van Steenbergen, M., 
Hennink, W. E., Zhong, Z., Feijen, J., and Engbersen, J. F. (2008) Bioreducible 
poly(amido amine)s with oligoamine side chains: synthesis, characterization, and 
structural effects on gene delivery. J Control Release 126, 166-74. 
(103) Lin, C., Zhong, Z., Lok, M. C., Jiang, X., Hennink, W. E., Feijen, J., and 
Engbersen, J. F. (2006) Linear poly(amido amine)s with secondary and tertiary 
amino groups and variable amounts of disulfide linkages: synthesis and in vitro 
gene transfer properties. J Control Release 116, 130-7. 
(104) Ou, M., Wang, X. L., Xu, R., Chang, C. W., Bull, D. A., and Kim, S. W. (2008) 
Novel biodegradable poly(disulfide amine)s for gene delivery with high 
efficiency and low cytotoxicity. Bioconjug Chem 19, 626-33. 
(105) Piest, M., Lin, C., Mateos-Timoneda, M. A., Lok, M. C., Hennink, W. E., Feijen, 
J., and Engbersen, J. F. (2008) Novel poly(amido amine)s with bioreducible 
disulfide linkages in their diamino-units: structure effects and in vitro gene 
transfer properties. J Control Release 130, 38-45. 
(106) Lin, C., and Engbersen, J. F. (2008) Effect of chemical functionalities in 
poly(amido amine)s for non-viral gene transfection. J Control Release 132, 267-
72. 
(107) Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. 
(2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. 
International Journal of Cancer 127, 2893-2917. 
(108) Society, A. C. (2005) Cancer Facts and Figures 2005. American Cancer Society. 
(109) El-Aneed, A. (2004) Current strategies in cancer gene therapy. Eur J Pharmacol 
498, 1-8. 
(110) McNeish, I. A., Bell, S. J., and Lemoine, N. R. (2004) Gene therapy progress and 




(111) Ogris, M., Brunner, S., Schuller, S., Kircheis, R., and Wagner, E. (1999) 
PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood 
components, extended circulation in blood and potential for systemic gene 
delivery. Gene Ther 6, 595-605. 
(112) Ogris, M., Steinlein, P., Carotta, S., Brunner, S., and Wagner, E. (2001) 
DNA/polyethylenimine transfection particles: influence of ligands, polymer size, 
and PEGylation on internalization and gene expression. AAPS PharmSci 3, E21. 
(113) Plank, C., Mechtler, K., Szoka, F. C., Jr., and Wagner, E. (1996) Activation of the 
complement system by synthetic DNA complexes: a potential barrier for 
intravenous gene delivery. Hum Gene Ther 7, 1437-46. 
(114) Verbaan, F. J., Oussoren, C., van Dam, I. M., Takakura, Y., Hashida, M., 
Crommelin, D. J., Hennink, W. E., and Storm, G. (2001) The fate of poly(2-
dimethyl amino ethyl)methacrylate-based polyplexes after intravenous 
administration. Int J Pharm 214, 99-101. 
(115) Kircheis, R., Schuller, S., Brunner, S., Ogris, M., Heider, K. H., Zauner, W., and 
Wagner, E. (1999) Polycation-based DNA complexes for tumor-targeted gene 
delivery in vivo. J Gene Med 1, 111-20. 
(116) Liu, Y., Mounkes, L. C., Liggitt, H. D., Brown, C. S., Solodin, I., Heath, T. D., 
and Debs, R. J. (1997) Factors influencing the efficiency of cationic liposome-
mediated intravenous gene delivery. Nat Biotechnol 15, 167-73. 
(117) Mahato, R. I., Anwer, K., Tagliaferri, F., Meaney, C., Leonard, P., Wadhwa, M. 
S., Logan, M., French, M., and Rolland, A. (1998) Biodistribution and gene 
expression of lipid/plasmid complexes after systemic administration. Hum Gene 
Ther 9, 2083-99. 
(118) Kang, J.-H., Toita, R., and Katayama, Y. Bio and nanotechnological strategies for 
tumor-targeted gene therapy. Biotechnology Advances 28, 757-763. 
(119) Davis, M. E., Chen, Z. G., and Shin, D. M. (2008) Nanoparticle therapeutics: an 
emerging treatment modality for cancer. Nat Rev Drug Discov 7, 771-82. 
(120) Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2001) Long-circulating and 
target-specific nanoparticles: theory to practice. Pharmacol Rev 53, 283-318. 
(121) Ferrara, N., and Kerbel, R. S. (2005) Angiogenesis as a therapeutic target. Nature 
438, 967-74. 
(122) Folkman, J. (2003) Fundamental concepts of the angiogenic process. Curr Mol 
Med 3, 643-51. 
(123) Kichler, A. (2004) Gene transfer with modified polyethylenimines. J Gene Med 6 
Suppl 1, S3-10. 
 
45 
(124) Kichler, A., Frisch, B., Souza, D. b. L. d., and Schuber, F. (2000) Receptor-
Mediated Gene Delivery with Non-Viral DNA Carriers. Journal of Liposome 
Research 10, 443-460. 
(125) Cristiano, R. J., and Roth, J. A. (1995) Molecular conjugates: a targeted gene 
delivery vector for molecular medicine. J Mol Med 73, 479-86. 
(126) Danhier, F., Vroman, B., Lecouturier, N., Crokart, N., Pourcelle, V., Freichels, 
H., Jerome, C., Marchand-Brynaert, J., Feron, O., and Preat, V. (2009) Targeting 
of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with 
paclitaxel. J Control Release 140, 166-73. 
(127) Diebold, S. S., Kursa, M., Wagner, E., Cotten, M., and Zenke, M. (1999) 
Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic 
cells. J Biol Chem 274, 19087-94. 
(128) Harbottle, R. P., Cooper, R. G., Hart, S. L., Ladhoff, A., McKay, T., Knight, A. 
M., Wagner, E., Miller, A. D., and Coutelle, C. (1998) An RGD-oligolysine 
peptide: a prototype construct for integrin-mediated gene delivery. Hum Gene 
Ther 9, 1037-47. 
(129) Jeong, J. H., Lee, M., Kim, W. J., Yockman, J. W., Park, T. G., Kim, Y. H., and 
Kim, S. W. (2005) Anti-GAD antibody targeted non-viral gene delivery to islet 
beta cells. J Control Release 107, 562-70. 
(130) Kim, W. J., Yockman, J. W., Jeong, J. H., Christensen, L. V., Lee, M., Kim, Y. 
H., and Kim, S. W. (2006) Anti-angiogenic inhibition of tumor growth by 
systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing 
mice. J Control Release 114, 381-8. 
(131) Kim, W. J., Yockman, J. W., Lee, M., Jeong, J. H., Kim, Y. H., and Kim, S. W. 
(2005) Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-
angiogenesis. J Control Release 106, 224-34. 
(132) Kunath, K., Merdan, T., Hegener, O., Haberlein, H., and Kissel, T. (2003) 
Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene 
Med 5, 588-99. 
(133) Zanta, M. A., Boussif, O., Adib, A., and Behr, J. P. (1997) In vitro gene delivery 
to hepatocytes with galactosylated polyethylenimine. Bioconjug Chem 8, 839-44. 
(134) Bouchelouche, K., Capala, J., and Oehr, P. (2009) Positron emission 
tomography/computed tomography and radioimmunotherapy of prostate cancer. 
Curr Opin Oncol 21, 469-74. 
(135) Ross, J. F., Chaudhuri, P. K., and Ratnam, M. (1994) Differential regulation of 
folate receptor isoforms in normal and malignant tissues in vivo and in established 
cell lines. Physiologic and clinical implications. Cancer 73, 2432-43. 
 
46 
(136) Antony, A. C. (1992) The biological chemistry of folate receptors. Blood 79, 
2807-20. 
(137) Kamen, B. A., and Capdevila, A. (1986) Receptor-mediated folate accumulation 
is regulated by the cellular folate content. Proc Natl Acad Sci U S A 83, 5983-7. 
(138) Dubey, P. K., Mishra, V., Jain, S., Mahor, S., and Vyas, S. P. (2004) Liposomes 
modified with cyclic RGD peptide for tumor targeting. J Drug Target 12, 257-64. 
(139) Sudimack, J., and Lee, R. J. (2000) Targeted drug delivery via the folate receptor. 
Adv Drug Deliv Rev 41, 147-62. 
(140) Sabharanjak, S., and Mayor, S. (2004) Folate receptor endocytosis and trafficking. 
Adv Drug Deliv Rev 56, 1099-109. 
(141) Pan, X., and Lee, R. J. (2004) Tumour-selective drug delivery via folate receptor-
targeted liposomes. Expert Opin Drug Deliv 1, 7-17. 
(142) Courter, D., Cao, H., Kwok, S., Kong, C., Banh, A., Kuo, P., Bouley, D. M., Vice, 
C., Brustugun, O. T., Denko, N. C., Koong, A. C., Giaccia, A., and Le, Q. T. 
(2010) The RGD domain of human osteopontin promotes tumor growth and 
metastasis through activation of survival pathways. PLoS One 5, e9633. 
(143) Wang, X., Yang, L., Chen, Z., and Shin, D. M. (2008) Application of 
Nanotechnology in Cancer Therapy and Imaging. CA: A Cancer Journal for 
Clinicians 58, 97-110. 
(144) Carmeliet, P. (2003) Angiogenesis in health and disease. Nat Med 9, 653-60. 
(145) Carmeliet, P., and Jain, R. K. (2000) Angiogenesis in cancer and other diseases. 
Nature 407, 249-57. 
(146) Weidner, N. (1998) Tumoural vascularity as a prognostic factor in cancer 
patients: the evidence continues to grow. J Pathol 184, 119-22. 
(147) Weidner, N. (1999) Tumour vascularity and proliferation: clear evidence of a 
close relationship. J Pathol 189, 297-9. 
(148) Folkman, J. (2004) Endogenous angiogenesis inhibitors. APMIS 112, 496-507. 
(149) Hanahan, D., Christofori, G., Naik, P., and Arbeit, J. (1996) Transgenic mouse 
models of tumour angiogenesis: the angiogenic switch, its molecular controls, and 
prospects for preclinical therapeutic models. Eur J Cancer 32A, 2386-93. 
(150) Nyberg, P., Xie, L., and Kalluri, R. (2005) Endogenous inhibitors of angiogenesis. 
Cancer Res 65, 3967-79. 
 
47 
(151) Relf, M., LeJeune, S., Scott, P. A., Fox, S., Smith, K., Leek, R., Moghaddam, A., 
Whitehouse, R., Bicknell, R., and Harris, A. L. (1997) Expression of the 
angiogenic factors vascular endothelial cell growth factor, acidic and basic 
fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial 
cell growth factor, placenta growth factor, and pleiotrophin in human primary 
breast cancer and its relation to angiogenesis. Cancer Res 57, 963-9. 
(152) Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M., Yerramalla, 
U., Benjamin, L. E., Lawler, J., Kieran, M., Shah, A., and Kalluri, R. (2005) 
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor 
suppressors. Proc Natl Acad Sci U S A 102, 2934-9. 
(153) Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., and 
Holash, J. (2000) Vascular-specific growth factors and blood vessel formation. 
Nature 407, 242-8. 
(154) Harris, A. L. (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev 
Cancer 2, 38-47. 
(155) Semenza, G. L. (2002) HIF-1 and tumor progression: pathophysiology and 
therapeutics. Trends Mol Med 8, S62-7. 
(156) Jain, R. K., Munn, L. L., and Fukumura, D. (2002) Dissecting tumour 
pathophysiology using intravital microscopy. Nat Rev Cancer 2, 266-76. 
(157) Folkman, J. (1972) Anti-angiogenesis: new concept for therapy of solid tumors. 
Ann Surg 175, 409-16. 
(158) Modzelewski, R. A., Davies, P., Watkins, S. C., Auerbach, R., Chang, M. J., and 
Johnson, C. S. (1994) Isolation and identification of fresh tumor-derived 
endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54, 336-9. 
(159) Ruoslahti, E., and Pierschbacher, M. D. (1987) New perspectives in cell adhesion: 
RGD and integrins. Science 238, 491-497. 
(160) Schiffelers, R. M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., 
Lu, P. Y., Scaria, P. V., and Woodle, M. C. (2004) Cancer siRNA therapy by 
tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. 
Nucleic Acids Res 32, e149. 
(161) Zhou, Q. H., Wu, C., Manickam, D. S., and Oupicky, D. (2009) Evaluation of 
pharmacokinetics of bioreducible gene delivery vectors by real-time PCR. Pharm 













MIXTURES OF POLY(TRIETHYLENETETRAMINE/CYSTAMINE- 
BIS-ACRYLAMIDE) AND POLY(TRIETHYLENETETRAMINE/ 
CYSTAMINE-BIS-ACRYLAMIDE)-g-POLY(ETHYLENE  






      Branched disulfide-containing poly(amido ethyleneimines) (SS-PAEIs) are 
biodegradable polymeric gene carrier analogs of the well-studied, nondegradable and 
often toxic branched poly(ethylene imines) (bPEIs), but with distinct advantages for 
cellular transgene delivery.  Clinical success of polycationic gene carriers is hampered by 
obscure design and formulation requirements.  This present work reports synthetic and 
formulation properties for a graft copolymer of poly(ethylene glycol) (PEG) and a 
branched SS-PAEI, poly(triethylenetetramine/cystamine-bis-acrylamide) 
(p(TETA/CBA)).  Several labs have previously demonstrated the advantages of PEG 
conjugation to gene carriers, but have also shown that PEG conjugation may perturb 
plasmid DNA (pDNA) condensation, thereby interfering with nanoparticle formation.  
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With this foundation, our studies sought to mix various amounts of p(TETA/CBA) and 
poly(triethylenetetramine/cystamine-bis-acrylamide)-grafted-poly(ethylene glycol) 2kDa 
(p(TETA/CBA)-g-PEG2k) together in order to alter the relative amount of PEG in each 
formulation used for polyplex formation and gene delivery. The influence of different 
PEG/polycation amounts in the formulations on polymer/nucleic acid nanoparticle 
(polyplex) size, surface charge, morphology, serum stability and transgene delivery were 
studied.  Polyplex formulations were prepared using p(TETA/CBA)-g-PEG2k, 
p(TETA/CBA), and mixtures of the two species at 10% p(TETA/CBA)5k-gPEG2k/90% 
p(TETA/CBA)5k (10% p(TETA/CBA)5k-g-PEG2k) or 50% p(TETA/CBA)5k-
gPEG2k/50% p(TETA/CBA)5k (50% p(TETA/CBA)5k-g-PEG2k) at a desired and 
relevant polymer/pDNA weight-to-weight ratios (w/w) for use.  As expected, increasing 
the amount of PEG in the formulation, adversely affects polyplex formation. However, 
optimal polymer mixtures could be identified using this facile approach to further clarify 
design and formulation requirements necessary to understand and optimize carrier 
stability and biological activity.  This work demonstrates the utility of the approach 
described to identify and potentially overcome typical problems observed when 
polycations are modified and thus avoid the need to synthesize multiple copolymers to 
identify optimal gene carrier candidates, which is often timely, laborious and cost 
prohibitive. This approach may be applied to other polycation-PEG preparations to alter 
polyplex characteristics for optimal stability and biological activity of newly developed 








 Gene therapy is a feasible alternative to conventional therapies that simply 
manage symptoms of diseases and lack an effective treatment. However, gene therapy’s 
clinical success is impaired by uncertain design and formulation requirements for safe 
and efficient nucleic acid delivery to cells.  Recent research advancements have improved 
carrier safety and efficacy through carrier chemical modification to alter surface charge 
and/or tissue specificity using poly(ethylene glycol) (PEG) and/or cell-specific targeting 
ligands (1).  Polymeric nonviral gene carriers have distinct advantages because if 
designed prudently they are nonimmunogenic and are easily modified to exhibit multi-
functional properties (2).  Nonviral polycations are also relatively cost-effective, easy to 
produce industrially and can carry relatively large amounts of therapeutic nucleic acid (3, 
4).  
 Many structurally different polymers and copolymers consisting of linear, 
branched or dendritic architectures have been tested for their efficacy and suitability for 
in vitro and in vivo gene delivery. Poly(ethylene imine) gene carriers (PEIs) have been 
most rigorously studied and are a standard for polycationic gene carriers because they 
easily condense pDNA into nucleic acid/polycation nanoparticles (polyplexes) that 
protect nucleic acid from serum nuclease degradation as well as facilitate relatively high 
transgene delivery and expression in many cell types in vitro and in vivo. Unfortunately, 
PEIs often exhibit cellular toxicity due to intracellular accumulation of non-degradable 
polycations (3, 5).  Increased PEI molecular weight and branching, which influence 
polycation charge density, correlate with increased transgene expression but also with 




that correlates with reduced transgene expression (6, 7).  As predicted, the design of 
degradable polycationic gene carriers such as the reducible disulfide-containing 
poly(amido amine)s (SS-PAAs) and poly(amido ethylenimines) (SS-PAEI), as well as 
hydrolyzable poly(!-amino ester) families have demonstrated comparable or improved 
cellular gene delivery and less cell toxicity when compared to PEIs (8-10). Reducible SS-
PAEIs are synthetic analogs of the PEI family but have the aforementioned advantages of 
improved biological activity and biocompatibility (11).  A recent abstract by Martello et 
al. showed that hyperbranched, SS-PAAs can condense plasmid DNA (pDNA) into 
polyplexes with sizes similar to bPEI 25 kDa, encouraging further functional studies (12).  
 Often cationic polyplexes interact with net negatively charged proteins found in 
serum, which leads to particle aggregation and reduced efficacy in vitro and in vivo (13-
15).  In order to overcome this hurdle, poly(ethylene glycol) (PEG) conjugation to 
polycations has been employed and studies have shown that PEGylation often improves 
carrier function in the presence of serum.  However, previous studies have also clearly 
shown that increasing targeting ligand and/or PEG conjugation to PEIs, especially to low 
molecular weight (LMW) PEI ~5kDA, adversely affects polyplex formation and carrier 
function (16, 17).  
 In order to better design and formulate hyperbranched SS-PAEIs and their 
corresponding graft PEG copolymers, several SS-PAEI polycationic gene carriers are 
synthesized and the influence of varying the relative PEG/polycation amounts on 
polyplex formation, size, surface charge, morphology, serum stability and ultimately 
biological activity are studied.  Polyplex formulations were prepared using pDNA and a 




its PEGylated counterpart p(TETA/CBA)5k-g-PEG2k, or mixtures of the two species at 
10/90% and 50/50% using various polymer to pDNA weight-to-weight ratios (w/w), 
respectively. Altering the amount of PEG in formulation mixtures was employed as a 
suitable strategy to easily control and alter gene delivery reagent physiochemical 
properties in order to identify a suitable gene delivery reagent with improved bioactivity. 




3.3 Materials and Methods 
 
3.3.1 Materials 
 Triethylenetetramine (TETA), tris(2-carboxyethyl)phosphine (TCEP), N-
ethylemaleimide (NEM), hyperbranched polyethylenimine (bPEI, Mw 25 000 
(bPEI25kDa)) and HPLC grade methanol were purchased from Sigma-Aldrich (St. Louis, 
MO).  N,N’-Cystamine-bis-acrylamide (CBA) was purchased from Polysciences, Inc. 
(Warrington, PA). Ultrafiltration devices and regenerated cellulose membranes (1kDa 
and 5kDa) were supplied by Millipore Corporation (Billerico, MA).  The reporter gene 
plasmid, pCMVLuc, was designed previously by insertion of luciferase cDNA into a pCI 
plasmid (Promega, Madison, WI) driven by the pCMV promoter and was purified using 
Maxiprep (Invitrogen, Carlsbad, CA) protocols. Dulbecco’s Modified Eagle’s Medium 
(DMEM), penicillin streptomycin, trypsin-like enzyme (TrypLE Express), and 
Dubelcco’s phosphate buffered saline were purchased from Gibco BRL (Carlsbad, CA). 
EBM-2 with EGM-2 singlequots was purchased from Lonza. Fetal bovine serum (FBS) 




3.3.2 p(TETA/CBA) Synthesis 
 Synthesis of p(TETA/CBA) was performed at 50°C using equimolar amounts of 
N,N’-cystamine-bis-acrylamide and triethylenetetramine monomers with minor 
adaptation of the previously described method (11). The polymerization reaction was 
split in half after the pH was adjusted to 7.0 and purified by ultrafiltration using a 1kDa 
or 5kDa MWCO regenerated cellulose membrane to yield p(TETA/CBA)1k or 
p(TETA/CBA)5k, respectively.  The polycations were subsequently lyophilized (Scheme 
1). Composition of the polymer was monitored using1H NMR (400 MHz, D2O). 
p(TETA/CBA) ! 2.61 (COCH2CH2NH, 4H), 2.72 (NHCH2CH2S-S, 4H), 2.90-3.21 
(COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-S, 4H). 
 
3.3.3 p(TETA/CBA)5k-g-2k Synthesis 
 Methoxy poly(ethylene glycol) 2 kDa (mPEG2k) was dried using anhydrous 
toluene and subsequently precipitated in anhydrous ice-cold ether. The white precipitate 
was collected and dried in vacuo.  The mPEG2k was then activated using p-nitrophenyl 
chloroformate in dichloromethane (DCM) as solvent and reacted on ice overnight while 
stirred. The activated PEG product was collected by precipitation in anhydrous ice-cold 
ether and dried in vacuo. Following NMR analysis to assess the degree of PEG 
activation, the amine reactive PEG-carbonate dissolved in anhydrous dimethyl sulfoxide  
(DMSO) was added dropwise to a solution of p(TETA/CBA)5k dissolved in anhydrous 
pyridine/DMSO as solvent.  The molar feed ratio of PEG-carbonate to p(TETA/CBA)5k 
was 1.2:1.  The reaction was stirred at room temperature and the release of p-




complete at approximately 16 hrs. the sample was purified by ultrafiltration (5kDa 
MWCO) before being lyophilized. The composition of the p(TETA/CBA)-g-PEG2k 
copolymer conjugate was monitored using 1H NMR (400 MHz, D20). p(TETA/CBA)5k-
g-PEG2k ! 2.5 (COCH2CH2NH, 4H), 2.72 (NHCH2CH2S-S, 4H), 2.90-3.21 
(COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-S, 4H), 3.5-3.6 (CH2CH20, 4H), 
2.2.5-2.38 (CH3, 3H). 
 
3.3.4 Polymer Characteristics 
 The absolute molecular weight was determined for p(TETA/CBA)1k,  
p(TETA/CBA)5k and p(TETA/CBA)5k-PEG2k using AKTA/FPLC (Amersham 
Pharmacia Biotech Inc.) coupled to a light-scattering detector and using the relevant 
polymer refractive index increment (dn/dc) for each sample. A SuperdexPeptide column 
HR 10/30 was used for the separation of p(TETA/CBA)1k (2mg/mL), whereas a 
Superose 6 10/300 GL column was used for p(TETA/CBA)5k (2mg/mL) and 
p(TETA/CBA)5k-g-PEG2k (2mg/mL) separation.  Poly[N-(2-
hydroxypropyl)methacrylamide] (poly(HPMA)) standards were used prior to analysis to 
ensure that the FPLC columns were clean and functional.  Experimental and standard 
polymer samples were dissolved in degassed and filtered (0.2 µm (Nylon, Alltech)) 0.3 M 











3.3.5 Determination of Polymer Disulfide Bonds 
 
 Disulfide bond content of each polymer was determined using 5,5-dithio-bis-(2-
nitrobenzoic acid) (Ellman's reagent) following the manufacturer’s protocol with minor 
adaptation (Pierce).  In brief, cysteine hydrochloride monohydrate was used as a standard 
to generate a standard curve for accurate analysis.  Absolute polymer molecular weights 
were used to estimate the number of disulfide bonds in each polymer sample and to 
ensure that the average thiolate concentration of the experimental polymers fell within the 
standard range for accurate analysis of disulfide bond content.   Each experimental 
polymer sample was reduced using 10x immobilized (tris(2-carboxyethyl)phosphine 
hydrochloride) (TCEP) gel in buffer (0.1 M sodium phosphate, pH 8, 1mM EDTA).  
Following 30 min. incubation of the polymer samples in the presence of immobilized 
TCEP reducing agent, the samples were centrifuged at 1000 x g for 2 min and the 
reduced polymer solutions were collected.  Reduced polymers were subsequently added 
to the Ellman’s reagent in the aforementioned buffer and were allowed to incubate at 
room temperature for 20 min durring constant mixing. The sample absorbance at 412 nm 
was measured using UV-Vis spectroscopy. The thiol concentration was determined using 
the standard curve and the absolute molecular weights of the polymers in order to 
determine the number of disulfide bonds per polymer (n=3). 
 
3.3.6 Polyplex Formation 
 In all cases polyplex was formed with a known amount of pDNA and a 
corresponding and desired amount of polymer dissolved in HEPES buffer (20 mM, pH 




and allowed to equilibrate for 30 min to form electrostatic complexes at room 
temperature.  When the 10% and 50% p(TETA/CBA)-g-PEG2k/p(TETA/CBA)5k 
polyplexes were formed, a 10% or 50% p(TETA/CBA)-g-PEG2k/p(TETA/CBA) 
polymer solution was prepared in HEPES buffer at a relevant concentration to obtain a 
desired w/w ratio with a known amount of pDNA. The respective polymer solutions were 
then mixed with the known amount of pDNA in HEPES buffer, the solution was lightly 
vortexed and allowed to equilibrate for 30 min to form electrostatic complexes as 
described above at room temperature.  
 
3.3.7 Polycation Branching 
           The relative degree of branching for each polymer sample was determined by the 
reduction of polymer disulfide bonds using Tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP) and subsequent free thiol protection using N-ethylmaleimide (NEM) prior to 
sample analysis using MALDI-TOF.  MALDI-TOF analysis was performed on the NEM 
conjugated polymer repeat units using a Voyager-DE STR Biospectrometry Workstation 
(PerSeptive Biosystems) in positive-ion mode with delayed extraction. Spectra were 
externally calibrated using a peptide standard mixture spanning a nominal mass range 
from 325 to 2465 Da.  The relative degree of branching (DB) for sample polymers was 





where Bseg is the total number of branched repeat unit segments and Lseq is the total ! 




number of linear repeat unit segments. 
 
3.3.8 Acid-Base Titrations 
           The buffering capacity of each polycation was determined using a previously 
established method (11). In brief, 6 mg polymer was dissolved in 30mL NaCl solution 
(0.1 M) and initially titrated to pH 10 with 0.1M NaOH.  The pH was subsequently 
lowered with the addition of 0.1 M HCl.  Because the absolute molecular weight is not 
known for these polymers, titration values were determined in µmols of HCl required to 
lower the pH of the polycation solution from 7.4-5.1. Branched PEI25kDa was used as a 
reference control. 
 
3.3.9 Light Scattering and "-Potential Measurements 
           The surface charge and polymer/pDNA particle (polyplex) diameters were 
measured at 25°C using a Zetasizer 2000 instrument  (DTS5001 cell) and a dynamic light 
scattering (DLS) unit on a Malvern 4700 system, respectively. Polyplexes were prepared 
by adding equal volume polymer solution (200µl) at increasing concentrations in HEPES 
buffer (20 mM, pH 7.4, 5% glucose) to a desired concentration of 8 µg pDNA in HEPES 
buffer (200µl).  Polyplexes were allowed to equilibrate for 30 min and were subsequently 
diluted in filtered miliQ water to a final 2 mL volume.   
     
3.3.10 Transmission Electron Microscopy (TEM) 
 Polyplex was prepared in HEPES buffer (20 mM, pH 7.4, 5% glucose) at 0.05 




removed by carefully rinsing each grid with filtered deionized water thrice. The samples 
were then stained with filtered phosphotungstenic acid (PTA) for 1 min before washing 
again with filtered deionized water.  Images were visualized using a Technai T12 scope 
(EFM) at 80 kV. Magnification ranging from 20,000 to 200,000x was utilized and the 
micrograph images were taken at 110,000x.  Particle sizes were analyzed using ImageJ 
software. 
     
3.3.11 Polyplex Stability in 90 % Fresh Rabbit Serum 
 Polyplex stability and resulting pDNA stability against nuclease activity in serum 
was evaluated using 500ng free pDNA as a control and 500ng pDNA complexed with 
polymer mixtures pre-formed in HEPES buffer. Polyplex formation was carried out by 
combining equal volume solutions of p(DNA) and polymer mixtures using a 
polymer/pDNA at N/P 50 (24 w/w) and allowed to equilibrate for 30 min. Pre-formed 
polyplex was then diluted in 90% fresh rabbit serum and incubated at 37°C over time.  25 
µl aliquots (125 ng pDNA) were taken at each time point and 10 µl stop buffer (250 mM 
NaCl, 25 mM EDTA, 2% SDS) was added to each. The samples were frozen at -70°C 
until further analysis.  Once the samples were thawed, they were incubated overnight at 
60°C to completely dissociate polycation from the pDNA and 2 µl of 50 mM 
Dithiothreitol (DTT) was added to each sample and incubated at 37°C for an additional 
30 min to ensure complete decomplexation.  Lastly, the samples were loaded onto a 2% 
agarose gel stained with ethidium bromide (EtBr) and subjected to electrophoresis at 96 
V for 30 min in TAE (40 mM Tris-acetate, 1 mM EDTA) buffer.  The gel image was 




3.3.12 Cell Culture 
 Mouse pancreatic islet endothelial cells (SVR) and colon adenocarcinoma cells 
(CT-26) (ATCC) were cultured in DMEM containing 10% FBS and 1% penicillin-
streptomycin at 37°C in a humidified incubator with an atmosphere containing 5% (v/v) 
CO2. Human Umbilical Vein Endothelial Cells (HUVEC) (Invitrogen) were cultured in 
EBM-2 media with EGM-2 singlequots at 37°C in a humidified incubator with an 
atmosphere containing 5% (v/v) CO2.  
 
3.3.13 In Vitro Transgene Expression 
 Luciferase reporter gene expression in cell culture was performed using each 
polymer and pCMVLuc plasmid DNA. Cells were plated in 24-well plates containing 
0.5mL media. Once the cells were approximately 70% confluent, polyplexes were 
prepared using 0.5µg pDNA at N/P 50 (24 w/w) in HEPES buffer.  Polyplexes were 
allowed to equilibrate for 30 min. and the cells were transfected in the presence of serum 
by adding 20 µl polyplex (0.5 µg pDNA) to each well for 4 hrs before replacing with 
fresh culture media. The cells remained in the incubator for a total of 48 hrs before they 
were washed with 1ml PBS and treated with cell culture lysis buffer (Promega). 
Luciferase quantification was performed using a Luciferase assay system (Promega) on a 
luminometer from Dynex Technologies, Inc. (Chantilly, VA). The amount of protein in 
the cell lysate was determined using a standard curve of bovine serum albumin (Sigma) 






3.3.14 Cell Viability Assay 
 Cells were plated in 24-well plates and gene transfections were carried out when 
the cells were approximately 70% confluent. Polyplexes were prepared as they were for 
the luciferase reporter gene assay. Respective cell cultures were transfected in the 
presence of serum with the addition of 20 µl equilibrated polyplex in HEPES buffer 
solution (0.5 µg pDNA) to each well. Cells were left to incubate for a total of 18 hrs 
before cell viability using an MTT assay was evaluated (Sigma).  Percent cell viability 
was determined relative to untreated control cells (n=6). 
 
3.3.15 Statistics 
 The experimental data in this report are assessed as mean ± SD.  A one-way 
ANOVA in conjunction with a Tukey’s post-hoc test is used to determine if treatment 




3.4.1 Synthesis and Characterization. 
 The premise of the studies herein was to develop a functional PEGylated 
copolymer of a previously developed and promising polycation, p(TETA/CBA).  
PEGylation of polycationic systems for gene delivery has been shown to improve 
polycationic carrier function in the presence of serum both in vitro and in vivo via 
reducing polyplex surface charge and providing a steric barrier against protein adsorption 
(18). Particles with a surface charge close to neutral tend to aggregate in solution due to 




and pH of the solution (19).  The generation of a PEGylated polycation sufficient to 
prevent protein adsorption and avoid aggregation often requires the synthesis and 
evaluation of many putative reagents with various degrees of modification in order to 
identify optimal candidates, which is often laborious, time consuming and costly.  In an 
attempt to avoid this problem, we sought to synthesize a p(TETA/CBA)5k-PEGylated 
product with a known degree of modification that could then be mixed with the 
polycationic counterpart p(TETA/CBA)5k and easily control the amount of PEG 
included in the gene delivery reagent formulations.  It is then easy to control and examine 
the effects of various PEG content on reagent complexation and carrier functionality to 
further identify optimal delivery reagents.  The synthesis and hypothetical scheme of the 
p(TETA/CBA) and the p(TETA/CBA)5k-PEGylated products and/or formulation 
mixtures tested in our studies are shown in Figures 3.1 and 3.3, respectively. 
 Polymerization of p(TETA/CBA) occurs via Michael-type addition of the amine-
containing monomer, TETA, to the N,N’-Cystamine-bis-acrylamide monomer and is 
shown in Figure 3.1.  Four reactive amine groups exist within the unprotected TETA 
monomer and as a result branched products are produced during polymerization of 
p(TETA/CBA).  In the present study, polymerization reactions were carried out at 
different temperatures in 100% MeOH and monitored by 1H NMR (Figure 3.2).  
Synthesis temperature was shown to correlate with the relative degree of branching in 
each sample (Table 3.1).  Purification of polymer products using a relatively high 
molecular weight cut-off membrane at 5 kDa (5 kDa MWCO) compared to a relatively 
low molecular weight cut-off membrane at 1 kDa (1 kDa MWCO) proved to eliminate 




molecular weight (Mn) increase over the sample purified at 1 kDa MWCO (Table 3.2).   
This finding is useful for subsequent PEG modification of p(TETA/CBA).  Commercial 
bPEI 25kDa was also analyzed as an external control for comparison using this method. 
The absolute Mn and weight average molecular weight (Mw) values for bPEI 25kDa 
determined using AKTA/FPLC and light scattering were lower than the value reported by 
the commercial provider and thus suggest extrapolations should be made to estimate 
p(TETA/CBA) molecular weight for subsequent modification.   
 To obtain the PEG modified p(TETA/CBA)5k, PEG chemical modification of an 
amine-reactive PEG-phenylcarbonate with p(TETA/CBA)5k was monitored by following 
the release of p-nitrophenolate in anhydrous solvent at 400 nm with a UV-Vis 
spectrophotometer.  The reaction was complete by 16 hrs and the product composition 
was confirmed using 1H NMR (Figure 3.4).  The only side reaction that may occur during 
PEG conjugation to p(TETA/CBA)5k is the hydrolysis of the amine reactive carbonate 
present on the activated PEG chain.  Analysis and comparison of 1H NMR peak AUC 
indicated the presence of 0.96 mol PEG to 1 mol p(TETA/CBA)5k (80% conversion) 
(Table 3.2).  These values were determined using the absolute molecular weight values 
obtained from AKTA/FPLC and light scattering analysis (Table 3.2).  The reduced PDI 
of p(TETA/CBA)-g-PEG2k compared to p(TETA/CBA)5k indicates further removal of 
un-reacted p(TETA/CBA)5k oligomer polycations during the second purification step 
used to obtain a pure p(TETA/CBA)-g-PEG2k sample.  Nonetheless, analysis of sample 
buffer capacity indicates that by collecting a higher molecular weight fraction of the 
produced product (p(TETA/CBA)5k) has similar buffering capacity to the product 




polycations of the product produced (p(TETA/CBA)1k).  Moreover, PEG modification of 
p(TETA/CBA)5k does not significantly affects product buffer capacity either, as titration 
values are not significantly different from each other (Table 3.2).  The number of 
disulfide bonds per molecule of the bioreducible polymer products is also reported for 
additional characterization of polymer samples (Table 3.2). 
 
3.4.3 Physiochemical Characterization of Polymers 
 The ability of p(TETA/CBA)5k and p(TETA/CBA)5k-g-PEG2k to form 
condensed polyplex was investigated by Dynamic Light Scattering (DLS) particle size 
analysis and polplex surface charge "-potential measurements were also taken.  Indeed, 
nanosized particles below or near 100 nm in diameter were formed for both potential 
gene carriers.  As expected, PEG conjugation interfered with polyplex formation at low 
polymer/pDNA weight-to-weight ratios (w/w) (Figure 3.7).    PEG conjugation 
significantly decreased polyplex surface charge, however, as mentioned above, an 
increased w/w is required to condense p(DNA) into sub-200nm complexes compared to 
p(TETA/CBA)5k (Figure 3.7).  
 Our findings coincide with previous studies that used PEGylated poly(ethylene 
imine) gene carriers (17) and show that PEGylation of p(TETA/CBA) perturbs nucleic 
acid condensation and polyplex size.  To overcome this problem and validate the 
possibility of premixing polymer/PEG-copolymer solutions in order to control the 
relative PEG/polycation amounts, as well as identify an ideal formulation that maintains 
homogenous and stable polyplex with reduced surface charge, polyplexes were prepared 




entities at 10/90% and 50/50%, respectively, at a summed polycation/pDNA N/P = 50 
(24 w/w).  As mentioned previously, mixtures are schematically represented in Figure 3.3 
and included to clarity the mixture formulations tested.  
  In order to test the influence of increasing PEG content on polyplex stability and 
pDNA protection against serum nuclease activity, polyplexes were formed and following 
a 30 min equilibration time, were added to fresh rabbit serum to a final serum 
concentration equal to 90 % at 37°C.  Aliquots were taken over time and electrophoresed 
on an agarose gel to visualize intact pCMVLuc at each time point.  Polymer/pDNA 
formulations were compared to un-complexed pDNA (control) at 0 hours.  Figure 3.8 
shows that pDNA complexed with polymer formulations is significantly more stable in 
the presence of serum than uncomplexed, free pDNA over 6 hrs.  As the amount of 
p(TETA/CBA)5k-g-PEG2k in each formulation is increased, lower protective effects are 
seen, indicating that PEG adversely affects complex stability and pDNA protection.  
Nonetheless, p(TETA/CBA)5k and 10% p(TETA/CBA)-g-PEG2k sufficiently protect 
80% of the pDNA from nuclease degradation over the 6 hrs incubation in 90% serum.  
Increasing p(TETA/CBA)5k-g-PEG2k to 50 or 100% reduces particle stability and offers 
less pDNA protection where approximately 60 % and 40 % pDNA is preserved, 
respectively, at 6 hrs incubation time. 
  For formulation ease and improved carrier function, stable polyplex was formed 
using different amounts of PEG.  Formulations should display unimodal polyplex size 
distribution and surface charge with uniform morphology. Polyplex size for each 
formulation was visualized using TEM (Figure 3.9) and their size and distribution were 




contained in Figure 3.9 (a-d) show representative polyplexes and the particle size was 
analyzed using ImageJ software. The values between TEM and DLS are in close 
agreement with each other. The TEM particle sizes are smaller than those determined 
using DLS because the polyplexes examined using TEM are in a dehydrated state, 
whereas polyplex analyzed by DLS are in aqueous buffer and are thus hydrated lending 
to a larger particle size.  Figures 3.9 (a-d) reveal that morphological changes and less 
compact polyplex occur as the amount of PEG in the formulation increases. 
p(TETA/CBA)5k-g-PEG2k exhibited aggregation (Figure 3.9 (d)).  This aggregation was 
also seen when analyzed using DLS.  The aggregation of these complexes is explained by 
their reduced surface charge, lending to reduced charge-charge repulsion of polyplex and 
potential PEG chain entanglement between polyplex and free polymer in solution. 
Therefore this formulation is excluded from the analysis and not shown.  
p(TETA/CBA)5k, 10% and 50% PEG formulations generate sub-150nm polyplexes in 
solution and the amount of PEG inversely correlates with polyplex surface charge, 
indication the charge-shielding capacity of PEG chains (Figure 3.9 (e)).  
     
3.4.4 Gene Carrier Function and In Vitro Biological  
Activity of PEG Formulations. 
 Often times polycationic species interact with and disrupt cell membrane 
function, and/or they interact with intracellular proteins and nucleic acids, which in turn 
perturbs intracellular and nuclear processes that leads to cellular toxicity (20, 21). 
Bioreducible polycations such as p(TETA/CBA) in principle mitigate these intracellular 




intracellular polycation accumulation and subsequent cellular toxicity when transgene 
delivery occurs using these reagents (22).  As such, the decreased toxicity of degradable 
polycations compared to nondegradable counterparts should be maintained irrespective of 
polycation molecular weight (22).  In addition to toxicity, serum proteins often reduce 
polycationic gene carrier performance by destabilizing polyplex, which leads to 
reticuloendothelial system (RES) uptake, in vivo, or exposes the therapeutic gene to 
serum nucleases where it is degraded and rendered inactive, thus providing another 
barrier for their successful therapeutic application.   
 The aforementioned AKTA/FPLC results shown in Table 3.2 indicate that 
p(TETA/CBA)5k has a slightly higher molecular weight and lower PDI than 
p(TETA/CBA)1k.  In lieu of this result and realizing that polycation molecular weight 
often influence carrier biological activity, reducing the PDI of p(TETA/CBA) by 
eliminating destabilizing oligomers and increasing the average molecular weight without 
perturbing carrier performance is preferred (17).  Because p(TETA/CBA)5k was used for 
subsequent PEG modification, it is imperative to ascertain that improved function of 
bioreducible polycations is not lost with an increase in absolute molecular weight.  It is 
also important to further evaluate the influence of PEG modification on the system’s in 
vitro biological activity.  Distinct physiochemical differences of these systems were 
observed between each other, which may influence their biological activity and putative 
application as cellular transgene delivery reagents.  When tested using several cell lines, 
the transfection efficiency of p(TETA/CBA)1k and pTETA/CBA)5k populations were 
significantly better than the ‘gold standard’ nondegradeable bPEI 25 kDa in the presence 




compared to bPEI 25 kDa (Figure 3.8).  There is no significant difference between the 
biological activity of p(TETA/CBA)1k and p(TETA/CBA)5k, which indicates that 
increasing the molecular weight of this polycation and eliminating oligomer polycations 
has no adverse effect on carrier bioactivity and p(TETA/CBA)5k can be used for 
modification (Figure 3.8).  Specifically, p(TETA/CBA)5k is significantly less toxic in 
primary HUVEC endothelial cells than bPEI 25kDA, as well as providing greater 
luciferase transgene expression in HUVEC and SVR endothelial cells or the colon 
adenocarcinoma cell line, CT-26 (Figure 3.8). The toxicity of bPEI 25kDa is likely due to 
the intracellular accumulation of high molecular weight polycationic species (3). The 
enhanced transgene expression of p(TETA/CBA)5k compared with bPEI 25kDa is also 
likely explained by its bioreducible nature that lends to its ability to more easily release 
pDNA intracellularly compared to the nondegradable counterpart bPEI 25kDa (6, 9).  
Three cell lines were used because if trends are seen in multiple cell lines, greater validity 
is given to the trend, and secondly, endothelial cells (SVR and HUVEC) as well as the 
adenocarcinoma cells (CT-26) are relevant to in vivo cancer therapy, which is of interest 
to out lab and is the next step following in vitro characterization.  Therefore, we tested 
the biological activity of our gene carriers using endothelial cells that would be exposed 
during systemic administration to examine potential activity as well as the 
adenocarcinoma cell line (CT-26) that is used in our lab for a mouse tumor model when 
testing therapeutic gene activity in vivo.  
 To evaluate carrier function of a panel of PEG-modified p(TETA/CBA) gene 
delivery reagents in an attempt to identify optimal candidates, the biological activity of 




adenocarcinoma cells (CT-26) in 10% serum-containing media.  Results from this 
experiment indicate that p(TETA/CBA)5k exhibits significantly better cellular trangene 
delivery than bPEI 25kDa in the presence of serum-conditioned media and that 
transfection using p(TETA/CBA)5k is less affected by the presence of serum than for 
bPEI 25kDa (Figure 3.9).  These were collected while evaluating the biological activity 
of the PEG formulations; however, comparison of p(TETA/CBA)5k with bPEI 25kDa in 
the presence and absence of serum is shown separately to clearly exemplify the effect of 
serum on polycation transfection as well as demonstrate the differences of serum effect 
on transfection between p(TETA/CBA)5k and bPEI 25kDa.  Transfection using 
p(TETA/CBA)5k is less affected by the presence of serum-conditioned media than for 
bPEI 25kDa, and it indicates potentially less serum adsorption to polyplexes prepared 
using p(TETA/CBA)5k than those prepared using bPEI 25kDa, as protein adsorption to 
polyplex often leads to polyplex aggregation and reduced delivery efficacy (23). Lower 
protein adsorption to p(TETA/CBA)5k polyplex compared to bPEI 25kDA polyplex is 
due to the lower charge density of p(TETA/CBA)5k compared to bPEI 25kDa (11).  
Evaluation of serum effects on gene transfection was performed solely on CT-26 cells 
because the data presented in Figure 3.8 showed similar trends as in the other two cell 
lines. 
 PEGylated p(TETA/CBA)5k formulation biological activity was tested in vitro 
along with p(TETA/CBA)5k and bPEI 25 kDa in the aforementioned study and results 
are shown entirely in Figure 3.10.  Specifically, two PEGylated formulations of 
p(TETA/CBA)5k compared with p(TETA/CBA)5k alone and the ‘gold standard’ bPEI 




kDa.  The p(TETA/CBA)5k-g-PEG2k alone provided very low transfection to these cells 
and is explained by their complex aggregation when combined with pDNA. None of the 
formulations proved toxic to these cells (Figure 3.10b). Moreover, the 10% and 50% PEG 
formulations are not significantly different from each other when used in the presence 
and absence of serum-containing media. Combined, these results demonstrate the 
advantages of p(TETA/CBA)5k over bPEI 25kDa and verify the advantage of 
PEGylating the p(TETA/CBA) system to generate a polycation with improved in vitro 
gene delivery capacity utilized in the presence of serum.  Most importantly, these results 
indicate that a panel of PEGylated polycation formulations can be easily derived by 
premixing various amounts of a PEGylated polycation and polycation to assist the 
identification of an optimal PEG-modified gene delivery reagent. 
 
3.5 Discussion 
 Clinical advancements of polycationic gene carriers is hampered by uncertain 
design and formulation requirements. In the present work, we show that a graft 
copolymer of poly(ethylene glycol) (PEG) and a branched SS-PAEI can be synthesized 
and used in formulation mixtures to alter the relative amount of PEG, thereby altering the 
physiochemical characteristics of the gene carrier in order to easily study the design and 
formulation requirements to improve gene carrier function.  If PEG conjugation to a 
polycation such as p(TETA/CBA) interferes with polyplex formation and carrier 
function, as seen here, this work demonstrates the feasibility to identify and potentially 
rectify this issues by preparing homogenous polyplex formulations using mixtures of 




formulations and identify reagents that are functionally viable.   More importantly, this 
approach may be applied to other polycation-PEG preparations to easily alter polyplex 
characteristics to optimize polyplex stability and biological activity in vitro.  Further 
studies need to be performed to understand the feasibility of using this approach for in 
vivo screening and evaluation of gene carriers.   
 When synthesizing p(TETA/CBA)5k-g-PEG2k, reducing the PDI of  
p(TETA/CBA) by removing polycationic oligomers with a limited ability to properly 
condense pDNA is preferred given that PEG conjugation may interfere with polyplex 
formation as it is.  Therefore, in order to reduce the PDI of p(TETA/CBA) following the 
Michael-addition of TETA with the bisacrylamide group, ultrafiltration was performed 
using a higher molecular weight cut-off membrane (5 kDa) than was used previously 
(11).  As expected, this approach was effective in reducing the polycation’s PDI and 
correlates with a relative increase in molecular weight.  Prior research has shown that 
increasing the molecular weight and branching profile of poly(ethylene imine)s correlates 
with increased transgene expression, but also cellular toxicity (24).  Therefore, the 
present study investigated this putative effect with regards to p(TETA/CBA) and found 
no significant influence on its biological activity in primary and immortalized cell lines 
(6, 7).  These results are explained by the gene carrier’s ability to exploit the intracellular 
redox potential and avoid disruption of intracellular function through relatively high 
molecular weight polycationic species (25). 
 While p(TETA/CBA) demonstrated significantly better transgene expression than 
bPEI 25kDa in serum-containing media due to a lower charge density by comparison, 




in the absence of serum.  Therefore, to reduce p(TETA/CBA)/pDNA polyplex 
interactions with serum proteins and thus improve carrier function in the presence of 
serum, poly(ethylene glycol) was conjugated to p(TETA/CBA)5k at 1.2/1 PEG-
carbonate/p(TETA/CBA)5k ratio and confirmed by 1H NMR following purification. The 
corresponding relative molecular weight was in agreement with what is expected for the 
degree of PEG conjugation (0.96/1 moles PEG/p(TETA/CBA)) when analyzed using 
AKTA/FPLC and light scattering.  Conjugating PEG2k to p(TETA/CBA)5k reduced 
polyplex surface charge, however, adversely affected nucleic acid condensation.  This 
result coincides with prior findings by our lab and others (16, 26).  Because poly(ethylene 
glycol) and/or ligand conjugation for cell-specific gene delivery commonly mitigates 
nucleic acid condensation, synthesis of multiple co-polymeric gene carriers is required to 
ascertain optimal ratios for maximal carrier performance.  
 In an attempt to overcome this problem and avoid the need to synthesize multiple 
carriers for screening, this study investigated the feasibility of altering and optimizing 
PEG/polycation amounts by formulating mixtures of a polycation and its corresponding 
PEGylated counterpart.  Polyplex stability in serum was evaluated in this study for 
p(TETA/CBA)5k-g-PEG2k alone, p(TETA/CBA)5k alone, and 10/90 or 50/50 mixtures 
of p(TETA/CBA)5k-g-PEG2k/p(TETA/CBA)5k, respectively.  Polyplex formed using 
p(TETA/CBA) and 10/90%, sufficiently protects up to 70% of the pDNA from serum 
nuclease degradation over 6 hrs. Increasing the p(TETA/CBA)5k-g-PEG2k amount to 50 
and 100% reduced the relative pDNA protection in serum, which correlates with the 
capability of each formulation to condense pDNA into nano-sized polyplex determined 




N/P (24 w/w) the N/P ratios could be significantly different between p(TETA/CBA) 
alone and the mixtures.  However, NMR results demonstrate that there is approximately 1 
PEG chain per TETA/CBA molecule.  If a 50 N/P (24 w/w) is used for formulations, 
there are approximately 1.2% of the amines PEGylated in the 100% p(TETA/CBA)5k-g-
PEG2k formulation, ~0.6% for the 50 % formulation, ~0.12% for the 10% formulation 
and 0% for p(TETA/CBA)5k. This being the case, the difference in N/P ratios between 
the formulations is insignificant. Moreover, the 10% formulation that demonstrated 
significantly better transgene expression than p(TETA/CBA)5k in the presence of serum 
has only 0.12% less amines for use in formulating polyplex. 
 Luciferase transgene expression and cell viability was investigated in cell culture 
using the aforementioned formulations to evaluate their bioactivity.  As expected, PEG 
was able to improve gene delivery in serum-containing media compared to 
p(TETA/CBA) alone.  However, this improvement was observed only at specific PEG-
formulations: 10 and 50% p(TETA/CBA)-g-PEG2k.  These two formulations exhibit a 
reduced surface charge of approximately 20 mV and 15 mV compared to p(TETA/CBA) 
at 35 mV, respectively, and their surface charge inversely correlates with PEG 
concentration.  By maintaining a reduced surface charge, protein association with the 
complexes via electrostatic interaction is mitigated.  Moreover, PEG provides a steric 
barrier for protein adsorption.  Taken together, complex aggregation is avoided and more 
efficient cellular uptake of the complexes is promoted.   Despite the reduced surface 
charge of 100% p(TETA/CBA)5k-g-PEG2k  compared to p(TETA/CBA), which can 
promote transfection in the presence of serum, efficient cellular uptake and transfection is 




provide evidence that PEG/polycation ratios can be easily controlled in order to evaluate 
formulation activity and optimize PEG ratios for improved gene carrier function, which 
depends on reagent physiochemical properties.  In doing so, one can avoid synthesis of 
multiple bio-reducible co-polymers with different physiochemical characteristics 
currently employed for gene carrier optimization. 
 
3.6 Conclusion 
 In the present study, we developed a novel gene carrier comprised of an efficient 
and non-toxic bioreducible polycation in conjunction with its PEGylated counterpart to 
improve carrier performance in the presence of serum. In addition we provide a feasible, 
multifaceted approach to tailor the relative amount of PEG in a polycationic gene carrier 
reagent by generating controlled mixtures of the polycation and PEGylated polycation for 
gene delivery in order to elucidate changes in reagent physiochemical properties ideal for 
gene carrier function.   By doing so, the laborious and costly synthesis of multiple 
candidate copolymers for gene delivery is avoided when designing a gene carrier with 
preferred physiochemical properties.  The methodology described herein may also be 
employed for other novel gene delivery reagents and can be further used for in vivo 












Table 3.1. Effect of synthesis temperature on polymer branching. 
 
Sample DBa 0 arm 1 arm 2 arm 3 arm 
p(TETA/CBA)-4°C 55% 45% 36% 18% 0% 
p(TETA/CBA)-30°C 82% 10% 60% 22% 8% 
p(TETA/CBA)-50°C 90% 10% 39% 42% 11% 
 
aPolymer degree of branching (DB) correlates with polymer synthesis temperature and 
influences the number of polymer arms per repeat unit.  The relative DB was determined 
using the equation described in section 3.2.7.  Polymer branching characteristics were 
determined by the reduction of polymer disulfide bonds with tris(2-
carboxyethyl)phosphine (TCEP) followed by protection of free sulfhydryls with N-
ethylemaleimide (NEM) and analyzed by MALDI-TOF
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8.2 1.95 25.2 ± 3.4 
 
23.2 ± 2.4 0.68 -- 
p(TETA/CBA)5k 5.8 
 
8.85 1.53 27.6 ± 2.8 27.1 ± 1.8 0.91 -- 
p(TETA/CBA)5k-
g-PEG2k 
8.9 10.6 1.19 22.3 ± 3.4 29.1 ± 2.6 -- 0.96 
bPEI 25 kDa 16.4 
 
21.0 1.28 32 ± 2.9 -- -- -- 
 
a Number average molecular weight (Mn), weight average molecular weight (Mw), and polydispersity (Mw/Mn) determined using 
AKTA/FPLC and light scattering using relevant polymer refractive index increments (dn/dc).  b  Polymer fraction buffer capacity 
titrations determined by the mol of HCl required to shift pH from 7.4 to 5.1 in 0.1M aqueous NaCl. c The number of disulfide bonds 
per molecule was determined by reduction of disulfide bonds with immobilized tris(2-carboxyethyl)phosphine (TCEP) followed by 
the reaction of free sulfhydryls with 5,5-Dithio-bis-(2-nitrobenzoic acid) and analyzed using UV-Vis spectrometry. d Degree branching 
was determined by reduction of disulfide bonds with tris(2-carboxyethyl)phosphine (TCEP) followed by protection of free sulfhydryls 
with N-ethylemaleimide (NEM) and analyzed by MALDI-TOF. e The molar ratio of PEG to p(TETA/CBA) was determined using 1H 
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Figure 3.5.  Physiochemical characteristics of p(TETA/CBA)5k and p(TETA/CBA)5k-g-
PEG2k/pCMVLuc polyplexes.  a) Particle size and b) !-potential measurements of each 
respective gene carrier at increasing polymer concentrations using a known amount of 
pDNA. PEG2k conjugation to p(TETA/CBA) reduces polyplex surface charge, but 






























Figure 3.6.  Polyplex stability in 90% rabbit serum at 37°C for p(TETA/CBA)5k, 
poly(TETA/CBA)5k-g-PEG2k, 10/90 (10% PEG) and 50/50 (50% PEG) formulations for 
p(TETA/CBA)5k-g-PEG2k and p(TETA/CBA)5k, respectively. 500ng pCMVLuc was 
complexed with each formulation N/P 50 (w/w 24). The relative percent of intact pDNA 
over time was determined by band pixel intensity using GelDoc software. Increasing the 








































Figure 3.7.  Polyplex formulations visualized with TEM (a-d) (scale bar equals 200nm) 
and studied using DLS (e) at 24 w/w. a) p(TETA/CBA)5k b) 10% PEG c) 50% PEG d) 
p(TETA/CBA)5k-g-PEG2k. e) Particle size and !-potential of polyplex formulations; 

















Figure 3.8. Transfection efficiency (a,c and e) and cell viability (b, d and f) in 10% serum 
on SVR, HUVEC and CT-26 cells for different p(TETA/CBA) molecular weight analogs 
compared to the positive control bPEI 25kDa. pCMVLuc was used as the reporter gene. 
Commercial bPEI 25 kDA and p(TETA/CBA) polyplexes were prepared at N/P 10 (1.3 











































































































































Figure 3.9. Comparison of p(TETA/CBA)5k/pCMVLuc transfection efficiency in the 
presence and absence of 10% serum in culture media. Transfection efficiency was 
evaluated by luciferase transgene expression in CT-26 cells. The presence of 10% serum 
in culture media mitigated transfection efficiencies for bPEI 25kDa N/P 10 (w/w 1.3) and 
p(TETA/CBA)5k at N/P 50 (w/w 24), however, p(TETA/CBA)5k provides significantly 
better transfection  than bPEI 25kDa in the presence of 10% serum containing media.  

































Figure 3.10. a) Transfection efficiency of p(TETA/CBA)5k,10/90, 50/50 and 0/100% 
p(TETA/CBA)5k/p(TETA/CBA)5k-g-PEG2k polyplex formulations with CMVLuc in 
the presence and absence of serum. The 10% and 50% PEG formulations provide 
significantly greater transgene expression than bPEI 25kDa and p(TETA/CBA) in the 
presence of serum.  Moreover, their transfection efficiencies are not significantly affected 
by the presence of 10% serum in conditioned media. b) Cell viability with analogous 
polyplex formulations in serum-containing media.  Data are represented as mean ± SD, 
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FUNCTIONAL PROPERTIES AND BIODISTRIBUTION OF POLY 
(TRIETHYLENETETRAMINE/CYSTAMINE-BIS-ACRYLAMIDE)  
AND POLY(TRIETHYLENETETRAMINE/CYSTAMINE- 
BIS-ACRYLAMIDE)-POLY(ETHYLENE GLYCOL)  
MIXTURES FORMED WITH NUCLEIC ACID2 
 
4.1 Abstract 
 The clinical success of nonviral gene delivery reagents is hampered by their 
inefficient cellular transgene delivery, which is largely influenced by carrier properties 
that are currently undefined and misunderstood. In an attempt to further define and 
understand the requirements for a safe and efficient nonviral gene delivery reagent, 
research labs often engineer and evaluate many putative products with subtle 
physiochemical differences in order to delineate requirements for improved in vitro and 
in vivo success of their novel systems.  The synthesis of many putative reagents is often 
time-intensive, laborious and costly.  In Chapter 3, two physiochemically different 
polycations were synthesized, poly(triethylenetetramine/cystamine-bis-acrylamide)5k 
                                                
2 Brumbach, J. H., Lee, Y. W., Kim, S. W. and Yockman, J. (In Review) Functional 
Properties and Biodistribution of poly(triethylenetetramine/cystamine bisacrylamide) and 
poly(triethylenetetramine/cystamine bisacrylamide)-pol(ethylene glycol) mixtures formed 
with nucleic acid. Journal of Controlled Release. (Reprinted with permission). 
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(p(TETA/CBA)5k) and its PEGylated counterpart, poly(triethylenetetramine/cystamine-
bis-acrylamide)5k-g-poly(ethylene glycol)2k (p(TETA/CBA)5k-g-PEG2k) and they were 
mixed together at different ratios in order to easily derive a panel of putative gene 
delivery reagents to study their physiochemical properties and biological activity with a 
range of PEG concentrations.  This approach proved to easily identify improved reagents 
in vitro, and it avoided the synthesis of many putative candidates for study.   The studies 
herein utilize the aforementioned facile approach to study chemically similar polycationic 
reagents that are obtained with synthetic ease via one-pot synthesis. Reagent 
physiochemical properties and in vitro bioactivity are studied prior to investigating their 
in vivo biodistribution profiles in a murine colon adenocarcinoma model.  Findings in 
these studies indicate that negatively charged complexes formed with the reagents and 
plasmid DNA (pDNA) exhibit greater passive tumor accumulation than positively 
charged complexes following their systemic administration.  These studies warrant 
further investigation into the use of negatively charged gene delivery reagents for passive 
tumor targeting, and they substantiate the use of polycation/PEG-polycation mixtures to 
easily derive a panel of putative gene delivery reagents for study in order to elucidate 




 Although polycationic gene carriers have been used in a laboratory setting for 
over a decade, their clinical application has been stalled because clinical requirements 
have not been fully achieved.  A better understanding of their synthesis, design and 
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implications of carrier structure and function on biological systems is imperative to their 
advancement from the lab to the clinic.  In addition to ensuring gene carrier safety and 
efficacy, it is important to design carriers that maintain synthetic ease and avoid laborious 
production methods that may be inefficient (1) . Probably the most important preclinical 
requirement for gene carrier success is their in vivo safety, followed by efficiency.  
Unlike viral methods of gene delivery, nonviral gene carriers are relatively safe if 
designed and/or modified prudently, as they are relatively nonimmunogenic.  Another 
advantage of nonviral gene carriers compared to viral delivery is that they can also be 
synthesized so that they exhibit multifunctional properties, similar to viral capsids, 
however, more cost-effectively and with production ease (2-4).  
 Since the dawn of gene delivery, a large number of nonviral polymers and 
copolymers have been designed, synthesized and tested for their safety and efficacy in 
vitro and in vivo.  Probably the most rigorously studied class of polycationic gene 
carriers is the poly(ethylene imine)s (PEIs). This is because they were among the first 
carriers to easily condense nucleic acids into nucleic acid/polycation nanoparticles 
(polyplexes) that sufficiently protected nucleic acid from serum nuclease degradation and 
they maintain relatively high transfection efficiency in multiple cell types.  In recent 
years, however, the synthesis and design of biodegradable polycations have been focused 
on because nondegradable polycations, such as PEI systems, exhibit cellular toxicity at 
relatively low concentrations.  This toxicity results from intracellular accumulation of 
high-molecular weight species that ultimately interfere with intracellular processes that 
ultimately lead to cell death (3, 5).  Interestingly, low molecular weight PEIs maintain 
relatively low cellular toxicity compared to high molecular-weight PEI and also produce 
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low levels of gene delivery and subsequent transgene expression (6-8).  Biodegradable 
polycations have gained attention because they can be synthesized as high molecular 
weight products for improved nucleic acid condensation, protection and transfection 
efficiency, all-the-while exhibit low cellular toxicity because they degrade into small 
molecular weight species and avoid intracellular accumulation and cell perturbation.  
Several noteworthy classes of biodegradable polycations include: hydrolysable poly(!-
amino ester)s, disulfide containing and reducible poly(amido amine)s (SS-PAAs) and 
poly(amido ethylenimines) (SS-PAEIs).  These classes, in general, have provided similar 
or improved cellular transgene delivery compared to PEIs; however, because of their 
degradability, they have proven to be significantly less toxic (9-12).  Moreover, 
degradable carriers including cationic methacrylamide-based polymers have been studied 
in vitro and in vivo using tumor models, and although their molecular weight exceeds the 
maximum molecular weight to allow efficient glomerular filtration (45 kDA), they 
maintain efficient renal clearance due to their degradation (13, 14). 
 As mentioned previously, preclinical advancement of polycationic gene carriers is 
hampered by their safety and efficacy in vivo.  Many previous reports have shown that 
cationic polyplexes interact with negatively charged macromolecules found in serum and 
the extracellular space.  These interactions are therapeutically unfavorable because they 
often lead to particle aggregation and reduced efficacy (15, 16).  Poly(ethylene glycol) 
(PEG) conjugation to various classes of polycations has been employed to overcome this 
problem and improve carrier performance in vivo.  By avoiding this problem, 
therapeutically active payload can be delivered and the circulation half-life of polyplex is 
increased, which can be a major advantage to in vivo gene delivery.  This is especially 
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true for cancer therapy where the Enhanced Permeability and Retention (EPR) effect may 
be exploited by long circulation half-lives of macromolecules (17, 18).  
 Previously published results included in Chapter 3 indicate that mixtures of a 
polycation and PEG-polycation can be used for gene delivery.  Moreover, by altering the 
relative amount of each species in the mixture, reagent properties could be easily 
manipulated for study and improved gene delivery candidates could be identified without 
synthesizing many putative products (19).  In this present work, chemically similar gene 
carriers are obtained using a new synthetic method with greater synthetic ease.  These 
products, however, are physiochemically different from those described in Chapter 3, 
having a higher absolute molecular weight and lower degree of PEG modification. 
Mixture formulations of these products are developed using the approach outlined in 
Chapter 3 and the results presented herein provide further evidence that formulation 
mixtures can be used to derive a panel of gene delivery reagents to study carrier 
physiochemical properties, bioactivity and their in vivo biodistribution following their 
systemic administration using a murine colon adenocarcinoma model. Moreover, in vivo 
studies indicate that negatively charged complexes formed with these reagents and 
plasmid DNA (pDNA) demonstrate improved passive tumor accumulation compared to 
positively charged complexes following their systemic administration.  These studies 
warrant additional investigation into the use of negatively charged gene delivery reagents 





4.3 Materials and Methods 
4.3.1 Materials 
     Hyperbranched poly(ethylene imine) (bPEI, Mw 25 000 (bPEI25kDa)), 
Triethylenetetramine (TETA) and HPLC grade methanol were purchased from Sigma-
Aldrich (St. Louis, MO).  N,N’-cystamine-bis-acrylamide (CBA) was purchased from 
Polysciences, Inc. (Warrington, PA). Ultrafiltration devices along with regenerated 
cellulose membranes (10 kDa) were purchased through Millipore Corporation (Billerico, 
MA).  The reporter gene plasmid, pCMVLuc, was previously designed by inserting 
luciferase cDNA into a pCI plasmid (Promega, Madison, WI) that is driven by the pCMV 
promoter.  The resulting plasmid was purified using Maxiprep (Invitrogen, Carlsbad, CA) 
protocols. Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin streptomycin, 
trypsin-like enzyme (TrypLE Express), and Dubelcco’s phosphate buffered saline were 
purchased from Gibco BRL (Carlsbad, CA). Fetal bovine serum (FBS) was purchased 
from Hyclone Laboratories (Logan, UT).  
    
4.3.2 p(TETA/CBA) Synthesis 
 Synthesis of p(TETA/CBA) was performed with minor adaptation to the synthesis 
described in Chapter 3 and that described elsewhere (10). The polymerization reaction 
was run at 30°C for 12 hrs using equimolar amounts of N,N’-cystamine-bis-acrylamide 
(CBA) and triethylenetetramine (TETA) monomers.  At 12 hrs, excess TETA was added 
to the reaction mixture to terminate polymerization. The reaction was allowed to run for 
an additional 24 hrs to ensure termination. The pH was subsequently adjusted to 7.0 and 
the polymer was purified by ultrafiltration using a 10kDa regenerated cellulose 
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membrane.  p(TETA/CBA) was obtained by lyophilization. Composition of the polymer 
was monitored using1H NMR (400 MHz, D2O). p(TETA/CBA) ! 2.61 (COCH2CH2NH, 
4H), 2.72 (NHCH2CH2S-S, 4H), 2.90-3.21 (COCH2CH2NHCH2CH2,16H), 3.41 
(NHCH2CH2S-S, 4H). 
 
4.3.3 p(TETA/CBA/PEG) Synthesis 
 The synthesis of p(TETA/CBA/PEG) was performed as a one-pot synthesis, 
which eliminated the purification step required in Chapter 3 to obtain p(TETA/CBA) 
prior to its PEG chemical modification.   This one-pot synthesis of p(TETA/CBA/PEG) 
began with  the original polymerization reaction conditions described above in Section 
4.3.2 for p(TETA/CBA).  However, following 10 hrs reaction time methoxy PEG-NHS 
was added to the reaction mixture and allowed to react for an additional 2 hrs before the 
addition of excess TETA (100%).  The reaction was allowed to proceed for an additional 
24 hrs before the pH was lowered to 7.0 and the polymer was purified using ultrafiltration 
(10 kDa) The composition of p(TETA/CBA/PEG) was also monitored using 1H NMR 
(400 MHz, D20). p(TETA/CBA/PEG); ! 2.61 (COCH2CH2NH, 4H), 2.72 
(NHCH2CH2S-S, 4H), 2.90-3.21 (COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-
S, 4H), 3.45-3.7 (CH2CH20, 4H). 
     
4.3.4 p(TETA/CBA) and p(TETA/CBA/PEG) Characterization 
       Absolute molecular weight analysis for p(TETA/CBA) and p(TETA/CBA/PEG) was 
performed using AKTA/FPLC (Amersham Pharmacia Biotech Inc.) coupled to a light-
scattering detector and using the polymer refractive index increment (dn/dc) for each 
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sample. A Superose 6 110/300 GL column was used for polymer sample separation. 
Poly[N-(2-hydroxypropyl)methacrylamide] (poly(HPMA)) standards were injected onto 
the column prior to experimental sample analysis in order to ensure the column was clean 
and functional. Experimental and standard polymer samples were dissolved in degassed 
and filtered (0.2 µm (Nylon, Alltech)) 0.3 M NaOAc, pH 4.4 with 30% (v/v) acetonitrile 
eluent buffer. The flow rate was set to 0.4 mL/min. 
 
4.3.5 Determination of Polymer Disulfide Bonds 
 Disulfide bond content of each polymer was determined using 5,5-Dithio-bis-(2-
nitrobenzoic acid) (Ellman's reagent) following the manufacturer’s protocol with minor 
adaptation (Pierce).  In brief, cysteine hydrochloride was used as a stardard to generate a 
standard curve monohydrate.  Polymer molecular weights were used to estimate the 
number of disulfide bonds in each polymer and to further normalize the average thiolate 
concentration so as to fall within the standard range.   Each polymer sample was reduced 
using 10x immobilized (Tris(2-carboxyethyl)phosphine hydrochloride) (TCEP) gel in 
buffer (0.1 M sodium phosphate, pH 8, 1mM EDTA).  Following 30 min incubation to 
ensure complete polymer reduction, the samples were centrifuged at 1000 x g for 2 min 
and the reduced polymer solutions were collected.  Reduced polymers were subsequently 
added to the Ellman’s reagent in buffer and allowed to incubate at room temperature for 
20 min after mixing. The sample absorbance at 412 nm was measured using UV-Vis 
spectroscopy. The thiol concentration was determined using the standard curve.  Polymer 
average molecular weights were then used to determine the number of disulfide bonds 
per polymer. 
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4.3.6 Polyplex Formation 
 In all cases polyplex was formed with a known amount of pDNA and a 
corresponding and desired amount of polymer suspended in HEPES buffer (20 mM, pH 
7.4, 5% glucose).  The two solutions were combined, lightly vortexed and allowed to 
equilibrate for 30 min at room temperature.  When mixtures of the two polymers were 
used to form polyplex, a known amount of pDNA was brought up in HEPES buffer and a 
corresponding and desired concentration of p(TETA/CBA) and p(TETA/CBA/PEG) were 
prepared in buffer.  The polymer solutions were mixed prior to polyplex formation at a 
given polymer concentration and a desired amount of each species before the resulting 
mixtures were added to the pDNA solution to form complex. 
     
4.3.7 Gel Retardation Assay 
 Polymer/pDNA complexation was investigated by generating polyplex prepared 
at increasing polymer-to-pDNA (p(TETA/CBA) or p(TETA/CBA/PEG)) weight-to-
weight ratios (w/w) in HEPES buffered solution (20 mM HEPES, pH 7.4, 5% glucose). 
Polyplex was formed using 500ng pDNA and a corresponding amount of polymer.  The 
polymer/pDNA mixtures were then allowed to incubate at room temperature for 30 min 
prior to being loaded on a 1% agarose gel that was stained with ethidium bromide (EtBr, 
5µg/mL) at 104 V for 30 min in TAE (40 mM Tris-acetate, 1 mM EDTA) buffer.  The 





4.3.8 Light Scattering and "-Potential Measurements 
 The surface charge and polymer/pDNA particle (polyplex) diameters were 
measured at 25°C using a Zetasizer 2000 instrument  (DTS5001 cell) and a dynamic light 
scattering (DLS) unit on a Malvern 4700 system, respectively. Polyplexes were prepared 
by adding equal volume polymer solution (200µl) at increasing concentrations in HEPES 
buffer (20 mM, pH 7.4, 5% glucose) to a desired concentration of 8 µg pDNA in HEPES 
buffer (200µl).  Polyplexes were allowed to equilibrate for 30 min and were subsequently 
diluted in filtered milliQ water to a final 2 mL volume. 
 
4.3.9 Polyplex Stability in Fresh Rabbit Serum 
 Polyplex stability and resulting pDNA stability against nuclease activity in serum 
was evaluated using 500ng free pDNA as a control and 500ng pDNA complexed with 
polymer mixtures pre-formed in HEPES buffer. Polyplex formation was carried out by 
combining equal volume solutions of pDNA and polymer mixtures using a 
polymer/pDNA at 12 w/w (N/P 25) and allowed to equilibrate for 30 min. Pre-formed 
polyplex was then diluted in 90% fresh rabbit serum and incubated at 37°C over time.  
Twenty-five microliter aliquots (125 ng pDNA) were taken at each time point and 10 µl 
stop buffer (250 mM NaCl, 25 mM EDTA, 2% SDS) was added to each. The samples 
were frozen at -70°C until further analysis.  Once the samples were thawed, they were 
incubated overnight at 60°C to completely dissociate polycation from the pDNA and 2 µl 
of 50 mM DTT were added to each sample and incubated at 37°C for an additional 30 
min to ensure complete decomplexation.  Lastly, the samples were loaded onto a 2% 
agarose gel stained with ethidium bromide (EtBr) and subjected to electrophoresis at 96 
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V for 30 min in TAE (40 mM Tris-acetate, 1 mM EDTA) buffer.  The gel image was 
viewed using GelDoc software (n=2). 
     
4.3.10 Cell Culture and In Vitro Transgene Expression 
 Mouse colon adenocarcinoma cells (CT-26) (ATCC) were cultured in DMEM 
containing 10% FBS and 1% penicillin-streptomycin at 37°C in a humidified incubator 
with an atmosphere containing 5% (v/v) CO2.  Subculturing of cells was performed when 
cells reached 70-80% confluency.  Luciferase reporter gene expression in mouse colon 
adenocarcinoma cells (CT-26) was performed in vitro using respective polymer and 
pCMVLuc plasmid DNA mixtures. Cells were plated in 24-well plates containing 0.5mL 
media. Once the cells were approximately 70% confluent, polyplexes were prepared 
using 0.5µg pDNA and a respective amount of polymer or polymer mixture in HEPES 
buffer.  Polyplexes were allowed to equilibrate for 30 min and the cells were transfected 
in the presence of serum by adding 20 µl polyplex (0.5 µg pDNA) to each well for 4 hrs 
before replacing with fresh culture media. The cells remained in the incubator for a total 
of 48 hrs before they were washed with 1ml PBS and treated with cell culture lysis buffer 
(Promega). Luciferase quantification was performed using a Luciferase assay system 
(Promega) on a luminometer from Dynex Technologies, Inc. (Chantilly, VA). The 
amount of protein in the cell lysate was determined using a standard curve of bovine 
serum albumin (Sigma) and a BCA protein assay kit (Pierce) (n=6).        




4.3.11 Cell Viability Assay 
 CT-26 cells were plated in 24-well plates and gene transfections were carried out 
when the cells were approximately 70% confluent. Polyplexes were prepared as they 
were for the luciferase reporter gene assay. Respective cell cultures were transfected in 
the presence of serum with the addition of 20 µl equilibrated polyplex in HEPES buffer 
solution (0.5 µg pDNA) to each well. Cells were left to incubate for a total of 18 hrs prior 
to analyzing their viability using an MTT assay (Sigma). Percent cell viability was 
determined relative to untreated cells (n=6). 
 
4.3.12 Erythrocyte Lysis Assay 
 Following anticoagulation, fresh rabbit erythrocytes were isolated using a ficoll 
density gradient using centrifugation on a Sorval 6 swing bucket rotor at 900 x g for 20 
min at room temperature. The supernatant was removed and the Red Blood Cell (RBC) 
pack was resuspended in 10ml of 0.5% NaCl and mixed thoroughly by pipetting. The 
solution was then spun at 600 x g in order to remove any remaining serum proteins. The 
erythrocytes were then diluted 100x in 20mM HEPES buffer containing 5% glucose. An 
equal number of cells were plated in each well using a 24-well cell culture dish. 
Polyplexes were formed as described above at increasing polymer concentrations using 
500ng pDNA and added to the culture dish. The study was done in triplicate with 





4.3.13 In vivo Polymer Biodistribution Study 
 Mouse colon adenocarcinoma cells (CT-26) suspended in 100µl sterile PBS were 
subcutaneously injected (1 x 106 cells) into the right flank of 6-week old female Balb/c 
mice. Primary tumors were allowed to form over 2 weeks or until they reached an 
average tumor volume near 80 mm3. Outliers were discarded to maintain this average.  A 
total volume of 200µl polyplex solution was injected intravenously into each mouse via 
the tail vein after polyplex was formed.  Polyplex was prepared using the p2CMVIL-12 
(Figure 4.1) plasmid and 25, 50 75 and 100% p(TETA/CBA/PEG) polymer formulations 
at 0.5 w/w and 3 w/w in HEPES buffer (20 mM HEPES, pH 7.4, 20% glucose).  The 
weight-to-weight (w/w) ratios were chosen based on particle size and surface charge.  
Mice were sacrificed at 40 hrs post-injection by isoflurane overdose and tissues (heart, 
lung, liver, spleen, kidneys, and tumors) were excised.  Excised tissues were immediately 
flash-frozen with liquid nitrogen (N2) and placed in 2ml shatter-proof tubes with 
zirconia/silica beads (Bio-Spec Products, Bartlesville, OK) that had been preweighed. 
The samples were weighed in the tubes and the previously recorded weight was 
subtracted to get the weight of the tissue. One milliliter of protease inhibitor solution 
(complete Ultra Tablets (Roche)) was added to each tube and the samples were 
homogenized on a mini-bead beater. Samples were subsequently stored at -80°C until 
used for DNA isolation.  DNA was isolated using a Wizard SV 96 Genomic DNA 
Purification Kit (Promega) in accordance with the manufacturer’s directions. The 
obtained DNA was measured by UV spectrophotometry using a Nanodrop ND-1000. 
260/280 values lower than 1.7 were discarded and re-processed.  qPCR was performed 
using FastStart Universal master mix and a StepOne Real-Time Thermocycler (Applied 
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Biosystems). Taqman primers specific for the p2CMVIL-12 plasmid were used.  A serial 
dilution of total DNA was set-up using an untreated control sample to generate a standard 
curve with spiked controls each time qPCR was run.  Concentrations ranged from 500 to 
10 ng in order to determine optimal concentrations with the spiked controls. Each 
concentration was spiked with 1 x 105 copies of p2CMVIL-12. The primer sequences are 
as follows: AmpF-CGTGTCGCCCTTATTCCCTTTT; AmpR-
AAACGCTGGTGAAAGTAAAAGATGC. The total copy number for each sample was 
determined and normalized to mg tissue. 
 
4.3.14 Statistics 
 The experimental data in this report are assessed as mean ± SD.  A one-way 
ANOVA in conjunction with a Tukey’s post-hoc test is used to determine if treatment 
groups are statistically different from each other.  A p < 0.05 was considered statistically 
significant (n=6).  For serum stability studies, a posttest for linear trend was performed in 
addition to a two-way ANOVA with a Bonferroni post-hoc test.  Data are represented as 
mean ± SD, p < 0.05 (n=3). 
 
4.4 Results 
4.4.1 p(TETA/CBA) and p(TETA/CBA/PEG) Synthesis  
and Characterization 
 The objective of the studies herein was to develop a co-polymeric gene carrier 
with the same chemical functionalities as that developed in Chapter 3 but with a higher 
molecular weight and different degree of modification in order to justify the use of gene 
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carrier mixture formulations for carrier optimization beyond the synthetic products 
produced previously in Chapter 3.  This newly synthesized co-polymeric gene carrier, 
deemed p(TETA/CBA/PEG), was produced using a one-pot synthetic approach.  
Evidence herein demonstrates that p(TETA/CBA/PEG) can be used alone for cellular 
transgene delivery of pDNA and in conjunction with p(TETA/CBA) to derive a panel of 
putative gene delivery reagents with various physiochemical properties that influence 
carrier bioactivity.  By doing so, efficacy studies are more easily performed to understand 
the design and formulation requirements that govern ideal nonviral gene carrier 
properties and their bioactivity in vitro and in vivo.  We have previously shown that a 
graft copolymer of PEG and p(TETA/CBA)5k (p(TETA/CBA)5k-g-PEG2k) can be used 
in this manner for similar studies in vitro (19).   
 1H NMR analysis was used to confirm the synthesis of p(TETA/CBA/PEG) and 
identify the degree of PEG modification for p(TETA/CBA/PEG) (Figure 4.2). 1H NMR 
confirmed that a 10 wt % feed ratio of PEG during synthesis resulted in a final 
conjugation of ~4 wt % PEG (0.68/1 moles PEG/p(TETA/CBA)) following purification 
(Table 4.1).  PEG conjugation to the p(TETA/CBA) backbone is competed by hydrolysis 
of the PEG-NHS-ester and/or reaction with un-polymerized TETA monomer that is 
eliminated during subsequent polymer purification, which explains why there is only 
40% conversion. Absolute molecular weight analysis using AKTA/FPLC indicates that 
similar molecular weight polymers were obtained following synthesis and purification, 
with polydispersity indices (PDIs) of 1.54 and 1.27 for p(TETA/CBA) and 
p(TETA/CBA/PEG)), respectively (Table 4.1).  Chemical conjugation of the amine-
reactive PEG-NHS-ester with unpolymerized TETA monomers will reduce the incidence 
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of TETA monomer addition to late-stage growing oligomer chains.  As such, 
p(TETA/CBA) oligomers generated during the final stages of polymerization more likely 
exist in the p(TETA/CBA) sample than p(TETA/CBA/PEG) and explain the lower PDI 
and higher Mn of p(TETA/CBA/PEG) compared to p(TETA/CBA). The number of 
disulfide bonds per molecule are similar between the two samples and were determined 
using Ellman’s reagent and calculated based on the molecular weight of each sample  
(Table 4.1).   Moreover, the degree of branching for p(TETA/CBA) is in agreement with 
our previously published result and those described in Chapter 3, which demonstrate that 
synthesis temperature influences the degree of branching for the obtained products (Table 
4.1) (19). 
 Plasmid DNA (pDNA) complexation using p(TETA/CBA) and 
p(TETA/CBA/PEG) were investigated.  Results from this study indicate that both gene 
carriers form interactions with pDNA as polymer concentrations increase.  The 
p(TETA/CBA) product demonstrates partial pDNA complexation at 0.1 w/w 
(p(TETA/CBA)/pDNA) and complete complexation as the polymer concentrations are 
increased to achieve  4 w/w (Figure 4.3).  Moreover, complexation with pDNA using 
p(TETA/CBA/PEG) begins around 0.2 w/w and complete pDNA encapsulation is 
achieved at 6:1 w/w (Figure 4.3).  The increased amount of p(TETA/CBA/PEG) (6 w/w) 
required to fully encapsulate the pDNA compared to p(TETA/CBA) (4 w/w) suggest that 
incorporation of PEG to p(TETA/CBA) mitigates complexation as seen in Chapter 3 and 
in other studies (20, 21).  The steric effects of the PEG chains reduce polycation 
association with pDNA. 
 Given the aforementioned influence of PEG on polyplex formation using 
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p(TETA/CBA/PEG) alone, mean particle diameter and surface charge were investigated 
using mixtures of  p(TETA/CBA) and p(TETA/CBA/PEG) at different ratios and as 
individual species.  Both gene carriers and the mixture formulations (25, 50 and 75% 
p(TETA/CBA/PEG)/p(TETA/CBA)) formed polyplex at or below 100nm when a 
polymer/pDNA w/w ratio equal to 3 and greater are used. A dramatic increase in particle 
size is seen at 1 w/w regardless of the formulation mixture tested, which indicates that 
complete pDNA/polymer complexation does not occur at or below this ratio and 
aggregation of the complexes occurs (Figure 4.4).  Aggregation is overcome as the 
polymer amount is increased to 3 w/w via charge-charge dispacement of the aggregated 
complexes and excess polycation.  When particle surface charge was evaluated for each 
formulation, positive polyplex was formed at 3 w/w (Figure 4.4), which further indicates 
that complete pDNA encapsulation occurs at this ratio.   
 The ability of each polymer formulation to condense and protect pDNA from 
serum nuclease degradation was evaluated.  Following polyplex formation using each 
polymer formulation at 12 w/w, the samples were added to fresh rabbit serum (90% 
serum) and allowed to incubate at 37°C for 6 hrs.  All formulations significantly enhance 
nucleic acid protection from serum nuclease degradation when compared to free pDNA at 
1, 2, 4 and 6 hrs (Figure 4.5).  A posttest for linear trend indicated significant changes in 
the percent of intact pDNA remaining over time for all treatments.  Moreover, increasing 
amounts of p(TETA/CBA/PEG) correspond with lower protective effects in serum, as 
75% and 100% p(TETA/CBAPEG) treatments provide approximately 25 and 20% less 
intact p(DNA) compared to p(TETA/CBA) at 6 hrs incubation in 90% serum, 
respectively.  Increasing the amount p(TETA/CBA/PEG) in reagent formulations 
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mitigates the protective affects of the polycation system because PEG sterically mitigates 
complexation with pDNA, which leads to less payload protection.  Despite their reduced 
capacity to protect pDNA from serum nuclease degradation, 75 and 100% 
p(TETA/CBA/PEG) protect approximately 65% pDNA over 6 hrs (Figure 4.5).  These 
data indicate the advantage of formulating pDNA with polycations for improved pDNA 
protection against serum nuclease degradation, and they demonstrate the influence of 
PEG content on formulation stability, which may be tailored to influence formulation 
stability and functional payload delivery in vitro and in vivo were serum proteins are 
present. 
     
4.4.2 p(TETA/CBA) and p(TETA/CBA/PEG) In Vitro Bioactivity 
 The bioactivity of each formulation was assessed in the mouse colon 
adenocarcinoma cell line CT-26.  To do so, luciferase transgene expression and cell 
viability were evaluated using each polymer mixture formulation (0, 25, 50 and 75% 
p(TETA/CBA/PEG)/p(TETA/CBA)). When p(TETA/CBA) was used alone for 
transfection, it provided similar transgene delivery to control bPEI 25kDA used at 0.5 
w/w (Figure 4.6) .  The transfection efficiency for bPEI 25kDA when performed at 1 w/w 
was not included because this condition exhibited significant cell toxicity and accurate 
transgene expression could not be determined for this treatment (Figure 4.6). The 
p(TETA/CBA) and p(TETA/CBA/PEG) formulations presented no toxicity to the cells 
when used at 12 w/w, exemplifying its biocompatibility in this cell line, as these 
concentrations are 12x greater than that used for bPEI 25kDa, which imposed 
approximately 80% cell death.  Moreover, the p(TETA/CBA/PEG) formulations showed 
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comparable, or greater, transgene delivery and expression compared to the relevant bPEI 
25kDa control (Figure 4.6).  Most importantly, the 75% p(TETA/CBA/PEG) reagent 
provided significantly better transfection than the other formulations when compared to 
the bPEI  25kDa control.  The other formulations tested do not provide significantly 
better transfection compared to bPEI 25kDa (Figure 4.6). 
 In order to study the effect of p(TETA/CBA) and p(TETA/CBA/PEG) on red 
blood cell (RBC) lysis, polyplexes were prepared at various polymer/pDNA w/w ratios 
and administered to each well, respectively. Cells were visualized by light microscopy 
following 4 hrs incubation with polyplex. Increasing concentrations of p(TETA/CBA), 
but not p(TETA/CBA/PEG), correlated with RBC aggregation and lysis (Figure 4.7).  
Most noticeably, nearly 85% of the erythrocytes had been lysed by p(TETA/CBA) 
treatments around 6 w/w over the 4 hrs incubation period, whereas, p(TETA/CBA/PEG) 
treatments at the same concentration had no noticeable lysis and/or increase in cell 
aggregation (Figure 4.7).  It is useful to also evaluate the affect of formulation mixtures 
on RBC lysis.  Formulations were not tested; however, these results indicate the 
advantage that p(TETA/CBA/PEG) has on maintaining RBC integrity. 
     
4.4.3 p(TETA/CBA) and p(TETA/CBA/PEG) In Vivo Biodistribution 
 The biodistribution of 25, 50, 75 and 100% p(TETA/CBA/PEG)/p(TETA/CBA) 
formulations was studied using a murine adenocarcinoma model (CT-26), following 
systemic administration via mouse tail vein.  The p(TETA/CBA) gene delivery reagent 
alone was not evaluated because previous studies have demonstrated the importance of 
PEG shielding in polyplex administration performed systemically and the RBC lysis 
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assay indicated adverse effect on RBC viability and aggregation (2, 22).  In lieu of this 
understanding and finding for the RBC assay, tumor bearing mice were injected with 
polyplex formulations at 0.5 and 3 w/w ratios using the panel of 25, 50, 75 and 100% 
p(TETA/CBA/PEG)/p(TETA/CBA) formulations.  
 Organ accumulation values at 48 hrs postinjection were determined using 
quantitative PCR (qPCR) and are represented as the Percent Initial Dose (%ID) for lung, 
liver, spleen kidney, heart and tumor (Table 4.2).  These data indicate that positively 
charged complexes formed at 3 w/w had markedly high liver accumulation (9.35 ± 7.19 - 
14.78 ± 5.14 %ID), compared to the other organs that ranged between 0.02 ± 0.00 and 
4.69 ± 5.99 %ID (Table 4.2).  No significant trend, however, was observed between the 
p(TETA/CBA/PEG) formulations.  Conversely, the negatively charged complexes had 
similar payload deposition between organs with the exception of heart that possessed 
nearly no pDNA accumulation.  One-hundred and 75% p(TETA/CBA/PEG) formulation 
used at 3 w/w exhibited lower liver accumulation but relatively higher spleen 
accumulation compared to the 50 and 25% p(TETA/CBA/PEG) formulations, which may 
be due to their relative size and surface charge.  No significant trend was observed 
between negatively-charged p(TETA/CBA/PEG) formulations.  
 The %ID values for the negatively charged complexes were markedly lower than 
those values obtained for the positively charged complexes, which indicates decreased 
encapsulation and/or protection of pDNA at 0.5 w/w compared to 3 w/w during systemic 
circulation.  Interestingly, however, negatively charged complexes exhibited greater 
passive tumor accumulation compared to the positively charged complexes and the data 
is represented graphically in Figure 4.8.  Moreover, despite the reduced pDNA protection 
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of the negatively charged complexes compared to positively charged complexes in vivo, 
the %ID values at the tumor site were similar between the two (Table 4.2 and Figure 4.8).  
By achieving similar payload delivery to the tumor site using complexes formed using 6x 
less polycation, potential dose-limiting toxicities from the polymer reagents can be 
avoided during systemic administration of nucleic acids using modified polycation 




 In the present work, a new synthetic strategy is employed in order to obtain a 
PEGylated SSPAEI (p(TETA/CBA/PEG)) that can be used in conjunction with the 
polycationic backbone polymer, p(TETA/CBA), and by itself for nucleic acid delivery.  
By formulating mixtures of the two species, the relative amount of each polymer can be 
easily altered to affect gene carrier characteristics that influence carrier efficacy, 
bioactivity and biodistribution. Using this facile approach, various gene carrier 
characteristics are studied more easily and identification of optimal candidates is 
expedited. 
 Pegylation of p(TETA/CBA) proved to reduce the ability of the gene carrier to 
condense and form complex with pDNA (Figure 4.3).  This finding is in agreement with 
previous reports, which showed that complexation is influenced by the molar amount and 
the chain length of PEG introduced to a polycation carrier that further influences complex 
size and stability (23).  DLS studies herein, in conjunction with findings provided in 
Chapter 3 corroborate this influence of PEG, as complex size and stability tend to 
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correlate with the amount of PEG in each formulation mixture (19).  Particles around 
100-120 nm in diameter were formed for all formulations when complexed at 3 w/w and 
above.  Interestingly, similar unimodal particle sizes (90-140 nm) were seen at 0.5 w/w 
ratios with a marked increase in size at 1 w/w.  This indicates that complete pDNA 
condensation does not occur below 3 w/w. The large particles found at 1 w/w appear to 
be partially complexed, not having enough polymer to fully condense the pDNA and 
large complex sizes indicate probable interparticle interaction and aggregation.  Charge-
charge displacement of these aggregates occurs as  the polycation concentration is 
increased to reach 3 w/w.  Moreover, the surface charge of polyplexes below 3 w/w are 
close to neutral and in some cases negatively charged, which further suggests the 
incomplete protection of pDNA by the polycation formulations. 
 In vitro bioactivity was evaluated for p(TETA/CBA) and the respective 
p(TETA/CBA/PEG) formulations, which include 25, 50, 75 and 100% by weight of the 
latter species.  Significant cell toxicity is seen using bPEI 25kDa at 1 w/w, while the 
bioreducible polymer formulations p(TETA/CBA) and p(TETA/CBA/PEG) imposed no 
toxicity at 12 w/w.  The amount of polycation used in the p(TETA/CBA) and 
p(TETA/CBA/PEG) formulations is significantly greater than that used for bPEI controls, 
thus exemplifying the advantage of using a degradable gene carrier system with respect 
to biocompatibility and cell toxicity.  Mixture formulations of 
p(TETA/CBA/PEG)/p(TETA/CBA) are able to deliver viable transgene to CT-26 cells as 
well or better than the bPEI 25kDa control at 0.5 w/w. Cells treated with 75% 
p(TETA/CBA/PEG)/pDNA showed a statistically significant increase in transgene 
expression compared to the bPEI 25kDa control. This formulation exhibited good 
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complexation characteristics with pDNA and due to the amount of PEG incorporated in 
this formulation likely maintains the steric repulsion of serum proteins present in the 
transfection media and avoids their adverse affect on transfection.  All the while this 
reagent’s positive surface charge assisted in cell association of complexes and their 
subsequent endocytosis (24). The 100% p(TETA/CBA/PEG) formulation may have 
provided less transgene expression than the 75% p(TETA/CBA/PEG) formulation despite 
sufficient PEG present to sterically reduce serum protein adsorption because this 
formulation showed a marked decrease in surface charge seen at this weight-to-weight 
ratio (12 w/w) (Figure 4.4)  This formulation also exhibited reduced stability and pDNA 
protection in serum during the initial hours of incubation.  Increasing amounts of 
p(TETA/CBA/PEG) in polyplex formulations corresponded with lower protective effects 
in serum over 6 hrs, and strong effects in the first 2 hrs, which may be explained by 
reduced nucleic acid condensation (Figure 4.5) (23).  
 The ability of p(TETA/CBA) and p(TETA/CBA/PEG) to induce RBC lysis were 
investigated prior to evaluating the biodistribution profiles of the polymer formulations.  
Noticeably, increasing concentrations of p(TETA/CBA), and not p(TETA/CBA/PEG), 
induced erythrocyte lysis and aggregation.  The difference in the behavior of these two 
treatment groups may be explained by their respective ability to disrupt RBC membrane 
stability, where cell membrane intercalation of polycationic chains is sterically reduced in 
the p(TETA/CBA/PEG) formulation due to the presence of PEG chains.  In addition, 
oxidant strength has been shown to influence RBC viability (25).   Because intracellular 
enzymes that facilitate the degradation of disulfide-containing systems function to protect 
the cell from oxidative stress, it is plausible that this difference of RBC lysis between 
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p(TETA/CBA) and p(TETA/CBA/PEG) is due to a slower degradation profile of 
p(TETA/CBA/PEG) compared to p(TETA/CBA).  A slower degradation rate for 
p(TETA/CBA/PEG) can occur due to the presence of PEG that sterically reduces 
enzymatic degradation of the gene delivery reagent.  If degradation is slowed due to the 
putative steric effects of PEG, the cell can manage oxidative stress more effectively, as 
the enzymes are more free to maintain their redox homeostasis and thus maintain RBC 
viability.   Further studies must be performed to determine this potential. 
 A biodistribution study was performed using a murine colon adenocarcinoma 
model in order to examine the potential differences in organ distribution of pDNA 
following systemic administration using each gene carrier formulation (25, 50, 75 and 
100% p(TETA/CBA/PEG)) in vivo. Injection of positively and negatively charged 
complexes was also investigated in order to study potential differences of their 
biodistribution profiles. Each aforementioned gene carrier formulation was administered 
using 0.5 or 3 w/w, which derive negatively or positively charged complexes, 
respectively (Figure 4.4).  Results from this study indicate that all p(TETA/CBA/PEG)  
formulations administered at 0.5 w/w exhibit significantly lower %ID values in each 
organ compared to the formulated complexes derived using 3 w/w.  The reduced %ID 
values determined in each organ following systemic delivery of the negatively charged 
complexes is explained by the insufficient protection of pDNA payload from serum 
nuclease degradation during circulation, as DLS results indicated that pDNA was not 
fully encapsulated by the formulations at 0.5 w/w.  Interestingly however, the negatively 
charged complexes showed greater passive tumor accumulation than positively charged 
complexes.  Moreover, those complexes formed at 0.5 w/w that possessed the greatest 
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negative surface charge, 75% p(TETA/CBA/PEG)  (-20 ± 2.5 mV) and 25% 
p(TETA/CBA/PEG)  (-9.8 ± 3.5 mV), exhibited greater tumor accumulation than 100% 
TCP (1.1 ± 0.9 mV) and 50% p(TETA/CBA/PEG)  (-4.3 ± 3.8 mV) at 0.5 w/w, which is 
irrespective of PEG content.  A similar result was found in a previous study and may be 
explained by the ability of negatively charged complexes to avoid interaction with 
glycosaminoglycans (GAGs) present at relatively high levels in the tumor environment.  
By avoiding interactions with GAGs, these complexes can penetrate tumors more 
effectively than complexes with a high positive surface charge that often adsorb to 
GAGs, which leads to their destabilization and tumor delivery (26, 27).  Taken together, 
these results suggest potential advantages of negatively charged gene and drug delivery 
reagents for passive tumor targeting and warrant further investigation using polycations 
or other polymeric delivery reagents.  
 The biodistribution profile of positively charged complexes demonstrated a high 
degree of liver accumulation compared to the other major organs that were evaluated.  
This finding is similar to other previously published results using PEGylated polycations 
as gene delivery reagents (28).  Moreover, positively charged complexes formed using 
100% and 75% p(TETA/CBA/PEG)  formulations demonstrated reduced liver deposition 
compared to 50% and 25% p(TETA/CBA/PEG)  formulations, with an inverse 
relationship toward their accumulation in the spleen.  A correlation between complex 
physiochemical characteristics and this difference in organ deposition does not exist.  
However 25% p(TETA/CBA/PEG)  complexes formed at 3 w/w did provide the lowest 
complex size and surface charge compared to the other formulations, which correlated 
with relatively high liver deposition and significantly low spleen accumulation.  This 
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distribution profile suggests potentially low interaction of these complexes with serum 
proteins and thus the evasion of the reticuloendothelial system (RES).  Moreover, the 
relatively small size of these complexes may facilitate their extravasation through liver 
endothelial fenestrae, as extravasation of nanoparticles is size dependant (29).  While this 
explanation may explain the observed organ distribution profile, more rigorous studies 
are required to assert this putative correlation, as the aforementioned differences are 
subtle and the correlation is not statistically definitive.  Nonetheless, these studies 
demonstrate that mixtures of a synthesized polycation and its PEGylated counterpart can 
be formulated together in order to easily alter and control the relative amount of each 
species in a gene delivery reagent formulation and delineate changes in gene carrier 
properties and influence on bioactivity and biodistribution.  This facile evaluation method 
is particularly useful for novel, PEG-modified delivery reagents that possess a high 
degree of PEG modification that needs to be easily manipulated or controlled to identify 
optimal reagents that are delicately balanced by the advantages PEG chemical 
modification offers all-the-while avoiding putative adverse effects often seen when 
chemical modification is not optimized. 
 
4.6 Conclusion 
 The clinical application of polycationic gene carriers is impeded by un-defined 
design and formulation requirements that optimize safety and efficacy in vitro and in 
vivo. The work herein demonstrates that a copolymer comprised of polyethylene glycol 
(PEG) and a branched SS-PAEI, p(TETA/CBA/PEG) can be easily synthesized and used 
alone or in combination with the polycation, p(TETA/CBA), in order to easily formulate 
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putative polymeric gene delivery reagents mixtures that possess different physiochemical 
properties and function in order to identify optimal properties or delivery reagents.  By 
using mixtures of a polycation and modified polycation, the synthesis of many putative 
gene delivery reagents is avoided, which is often required to study reagent characteristics 
on biological activity in order to identify products that are functionally viable for in vitro 
and in vivo use.  Most importantly, this approach should be applied to other novel 
polycation-PEG preparations for this purpose and that described in Chapter 3.  Lastly, 
biodistribution results suggest the potential advantage of negatively charged, nano-sized 
delivery reagents for passive tumor targeting compared to positively charged reagents 












































21.7 33.4 1.54 0.79 82.3 ± 3.2 - 
p(TETA/CBA/PEG) 24.5 31 1.27 - 70.4 ± 2.7 0.68 
 
aAbsolute number average molecular weight (Mn), weight average molecular weight 
(Mw), and polydispersity (Mw/Mn) were determined using AKTA/FPLC.  bDegree 
branching (DB) was determined by reduction of disulfide bonds with tris(2-
carboxyethyl)phosphine (TCEP) followed by the protection of free sulfhydryls with N-
ethylemaleimide (NEM) and analyzed by MALDI-TOF.  DB was calculated using the 
equation presented in Chapter 3, Section 3.3.7.  c The number of disulfide bonds per 
molecule was determined by reduction of disulfide bonds with immobilized TCEP 
followed by the reaction of free sylfhydryls with 5,5-Dithio-bis-(2-nitrobenzoic acid) and 
analyzed using UV-Vis spectrometry.  dNMR was used to determine the molar ratio of 
PEG to p(TETA/CBA) backbone polycation by integrating p(TETA/CBA) and 
p(TETA/CBA/PEG) peak area under the curve (AUC). 
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Table 4.2. Biodistribution percent initial dose (%ID) of p(TETA/CBA/PEG) formulations 
Formulation w/w Lung Liver Spleen Kidney Heart Tumor 
25% TCP 3 2.03 ± 0.94 14.78 ± 5.14 0.72 ± 0.78 2.02 ± 0.88 0.33 ± 0.67 0.61 ± 0.44 
50% TCP 3 2.69 ± 1.30 14.67 ± 10.08 1.18 ± 0.39 0.27 ± 0.21 0.01 ± 0.00 0.32 ± 0.11 
75% TCP 3 1.01 ± 2.23 9.35 ± 7.19 4.69 ± 5.99 0.46 ± 0.66 0.02 ± 0.00 0.35 ± 0.28 
100% TCP 3 4.26 ± 3.28 10.59 ± 9.38 
 
3.35 ± 1.69 
 
0.88 ± 0.75 
 
0.54 ± 0.99 
 
1.37 ± 1.09 
25% TCP 0.5 0.17 ± 0.10 0.22 ± 0.12 0.35 ± 0.07 0.16 ± 0.08 0.01 ± 0.02 0.52 ± 0.03 
50% TCP 0.5 0.03 ± 0.01 0.14 ± 0.03 0.16 ± 0.07 0.01 ± 0.01 0.00 ± 0.00 0.30 ± 0.08 
75% TCP 0.5 0.23 ± 0.03 0.22 ± 0.13 0.35 ± 0.06 0.08 ± 0.09 0.01 ± 0.02 0.52 ± 0.05 
100% TCP 0.5 0.18 ± 0.11 0.63 ± 0.27 0.34 ± 0.15 0.14 ± 0.11 0.02 ± 0.00 0.24 ± 0.07 
 
*Values are shown as percent of injected dose (%ID) 48 hrs. following systemic injection and represent the mean ± standard deviation 







Figure 4.1.  p2CMV-mIL12 plasmid map  
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Figure 4.3.  Polymer/pDNA complexation was assessed using a gel retardation assay.  An 
equal volume solution of a) p(TETA/CBA) or b) mixture of 
p(TETA/CBA)/p(TETA/CBA/PEG) (75% p(TETA/CBA/PEG) was added to 500ng 
pDNA in HEPES buffered saline and allowed incubate for 30 min before being loaded on 
a 1% agarose gel, stained with EtBR, and then run for 30 min in TAE buffer.  Total 
polymer amounts in solution used for both experiments (a and b) where 1) 0.0µg (0 w/w), 
2) 0.025µg (0.05 w/w), 3) 0.05µg (0.1 w/w), 4) 0.1µg (0.2 w/w), 5) 0.5µg (1 w/w), 6) 
1µg (2 w/w), 7) 2µg (4 w/w), 8) 3µg (6 w/w), 9) 6µg (12 w/w), 10) 8µg (16 w/w). Gel 
























Figure 4.4.  Light scattering and !-potential measurements were performed to determine   
polymer/pDNA (polyplex) particle size (a) (diameter) and surface charge (b) at 
increasing polymer concentrations, indicated by polymer/pDNA weight-to-weight ratios 




























Figure 4.5.  Polymer protection of pDNA from serum nuclease degradation was assessed 
over time.  Free pDNA or polymer/pDNA mixtures at increasing polymer concentrations 
incubated in fresh rabbit serum. Samples were taken at 0, 1, 2, 4 and 6 hrs and evaluated 
for intact pDNA using gel electrophoresis (1% agarose).  Percent intact pDNA was 
normalized to the amount of intact free (unprotected) pDNA at 0 hrs. using GelDoc 
software.  All treatments offered significantly greater amounts of intact p(DNA) when 
compared to untreated control (Free p(DNA)) at 1, 2, 4 and 6 hrs.  A posttest for linear 
trend proved significant for each treatment group and the percent intact p(DNA) at 6 hrs. 
was significantly different between all treatment groups with the exception of 50% 
















Figure 4.6.  Transfection efficiency and cell viability for each polymer formulation were 
assessed in CT-26 cells. The formulations are denoted at the bottom of the graph. The 
wt% p(TETA/CBA/PEG) formulations are abbreviated as % PEG.  bPEI was used at 
0.5/1 and 1/1 w/w ratio for transfections.  The other formulations were used at 12 w/w.  
The RLU/mg protein was not included for bPEI 1/1 due to the significant toxicity 
observed.   The transfection data for 75% p(TETA/CBA/PEG) proved to be significantly 
better than p(TETA/CBA) and all other data sets were not significantly different from 







Figure 4.7.  The erythrocyte lysis assay demonstrates that Red Blood Cell (RBC) lysis 
and aggregation occur at increasing concentrations of p(TETA/CBA) (A-F); whereas 
high concentrations of p(TETA/CBA/PEG) do not correlate with RBC lysis. Polymer 
concentrations are as follows: A and G, 0.277µg; B and H, 0.415µg; C and I, 0.83µg; D 


































Figure 4.8.  Biodistribution of pDNA following systemic injection using 100, 75, 50 and 
25% p(TETA/CBA/PEG) formulations as delivery agents in a murine colon 
adenocarcinoma model. Data are represented as mean ± standard deviation (n = 5) of 
Percent Initial Dose (%ID).  a) Positively charged complexes formed at 3 w/w.  b) 
Negatively charged complexes formed at 0.5 w/w.  
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ACRYLAMIDE) AND POLY(TRIETHYLENETETRAMINE/ 
CYSTAMINE-BIS-ACRYLAMIDE)-g-POLY(ETHYLENE  
GLYCOL)-c(RGDfC) TO ENHANCE siRNA DELIVERY  
TO CANCER-RELATED CELLS 
 
5.1 Abstract 
 The cell-specific delivery of therapeutic nucleic acids using targeted gene carriers 
is vital for the clinical success of gene therapy.  This is especially advantageous for 
cancer gene therapy regimens, as these therapeutics often abrogate cell proliferation and 
survival, which is detrimental to noncancerous tissues and may lead to adverse side 
effects.  In the previous chapters, empirical evidence has shown that polycations can be 
used in conjunction with their PEGylated counterparts to improve the biological activity 
of gene carrier systems.  The studies presented herein provide evidence that peptide-
targeted gene carriers can also be used in conjunction with their nontargeted counterpart 







 The delivery of nucleic acid payload constitutes one of the most critical steps for 
successful gene therapy (1, 2).  Despite extensive research in the field, a major limitation 
for the clinical success of nonviral gene delivery reagents is their low transfection 
performance.  Nonetheless, further research perseveres to modulate structural sizes, 
shapes and functional surface properties to improve their delivery.  This research has 
proven to be quite slow and often costly, as multiple optimization steps and synthetic 
products are required to gradually improve the performance of gene delivery systems.  In 
the previous two chapters, a novel approach through combining a polycation gene carrier 
with its modified/PEGylated counterpart has proven effective for easily altering gene 
carrier characteristics to identify optimal candidates for pDNA delivery. Using this 
approach, the synthesis of multiple candidates during the optimization process is avoided.   
The work outlined in this chapter covers the synthesis of a peptide-targeted polycation 
system to improve the delivery of therapeutic siRNA to targetable, cancer-related cells.  
Following synthesis, this putative siRNA delivery reagent will be evaluated, in 
conjunction with its nontargeted PEG-polycation and polycation counterpart for its ability 
to condense siRNA into nano-sized polyplex and enhance the delivery of therapeutic 
siRNA to specific cells that are pertinent to cancer and its therapy. 
 Since its discovery, RNA interference (RNAi) has showed increasing promise as a 
new approach toward the inhibition of gene expression in vitro and in vivo.  As such, it 
presents large potential for the treatment of human diseases (3-5).  The inhibition of gene 
expression via RNAi occurs with the sequence-specific binding of siRNA to the target 
messenger RNA (mRNA) and subsequent mRNA degradation, which halts the translation 
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of the encoded protein. Specifically, once inside the cell, duplexed siRNA associates with 
a multiprotein complex known as RNA induced silencing complex (RISC) and upon its 
incorporation, the siRNA sense strand is cleaved while the antisense strand remains 
incorporated and directs the RISC complex to the target mRNA for cleavage (6).  Once 
the mRNA is cleaved, the antisense strand loaded RISC can cleave additional target 
mRNAs, thus making RISC-mediated regulation of gene expression a powerful catalytic 
event (7). 
 The ability of siRNA to down-regulate the production of specific mRNA 
sequences is particularly useful for the treatment of diseases that arise from the over-
expression of specific genes, which is often the case for cancer.  A major genetic player 
for cancer progression and metastasis is hypoxia-inducible factor 1 (HIF-1), which 
regulates the transcription of multiple genes involved in cancer cell survival, cell 
differentiation, vascularization of surrounding tissues and metastasis.  HIF-1! over-
expression, specifically, is a prognostic factor in many cancers and is associated with 
increased patient mortality.  As a result, HIF-1! inhibitors have been developed as novel 
anticancer agents and have shown clinical promise (8, 9).  RNAi of HIF-1! over-
expression provides a promising therapeutic approach as well.  However, in order to be 
therapeutically viable, delivery of RNAi sequences to the appropriate cells is mandatory.  
As with other nucleic acid based therapeutics, RNAi sequences have a difficult time 
crossing the cell membrane, as they have relatively high molecular weight (~13 kDa) and 
strong anionic charge imposed by the phosphodiester backbone.  Naked siRNA is also 
highly susceptible to nuclease degradation, which renders it inactive.  Therefore, the 
development of safe and efficient delivery vehicles for siRNA therapeutics is imperative 
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to circumvent these obstancles.  As with pDNA, non-viral polycations offer great 
potential as siRNA delivery reagents (10). 
 Previous reports have demonstrated the enhanced delivery and tissue specificity 
of nucleic acid payload to cancer-related cell types that overexpress the cell-surface 
integrin receptor, !V"3, which is a known marker of angiogenic vascular tissue and 
cancer cells although it is also expressed at relatively low levels on other cell types such 
as macrophages (11, 12). Enhanced gene delivery to these tissues was accomplished by 
incorporation of the !V"3 integrin-binding peptide motif, RGD on the polycationic gene 
carrier branched polyethylenimine (bPEI) with a hydrophilic poly(ethylene glycol) (PEG) 
spacer (13, 14).   
 Based on these previous studies, a peptide-targeted polycation system was 
developed to improve the delivery of therapeutic siRNA against HIF-1! to !V"3 
expressing cells.  This peptide targeted gene carrier was developed using a known !V"3 
integrin-binding RGD peptide with high affinity, c(RGDfC), in conjunction with a PEG 
spacer chemically conjugated to the biocompatible polycation used in Chapter 3, 
p(TETA/CBA) (15, 16).  Mixtures of this targeted polycation, p(TETA/CBA)-g-PEG-
c(RGDfC) and p(TETA/CBA) are evaluated to study their ability to complex with the 
therapeutic HIF-1! siRNA cargo as well as there biological activity in vitro.  In vitro 
biological activity is investigated using a lung carcinoma cell line (A549), fibrosarcoma 
cell line (HT-1080) and an endothelial cell line (HUVEC) that are known to exhibit high 
levels of !V"3 integrin and the therapeutic target, HIF-1! (17-21).  To evaluate the tissue 
specificity of the gene carrier mixtures, an epithelial cell line (HEK293T) devoid of !V"3 
expression was used as a negative control (22).  The results herein provide a promising 
  
136 
foundation for the use of polymeric mixtures to study targeted polymeric gene carrier 
systems and their use in siRNA delivery. 
 
5.3 Materials and Methods 
5.3.1 Materials 
 Triethylenetetramine (TETA), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC), N-hydroxysulfosuccinimide (sulfo-NHS) and HPLC grade 
methanol were purchased from Sigma-Aldrich (St. Louis, MO).  N,N’-Cystamine-bis-
acrylamide (CBA) was purchased from Polysciences, Inc. (Warrington, PA). 
Ultrafiltration devices and regenerated cellulose membranes (10 kDa) were supplied by 
Millipore Corporation (Billerico, MA). HO-PEG3500-COOH and MAL-PEG3500-NHS 
were purchased from JenKem USA (Allen, TX). The c(RGDfC) peptide was purchased 
from Peptides International, Inc. (Louisville, KY).  siRNA sequences were purchased 
from Integrated DNA Technologies (IDT) (San Diego, CA).  Primers specific for HIF-1! 
and GAPDH mRNA were obtained from the University of Utah Protein/Nucleic Acid 
Core Facility (Sat Lake City, UT).  RNAeasy Purification columns were purchased from 
Qiagen (Valencia, CA). SuperScript III First-Strand synthesis system for RT-PCR was 
supplied by Invitrogen, Corp. (Carlsbad, CA) and the GoTaq Green Master Mix for PCR 
was obtained through Promega (Madison, WI).  Dulbecco’s Modified Eagle’s Medium 
(DMEM), penicillin streptomycin, trypsin-like enzyme (TrypLE Express), and 
Dubelcco’s phosphate buffered saline were purchased from Gibco BRL (Carlsbad, CA). 
EBM-2 with EGM-2 singlequots was purchased from Lonza. Fetal bovine serum (FBS) 
was purchased from Hyclone Laboratories (Logan, UT).  
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5.3.2 p(TETA/CBA) Synthesis 
 Synthesis of p(TETA/CBA) was performed with minor adaptation of the 
previously described method. The polymerization reaction was run at 30°C for 12 hrs, at 
which time excess TETA was added to the reaction mixture and the reaction was allowed 
to run for an additional 24 hrs to ensure that the reaction had been terminated. The pH 
was subsequently adjusted to 7.0 and the polymer was purified by ultrafiltration using a 
10kDa regenerated cellulose membrane.  p(TETA/CBA) was obtained by lyophilization. 
Composition of the polymer was monitored using1H NMR (400 MHz, D2O). 
p(TETA/CBA) ! 2.61 (COCH2CH2NH, 4H), 2.72 (NHCH2CH2S-S, 4H), 2.90-3.21 
(COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-S, 4H). 
 
5.3.3 p(TETA/CBA)-g-PEG Synthesis 
 The carboxylic acid of HO-PEG-COOH was activated via NHS/EDC coupling 
using 4x molar excess of NHS and EDC to HO-PEG-COOH for 1 hr in PBS buffer (pH 
7.4).  The active HO-PEG-NHS ester was subsequently added dropwise to a stirred 
solution of p(TETA/CBA) dissolved in PBS buffer (pH 7.4). The reaction proceeded at 
room temperature for 4 hrs.  When the reaction was complete, the sample was purified by 
ultrafiltration (10kDa MWCO) before being lyophilized. The composition of 
p(TETA/CBA)-g-PEG3500 copolymer conjugate was analyzed using 1H NMR (400 
MHz, D20). p(TETA/CBA)-g-PEG3500 ! 2.61 (COCH2CH2NH, 4H), 2.72 
(NHCH2CH2S-S, 4H), 2.90-3.21 (COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-




5.3.4 p(TETA/CBA)-g-PEG-c(RGDfC) Synthesis 
 The synthesis of p(TETA/CBA)-g-PEG-c(RGDfC) began by dissolving a known 
amount of p(TETA/CBA) in PBS buffer (pH 7.4),  While the p(TETA/CBA) solution 
stirred at room temperature, 1.3x molar excess of MAL-PEG3500-NHS solution was 
added dropwise to p(TETA/CBA).  The reaction proceeded for 30 min, at which time 2x 
molar excess c(RGDfC) dissolved in 3% acetic acid was added to the reaction mixture.  
The pH of the reaction mixture was quickly adjusted to pH 7 using a NaOH. The reaction 
proceeded for 2 additional hours to allow the free sulfhydryl on the free cysteine 
contained in c(RGDfC) to react with the maleimide moiety at the distal end of the PEG 
chains.  The reaction mixture was subsequently purified by ultrafiltration (10kDA) in 
order to remove un-reacted peptide and PEG before being lyophilized. The composition 
of p(TETA/CBA)-g-PEG-c(RGDfC) copolymer was analyzed using 1H NMR to 
determine degrees of chemical conjugation to p(TETA/CBA). 1H NMR (400 MHz, D20). 
p(TETA/CBA)-g-PEG-c(RGDfC) ! 2.61 (COCH2CH2NH, 4H), 2.72 (NHCH2CH2S-S, 
4H), 2.90-3.21 (COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-S, 4H), 3.45-3.7 
(CH2CH20, 4H),  7.1-7.3 (CH, 5H). 
 
5.3.5 Polymer Characteristics 
 Absolute molecular weight analysis for p(TETA/CBA), and p(TETA/CBA)-g-
PEG and p(TETA/CBA)-g-PEG-c(RGDfC) was performed using AKTA/FPLC 
(Amersham Pharmacia Biotech Inc.) coupled to a light-scattering detector and using the 
polymer refractive index increment (dn/dc) for each sample. A Superose 6 110/300 GL 
column was used for polymer sample separation. Poly[N-(2-
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hydroxypropyl)methacrylamide] (poly(HPMA)) standards were injected onto the column 
prior to experimental sample analysis in order to ensure the column was clean and 
functional. Experimental and standard polymer samples were dissolved in degassed and 
filtered (0.2 µm (Nylon, Alltech)) 0.3 M NaOAc, pH 4.4 with 30% (v/v) acetonitrile 
eluent buffer. The flow rate was set to 0.4 mL/min. 
 
5.3.6 Determination of Polymer Disulfide Bonds 
 Disulfide bond content of each polymer was determined using 5,5-Dithio-bis-(2-
nitrobenzoic acid) (Ellman's reagent) following the manufacturer’s protocol with minor 
adaptation (Pierce).  In Brief, cysteine hydrochloride was used as a stardard to generate a 
standard curve monohydrate.  Polymer molecular weights were used to estimate the 
number of disulfide bonds in each polymer and to further normalize the average thiolate 
concentration so as to fall within the standard range.   Each polymer sample was reduced 
using 10x immobilized (Tris(2-carboxyethyl)phosphine hydrochloride) (TCEP) gel in 
buffer (0.1 M sodium phosphate, pH 8, 1mM EDTA).  Following 30 min incubation to 
ensure complete polymer reduction, the samples were centrifuged at 1000 x g for 2 min 
and the reduced polymer solutions were collected.  Reduced polymers were subsequently 
added to the Ellman’s reagent in buffer and allowed to incubate at room temperature for 
20 min after mixing. The sample absorbance at 412 nm was measured using UV-Vis 
spectroscopy. The thiol concentration was determined using the standard curve.  Polymer 





5.3.7 Polyplex Formation 
 In all cases polyplex was formed with a known amount of siRNA and a 
corresponding and desired amount of polymer each suspended in HEPES buffer (20 mM, 
pH 7.4, 5% glucose).  The two solutions were combined, lightly vortexed and allowed to 
equilibrate for 30 min. When mixtures of two different polymers were used to form 
polyplex, a known amount of siRNA was brought up in solution and a corresponding and 
desired concentration of p(TETA/CBA) and p(TETA/CBA)-g-PEG or p(TETA/CBA)-g-
PEG-c(RGDfC) were prepared by mixing the appropriate species at specified ratios 
before being added to the siRNA solution, lightly vortexed and allowed to equilibrate. 
      
5.3.8 Light Scattering Measurements 
 The particle size of polymer/siRNA particles (polyplex) was measured at 25°C on 
a dynamic light scattering (DLS) unit, BI-9000AT with a Digital Autocorrelator. 
Polyplexes were prepared by adding equal volume polymer or polymer mixture  solutions 
(200µl) at increasing concentrations in filtered HEPES buffer (20 mM, pH 7.4, 5% 
glucose) to a desired amount of siRNA (40µg), also suspended in filtered HEPES buffer 
(200µl).  Polyplexes were allowed to equilibrate for 30 min and were subsequently 
diluted in filtered milliQ water to a final 2 mL volume.  
  
5.3.9 Gel Retardation Assay 
 Polymer/siRNA complexation was  investigated by forming polyplex prepared at 
increasing polymer-to-siRNA weight-to-weight ratios (w/w) in HEPES buffered solution 
(20 mM HEPES, pH 7.4, 5% glucose). Polyplexes were formed using 200ng siRNA and  
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corresponding amount of polymer or polymer mixture.  The polymer/siRNA solutions 
were mixed, lightly vortexed and were then allowed to incubate at room temperature for 
30 min.  Following equilibration, the solutions were loaded on a 1% agarose gel that was 
stained with ethidium bromide (EtBr, 5µg/mL) at 104 V for 30 min in TAE (40 mM Tris-
acetate, 1 mM EDTA) buffer.  The siRNA was visualized using GelDoc software. 
 
5.3.10 Cell Culture 
 Human lung carcimoma cells (A549), human fibrosarcoma cells (HT-1080) and 
human embryonic kidney cells (HEK293T) were all cultured in DMEM containing 10% 
FBS and 1% penicillin-streptomycin at 37°C in a humidified incubator with an 
atmosphere containing 5% (v/v) CO2. Human Umbilical Vein Endothelial Cells 
(HUVEC) (Invitrogen) were cultured in EBM-2 media with EGM-2 singlequots at 37°C 
in a humidified incubator with an atmosphere containing 5% (v/v) CO2.  
     
5.3.11 In Vitro Transfections 
 The delivery of siRNA sequences against HIF-1! mRNA in cell culture was 
performed using polyplex formed by the addition of p(TETA/CBA), 75% 
p(TETA/CBA)-g-PEG/25% p(TETA/CBA) and/or 75% p(TETA/CBA)-g-PEG-
c(RGDfC)/25% p(TETA/CBA) to 0.115µg siRNA in HEPES buffer at polymer-to-
siRNA 6 w/w and equilibration for 30 min. Cells were previously plated in 24-well plates 
containing 0.5mL media. When HUVEC cells were plated, the media was supplemented 
with 200ng/mL VEGF165.  Once the cells were approximately 70% confluent, the 
polyplexes prepared, as described above, were added to each respective well (20nM 
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siRNA) containing fresh culture media with 10% FBS. The cells remained in the 
incubator for a total of 48 hrs before being collected and analyzed for HIF-1! mRNA 
expression.  A c(RGDfC) competition assay was performed using each cell line by pre-
incubating the cells with a 20-fold molar excess of free peptide (1.5µM)  30 min. prior to 
transfection as previously described (23, 24).   The siRNA sequences specific for HIF-1! 
mRNA were: 5’-TAGUUGGGUCUGUAUAGGUG-3’and 5’-
TCACCUAUACAGACCCAACU-3’.  The scrambled siRNA sequences were: 5’-
TUUUAAGGGCGCAAUGCGCA-3’ and 5’-TTGCGCATTGCGCCCTTAAA-3’. 
      
5.3.12 Cell Viability Assay 
 Cells were plated in 24-well plates and gene transfections were carried out when 
the cells were approximately 70% confluent. Polyplexes were prepared as they were for 
transfection experiments. The respective cell cultures were transfected in the presence of 
serum with the addition of 20 µl equilibrated polyplex in HEPES buffer solution 
(0.115µg siRNA) to each well. Cells were left to incubate for a total of 18 hrs before 
analyzing cell viability using an MTT assay (Sigma) following the manufacturers 
directions. Percent cell viability was determined relative to untreated cells (n=6). 
 
5.3.13 RT-PCR 
 In order to semiquantitatively evaluate HIF-1! mRNA expression and its 
potential knockdown following cell transfection, 48 hrs following treatment the cells 
were rinsed with 1ml PBS and collected using trypsin digestion. Total RNA was 
collected using Qiagen RNeasy Mini Spin Columns by following the manufacture’s 
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directions and the amount of RNA collected was assessed using a Nanodrop ND-1000 
UV spectrophotometer (Absorbance 240nm).  A total of 200ng of RNA was reverse 
transcribed using SuperScript III First-Strand synthesis system (Invitrogen).  Resulting 
cDNA was further amplified (2µl) using GoTaq Green Master Mix for PCR (Promega).  
The sequence of the specific nucleotide primers HIF-1! (176 bp) were forward: 5’-
TGGTTCTCACAGATGATGGTGAC-3’ reverse: 5’- GCTTCGCTGTGTGTTTTGTTC-
3’, GAPDH (216 bp) forward: 5’-GACCCCTTCATTGACCTCAACTAC-3’ reverse: 5’- 
AGATGATGACCCTTTTGGCTCC-3’.  The PCR reaction consisted of 95°C for 2 min, 
28 cycles at 95°C for 30 sec then 57°C for 30 sec and 72°C for 30 sec, which was 
followed by an extension of 5 min at 72°C before the PCR block dropped to 4°C to 
maintain the PCR product.  PCR products were separated by electrophoresis in a 2% 
agarose gel stained with ethidium bromide (EtBr, 5µg/mL) and run at 110 V for 30 min. 
Products were visualized using GelDoc software. 
 
5.3.14 Statistics 
 The experimental data for cell viability are assessed as mean ± SD (n = 6).  For 
RT-PCR analysis and mRNA knockdown, the data are represented as mean ± SEM 
derived from two separate experiments where n = 3.  A one-way ANOVA is used in 
conjunction with a Tukey’s post-hoc test to determine if treatment groups are statistically 







5.4.1 p(TETA/CBA)-g-PEG and p(TETA/CBA)-g-PEG-c(RGDfC)  
Synthesis and Characterization 
 The nucleic acid carrier p(TETA/CBA)-g-PEG-c(RGDfC) was synthesized to 
enhance the delivery of siRNA to cancer-related cell types compared to non-cancerous 
cells, and to provide evidence  that polymeric gene carrier mixtures can be used for 
targeted nucleic acid delivery systems in addition to the PEGylated systems covered in 
Chapters 3 and 4.   The use of mixtures for gene carrier formulation can assist in carrier 
development without the need of synthesizing many different putative products, which 
can be time and labor intensive as well as costly.  The synthesis scheme for 
p(TETA/CBA)-g-PEG-c(RGDfC) and the structure of the c(RGDfC) peptide used are 
shown in Figure 5.1.  1H NMR was used to confirm the synthesis of p(TETA/CBA)-g-
PEG-c(RGDfC) (Figure 5.2)  and p(TETA/CBA)-g-PEG (Figure 5.3) as well as estimate 
the amount of PEG-c(RGDfC) or PEG incorporated in the respective gene carrier 
products by integrating peak AUC.  Peak integration indicates approximately 0.88 and 
0.93 moles PEG incorporated in p(TETA/CBA)-g-PEG-c(RGDfC) and p(TETA/CBA)-g-
PEG, respectively.  1H peak integration also indicates 97% of the PEG chain chemically 
conjugated to p(TETA/CBA) had c(RGDfC) peptide also present (Table 5.1). Molecular 
weight analysis using FPLC indicates similar molecular weights and polydispersity 
indices (PDIs) below 1.8 for all three polymers used.  Molecular weight and PDI 
differences between the three polymer products were observed.  Specifically, 
p(TETA/CBA) had a relatively low absolute molecular weight and high PDI.  Because 
p(TETA/CBA) was only purified once, while the modified p(TETA/CBA) products were 
  
145 
obtained following two purification steps, oligomer polycations may not have been 
completely eliminated from the sample.  Moreover, p(TETA/CBA)-g-PEG-c(RGDfC) 
had the a relatively high molecular weight and PDI.  Because c(RGDfC) was conjugated 
to this product via its free sulfhydryl group, potential disulfide exchange with the 
p(TETA/CBA) backbone may occur as a side reaction, which will lead to uncontrolled 
crosslinking of the polycation resulting in higher molecular weight products and an 
increase in PDI.  The number of disulfide bonds per molecule is also presented for 
completeness (Table 5.1). 
 The complexation of  siRNA with p(TETA/CBA), 
25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG, 25%p(TETA/CBA)/75%p(TETA/CBA)-
g-PEG-c(RGDfC) and p(TETA/CBA)-g-PEG-c(RGDfC) alone was tested by gel 
retardation.  Results from this study demonstrate strong interaction of p(TETA/CBA) 
with siRNA as the amount of polymer is increased, as siRNA migration through the gel is 
abrogated at 1 w/w and above indicating complete complexation of the two entities.  
Interaction between siRNA and p(TETA/CBA)-g-PEG-c(RGDfC) appears to occur  at 3 
w/w, as indicated by a shift in siRNA band migration, however, complete entrapment of 
siRNA does not occur at 12 w/w or below.  Combining p(TETA/CBA) with 
p(TETA/CBA)-g-PEG-c(RGDfC) at 25%/75%, respectively, improves siRNA 
complexation compared to p(TETA/CBA)-g-PEG-c(RGDfC) alone and fully 
encapsulated the siRNA at 3 w/w ratio and above.  Complete siRNA encapsulation is also 
seen at 3 w/w using 25%/75% p(TETA/CBA) and p(TETA/CBA)-g-PEG, respectively 
(Figure 5.4).   As shown in previous chapters, increased polymer concentrations of the 
modified polycations are required to encapsulate nucleic acid, which indicates that PEG 
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and/or PEG-ligand modification of a gene carrier can mitigate its ability to interact with 
the payload of interest.  This effect has been seen in studies where PEG and targeting 
ligand conjugation affect nucleic acid condensation (14, 24). 
 To further investigate the influence of PEG-ligand modification on nucleic acid 
complexation, mean particle diameter of polyplex formed between siRNA and the 
aforementioned gene carrier formulations was assessed using Dynamic Light Scattering 
(DLS).  The p(TETA/CBA), 25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG and 
25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC) formulations form particles 
near 200nm at 6 w/w.  The p(TETA/CBA)-g-PEG-c(RGDfC) copolymer generates 
slightly larger particle than these formulations when combined with siRNA at 6w/w.  No 
further siRNA condensation is accomplished when p(TETA/CBA)-g-PEG-c(RGDfC) is 
used at 12 w/w (Figure 5.5).  These complexation results corroborate those from the gel 
retardation study.  The mean particle sizes using the p(TETA/CBA) formulation at 6 w/w 
began to show smaller particle sizes biased by excess, uncomplexed polymer in solution.  
This effect was seen using 25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG  and 
25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC) formulations at 12 w/w.  This, 
however, did not occur when p(TETA/CBA)-g-PEG-c(RGDfC) was used alone, which 
indicates that complete siRNA condensation does not occur at or below 12 w/w and that 







5.4.2 p(TETA/CBA)-g-PEG and p(TETA/CBA)-g-PEG-c(RGDfC)  
In Vitro Bioactivity 
 The bioactivity of p(TETA/CBA), 25%p(TETA/CBA)/75%p(TETA/CBA)-g-
PEG  and 25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC) formulations was 
assessed in vitro.  These specific formulations were chosen based on the aforementioned 
results obtained from the complexation studies, which indicated that these gene carrier 
formulations could completely complex with siRNA cargo at 6 w/w.  Each formulation 
was complexed with HIF-1! siRNA for a final concentration equal to 20 nM siRNA per 
well.   Formulation transfection efficiency was evaluated by assessing the relative 
knockdown of HIF-1! mRNA relative to untreated control in a lung carcinoma cell line 
(A549), a fibrosarcoma cell line (HT-1080) and an endothelial cell line (HUVEC) all 
known to express relatively high levels of !v"3 integrins on their cell surface compared to 
normal, noncancerous tissues (17-21).  Transfections were also performed in Human 
Embryonic Kidney cells (HEK293T), which serves as a negative control, as the basal 
levels of !v"3 integrin expression are extremely low (22).   For accurate analysis HIF-1! 
expression levels were normalized by the internal control, GAPDH.   
 Significantly enhanced HIF-1! mRNA knockdown occurred in the !v"3 
expressing cell lines when p(TETA/CBA)-g-PEG-c(RGDfC) was used in formulation 
with P(TETA/CBA) to deliver HIF-1! siRNA compared to the untargeted formulations, 
p(TETA/CBA) and p(TETA/CBA)-g-PEG (Figure 5.6).  This result indicates that 
incorporation of the targeting peptide c(RGDfC) on the p(TETA/CBA)-g-PEG backbone 
is sufficient to enhance nucleic acid delivery to these cell lines.  When these cells are pre-
incubated with 20-fold excess soluble c(RGDfC) peptide prior to transfection with the 
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formulation including p(TETA/CBA)-g-PEG-c(RGDfC), HIF-1! siRNA transcellular 
delivery is abrogated (Figure 5.6).  This result suggests that the c(RGDfC) peptide is 
necessary for enhanced nucleic acid delivery to these cell types.  Conversely, when 
HEK293T cells are treated with the same formulations, no significant HIF-1! mRNA 
knockdown is seen, which further indicates that the enhancement in siRNA delivery 
using p(TETA/CBA)-g-PEG-c(RGDfC) is enhanced by high levels of  !v"3 integrin 
expression an specific cell lines (Figure 5.6).  In all cell lines, the delivery of scrambled 
HIF-1! siRNA using the p(TETA/CBA)-g-PEG-c(RGDfC) formulation resulted in no 
significant knockdown in HIF-1! mRNA (Figure 5.6).  This result indicates that the HIF-
1! siRNA used for the transfection experiments is sequence specific for HIF-1! mRNA.  
Moreover, the cell viability of each cell line was assessed following treatment with each 
gene carrier formulation.  No significant toxicity was observed, indicating that the nucleic 
acid formulations tested are biocompatible and preincubation with free c(RGDfC) peptide 
imposes no cellular toxicity (Figure 5.6). 
 
5.5 Discussion 
 The co-polymer, p(TETA/CBA-g-PEG-c(RGDfC), was synthesized to develop a 
nucleic acid carrier that can enhance payload delivery to cancer-related cell types.  The 
studies described in this chapter provide evidence that peptide-targeted gene carriers can 
be used in conjunction with their nontargeted counterpart to formulate a gene carrier to 
improve cell-specific delivery of nucleic acid compared to carriers devoid of the targeting 
peptide in vitro.  Cell specific targeting of cancer-related cell types was accomplished 
using a peptide moiety, c(RGDfC) that has known affinity for !v"3  integrin, which is 
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often highly expressed in the tumor environment compared to normal tissues (14, 23).    
The high expression levels of these integrins on related cell types can be exploited using 
peptide moieties that confer specificity for these integrins to drive cellular uptake of 
nucleic acid payload.  
 Complexation studies using gel electrophoresis and Dynamic Light Scattering 
(DLS) revealed that p(TETA/BA), 25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG and 
25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC) could efficiently form 
polyplex with siRNA  at 6 w/w.  Conversely, p(TETA/CBA)-g-PEG-c(RGDfC) alone 
was not able to completely complex siRNA at 6 w/w.  These results indicate that the 
covalent attachment of PEG-c(RGDfC) to the p(TETA/CBA) backbone interferes with 
siRNA condensation.  This effect could be overcome using a gene carrier mixture 
comprised of 25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC).  In order to 
confirm that this mixture formulation maintained p(TETA/CBA)-g-PEG-c(RGDfC) in 
the polyplexes formed, and thus improve cell-specific delivery to cells containing high 
levels of !v"3 integrin expression, cell transfection experiments were performed.  
 Cell transfection experiments using the 25%p(TETA/CBA)/75%p(TETA/CBA)-
g-PEG-c(RGDfC) formulation demonstrated enhanced and cell-specific delivery of HIF-
1! siRNA to !v"3 integrin expressing cell lines, indicating that this formulation 
maintained the p(TETA/CBA)-g-PEG-c(RGDfC) species in polyplexes formed.  This 
finding is particulary important for this study, which aims to extend the use of mixture 
formulations to targeted nucleic acid delivery systems.  A previous report, and that which 
is outlined in Chapter 3, indicates that polycation and PEG-polycation mixtures can be 
used to alter gene carrier properties and improve their bioactivity.  If both species are not 
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incorporated into formed polyplex, altering the relative amount of each species between 
the formulations to monitor effective changes on bioactivity or biocompatibility is moot.  
It is possible that because of steric implications or charge masking effects, that the 
PEGylated or targeted species will exhibit a reduced capacity to complex with nucleic 
acid.  If this is the case, when high N/P or w/w ratios are used for polyplex formation and 
nucleic acid delivery, free uncomplexed polymer can interact with serum proteins to 
prevent serum interaction with polyplex, which may otherwise abrogate transcellular 
delivery, and will result in high transgene delivery that is nonspecific.  Because this study 
reveals that enhanced delivery occurs using a mixture with a targeted gene carrier, 
compared to nontargeted formulations, the enhanced nucleic acid delivery observed is not 
a product of nonspecific masking of serum proteins by free polymer, but rather receptor 
mediated enhancement due to the incorporation of the targeted species in the polyplexes 
formed.  
 The putative cell toxicity of each formulation was examined in the cell lines used 
to evaluate transcellular delivery of HIF-1! siRNA.  The formulations used were non-
toxic to all cell lines.  Previous reports have indicated that free, soluble peptide that 
contain the RGD motif used in our studies, can adversely affect the cell viability of 
human endothelial cells (HUVEC) and human leukemia cells (HL-60) (25).  If cell 
viability is compromised, transfection results have limited validity.  In fact, our studies 
indicate no cell toxicity of soluble c(RGDfC) in any of the cell lines tested, including 
cells pretreated with free c(RGDfC) peptide to perform the competition assay.  The 
discrepancy between the previous studies and ours is likely explained by the amount of 
free peptide used in the respective experiments.  Chemotaxis and cell viability of 
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HUVEC cells was compromised when peptide concentrations reached approximately 380 
µM, whereas the free peptide concentration used for the competition assay in this study 
was substantially less (1.5 µM) (25). Taken together, the studies described in this chapter 
provide evidence for the use of polymeric mixtures to study peptide-targeted gene carrier 
systems to improve gene carrier performance and biological activity.  
   
5.6 Conclusion 
 In conclusion, the empirical studies herein demonstrate that polymeric mixtures 
comprised of a peptide-targeted gene carrier and a corresponding polycationic backbone 
can be used to improve gene carrier properties and achieve enhanced siRNA delivery to 
targeted cell types. These findings are important for more rapid and cost-effective 
development of improved nucleic acid carriers, as this approach may be applied to other 
peptide-targeted preparations to easily alter carrier characteristics and identify optimal 























aNumber average molecular weight (Mn), weight average molecular weight (Mw), and 
polydispersity (Mw/Mn) determined using FPLC.  b Degree branching (DB) was 
determined by reduction of disulfide bonds with Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) followed by the protection of free sulfhydryls with N-
ethylmaleimide (NEM) and analyzed by MALDI-TOF.  Calculation was performed using 
the equation presented in Chapter 3 Section 3.3.7.  c The number of disulfide bonds per 
molecule was determined by reduction of disulfide bonds with immobilized TCEP 
followed by the reaction of free sulfhydryls with 5,5-dithio-bis-(2-nitrobenzoic acid) and 
analyzed using UV-Vis spectrometry.  d NMR was used to determine the amount of PEG 
and c(RGDfC) in the samples and the values are expressed as the molar ratio of PEG or 
c(RGDfC) per mole p(TETA/CBA).  The molar ratio was determined by integrating peak 
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Figure 5.1. p(TETA/CBA)-g-PEG-c(RGDfC) a) synthesis scheme and b) structure of 
















































Figure 5.4.  Polmer/siRNA complexation assessed using a gel retardation assay.  Equal 
volume solutions of a) p(TETA/CBA), b) 25% p(TETA/CBA)/75%p(TETA/CBA)-g-
PEG, C) p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC) or D) 100% 
p(TETA/CBA)-g-PEG-c(RGDfC) and 200 ng siRNA in HEPES buffered saline were 
combined at 0, 1, 3, 6, and 12 polymer to siRNA w/w ratios, respectively.  Following 30 
min equilibration, each sample was loaded on a 2% agarose gel, stained with EtBR, and 
then run for 30 min in TAE buffer. Gel images were obtained using GelDoc Software.  
Combining 25% p(TETA/CBA) with p(TETA/CBA)-g-PEG or p(TETA/CBA)-g-PEG-































Figure 5.5.  Intensity-based particle sizes of gene carrier formulations with siRNA using 
Dynamic Light Scattering (DLS). Formulation mixtures of 
25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC) show improved siRNA 

























Figure 5.6.  Transfection efficiency and cell viability in a) A549 cells b) HT-1080 cells c) 
HUVEC cells d) HEK293T cells.  In all graphs, 1) Untreated control 2) p(TETA/CBA) 3) 
p(TETA/CBA)-g-PEG 4) p(TETA/CBA)-g-PEG-c(RGDfC) 5) p(TETA/CBA)-g-PEG-
c(RGDfC)/c(RGDfC) competition 6) p(TETA/CBA)-g-PEG-c(RGDfC)/scRNA. HIF-1! 
and GAPDH RT-PCR products are shown below each graph.  Each formulation was 
combined with 20nM siRNA at 6 w/w. Transfection data are represented as mean ± SEM, 
*p < 0.05 or ***p < 0.0001 using a One-way ANOVA and Tukey’s post-hoc test (n=2). 
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SYNOPSIS OF RESULTS, CONCLUSIONS AND  
FUTURE PROSPECTS 
 
6.1 Synopsis of Results and Conclusions 
 Gene therapy offers a promising therapeutic alternative to conventional therapies 
that are currently marketed.  Its clinical success, however, is hampered by undefined 
design and formulation requirements to engineer a safe and efficient nucleic acid delivery 
vehicle. Previous studies have demonstrated that the use of disulfide-containing 
polycations, such as bioreducible poly(amido amine)s (SS-PAAs) and poly(amido 
ethyleneimine)s (SS-PAEIs), provide increased transgene expression and reduced cell 
toxicity compared to the ‘gold’ standard, poly(ethylene imine) systems (1, 2).  While 
these degradable systems maintain promising attributes for safe and efficient gene 
delivery vehicles, as with all other nonviral polycationic gene carriers, they must be 
further modified to improve their biocompatibility and maintain efficient application in 
vivo.  The chemical conjugation of a neutrally charged and hydrophilic polymer, 
poly(ethylene glycol) (PEG), to nonviral polycations has proven effective in promoting 
biocompatibility in vitro and in vivo, and it can also accommodate the incorporation of a 
targeting moiety to improve cell-specific activity (3). While PEG and/or PEG-ligand 
modification can be advantageous, it has also been shown to adversely affect nucleic acid 
 
163 
condensation and carrier performance depending on the gene carrier being used and the 
degree to which the carrier is modified (4, 5).  Resultantly, multiple synthetic products 
and optimization steps are required to gradually identify or improve the performance of 
gene therapy reagents (6).   In lieu of these findings, several copolymers were synthesized 
using the SSPAEI backbone, poly(triethylenetetramine/cystamine-bis-acrylamide) 
(p(TETA/CBA)), chemically grafted with PEG or PEG-peptide to improve the bioactivity 
and-or cell specificity of the SS-PAEI in the presence of serum.  Moreover, a novel 
method was employed to study the influence of PEG modification on the SSPAEI, which 
allowed easy manipulation over the relative amount of PEG-to-SSPAEI polycation 
incorporated in a gene carrier reagent to easily study and optimize formulations and avoid 
the synthesis of multiple potential candidates for optimization.  Each of the synthesized 
products was characterized by 1H NMR, acid-base titration linking an inverse correlation 
with the degree of PEG modification and buffer capacity, and FPLC for molecular weight 
analysis. 
 The ability of each synthetic product to form electrostatic interaction with nucleic 
acid (pDNA or siRNA) was evaluated at increasing polymer-to-nucleic acid 
concentrations by gel electrophoresis and/or dynamic light scattering (DLS) 
measurements.  Chemical modification of the polycations with PEG or PEG-ligand 
proved to mitigate the gene carrier’s ability to electrostatically interact with nucleic acid 
payload.  Incorporation of the polycation with the co-polymer formulation proved to 
overcome this effect and drive complexation of the polycation formulation with nucleic 
acid.  When various gene carrier mixtures were used to test their ability to protect pDNA 
from serum nuclease degradation, the formulations significantly enhanced the amount of 
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viable pDNA available after 6 hrs when compared to unformulated, free pDNA.  The 
results also indicated an inverse correlation between the amount of PEG maintained in a 
formulation and the protection of pDNA from serum nuclease degradation. 
 The bioactivity of the polymer formulations complexed with p(DNA) 
demonstrated that PEG modification of p(TETA/CBA) could improve cellular transgene 
delivery and expression in the presence of serum compared to the unmodified polycation 
and bPEI, however, the amount of PEG incorporated in the formulation had to be tailored 
to achieve an optimum, which is similar to previous reports (7). Tailoring the amount of 
PEG in the gene carrier formulations was made easy by using the aforementioned 
method, where the polycation and PEG-polycation species are mixed at different ratios.  
This facile method can be used for other gene delivery reagents in order to facilitate the 
optimization process and avoid the synthesis of many putative candidates. 
 The biodistribution of several mixture formulations was evaluated at a polymer-
to-pDNA weight-to-weight ratio that resulted in net-negatively charged polyplex and a 
weight-to-weight ratio that resulted in a net-positive charge.  Polyplex size of the 
formulations injected was similar irrespective of charge.  The relative amount of PEG 
present in each formulation provided no significant trend on biodistribution, however, 
differences between formulations were observed.  More noteworthy was that the 
formulations that maintained a net-negative charge exhibited significantly greater tumor 
accumulation compared to other major organs.  Conversely, the formulations that 
maintained a net-positive charge on polyplexes did not show any enhanced tumor 
accumulation compared to other organs, but they did deposit more payload in the 
respective tissue than the negatively charged polyplexes.   
 
165 
 Similar to the PEG-copolymers synthesized and evaluated in Chapters 3 and 4, 
the targeted siRNA delivery reagent, p(TETA/CBA)-g-PEG-c(RGDfC), showed a 
reduced ability to electrostatically interact with siRNA when compared to p(TETA/CBA) 
alone.  Moreover, incorporation of p(TETA/CBA) with p(TETA/CBA)-g-PEG-
c(RGDfC) in solution, helped drive electrostatic interaction with siRNA to encapsulate 
the siRNA and maintain nanosized particles (<200nm) that are sufficient for cellular 
uptake.  More importantly, in vitro cell transfection experiments using a 
25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-c(RGDfC) formulation mixture proved 
to enhance the delivery of HIF-1! siRNA specifically to !V"3 integrin expressing cell 
lines and not to cells devoid of this integrin receptor.  All formulations were non-toxic to 
the cell lines tested.  Enhanced transfection was abrogated in !V"3 integrin expressing 
cell lines when a competition assay was performed using free, soluble c(RGDfC) peptide, 
indicating that enhanced delivery to these respective cells is specific and driven by the 
!V"3 integrin-binding peptide, c(RGDfC).  This cell specific, enhanced delivery 
unequivocally indicates the inclusion of the p(TETA/CBA)-g-PEG-c(RGDfC) species in 
the polyplexes formed and substantiates the use of mixture formulations to study targeted 
gene delivery reagents.  For this practice to be commonly employed in order to expedite 
the product development of gene delivery reagents, further studies are inevitable. 
 
6.2 Future Prospects 
 The studies outlined in this dissertation demonstrate the improved bioactivity and 
tissue-specificity of PEG or PEG-ligand modified p(TETA/CBA), respectively.  In both 
cases, combining the polycation, p(TETA/CBA) with its modified counterpart proved to 
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influence carrier properties and bioactivity.  The use of gene carrier mixtures provides a 
promising approach to easily study the effects of modification on a nucleic acid delivery 
reagent and identify an optimal candidate.  Once the relative abundance of each species 
in an optimal delivery reagent is known, further research studies should retroactively 
engineer a copolymer system that is a direct counterpart to the optimal formulation and 
test the two gene carrier reagents against each other. In principle, the two reagents should 
exhibit similar biocompatibility and bioactivity. Additional studies are required to affirm 
this principle and provide stronger evidence for using mixture formulations to expedite 
the development of improved nucleic acid delivery vehicles. 
 While PEG modification of p(TETA/CBA) and the use of 
p(TETA/CBA)/p(TETA/CBA)-g-PEG mixtures has proven useful to improve the 
bioactivity of p(TETA/CBA), previous reports have indicated that PEG modification of a 
polycation can interfere with its buffering capacity and thus the intracellular release of 
nucleic acid from the endosome (8).  The reports herein indicate a modest reduction in 
buffering capacity of the PEG modified polycations, however, no significant adverse 
effect was seen on bioactivity. The buffering capacity of the mixture formulations was 
likely rescued by the presence of unmodified p(TETA/CBA).  Additional studies 
characterizing the number of 1°, 2° and 3° amino groups in the gene delivery reagents 
and respective formulations would be useful, as the composition of amino groups in a 
polycationic system critically influences buffering capacity and complexation properties 
with nucleic acid.  The amino content can be determined via Ninhydrin and 2,4,6-
trinitrobenzenesulfonic acid (TNBS) assays.  Moreover, to further improve the bioactivity 
of PEG-modified polycations, PEG conjugation that results in a physiologically triggered 
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release of the PEG chain should be evaluated.  Possible triggers may include changes in 
pH, enzyme concentrations or redox potential.  Acid-labile and disulfide-containing 
conjugates, or linkers susceptible to acid protease cleavage via cathepsins are all 
plausible for physiological release of PEG (1, 9, 10).   In addition, because the PEG 
content of formed polyplexes is an important parameter influencing their function, future 
studies that utilize mixture formulations as described throughout this dissertation should 
elucidate PEG and/or PEG-ligand content present in polyplexes formed.  Evidence in this 
dissertation demonstrated correlating trends between the amount of PEG included in 
formulation mixtures and reagent physiochemical and functional properties, however, a 
more thourough understanding of precise PEG/PEG-ligand incorporation to polyplex is 
important to further undrstand and advance gene delivery reagents. 
 
6.2.1 c(RGDfC) Binding Activity with !v"3 Integrins In Vitro 
 Additional studies should be performed to further assert c(RGDfC) activity in 
vitro, and evaluate the putative effect of polymer formulations on peptide binding affinity 
with the !V"3 integrin. The binding activity of free c(RGDfC) and c(RGDfC)-copolymer 
mixtures with the !V"3 integrin receptor on respective cell lines can be assessed using a 
competitive binding assay with 125I-echistatin, a known !V"3 integrin agonist (11, 12). 
This is performed by washing !V"3 integrin expressing cells with sterile PBS and 
subsequently re-suspending them in binding buffer (20mM Tris,  pH 7.4, 150mM NaCl, 2 
mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, 0.1%bovine serum alumina (BSA)) before 
seeding them in 96-well Multiscreen HV filter plates (0.45 µm; Millipore, Billerica, 
MA). At 5x104 cells/well.  The cells are then co-incubated with 125I-echistatin (0.05 nM) 
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and increasing concentrations of free peptide or equivalent concentrations of c(RGDfC)-
copolymer mixtures (0-100µM) at 4°C for 2 hrs in a final 200µl volume of buffer.  
Following co-incubation, the plates are subsequently filtered using a Multiscreen 
manifold with vacuum  (Millipore) and rinsed several times with cold binding buffer. In 
this case, 125I-echistatin can be harvested from the filters and the cell-bound 125I-
echistatin can be quantified using an automatic gamma-counter to determine binding 
activity. A nonlinear regression analysis can be used to determine IC50 values indicative 
of peptide binding affinity.  It is expected that the binding affinity of free and polymer-
bound c(RGDfC) is similar for the 25%p(TETA/CBA)/75%p(TETA/CBA)-g-PEG-
c(RGDfC) mixture given the in vitro cell culture results that indicate strong !V"3 integrin 
targeting of this formulation. 
 
6.2.2 In Vivo Biodistribution Study of p(TETA/CBA)-g-PEG-c(RGDfC)  
for siRNA Delivery to Primary Tumors 
 The synthesis and use of p(TETA/CBA)-g-PEG-c(RGDfC) produced promising 
in vitro results for the delivery of therapeutic HIF-1! siRNA to multiple cancer cell lines 
and angiogenic endothelial cells that have high levels of !V"3 integrin expression.  To 
continue this positive data and fully understand the therapeutic potential of this gene 
therapy combination, in vivo biodistribution and efficacy studies must be performed in an 
animal cancer model.  To perform the in vivo biodistribution study, an IVIS 200 Series 
Living image device (Xenogen) can be used, which would allow gene carrier dosing and 
biodistribution to be studied concurrently prior to the efficacy studies.  For this 
application, CT-26-Luc/GFP expressing colon carcinoma cells should be injected into 
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female BALB/c mice and allowed to grow until the average tumor volume is 
approximately 100mm3. Respective formulations should be complexed with cy3-labeled 
siRNA against luciferase or cy3-labeled scrambled siRNA as a negative control.  Three 
appropriate but different w/w ratios should be used for polyplex formation. Buffer 
(20mM HEPES with 20% glucose) and naked siRNA controls should also be used. The 
mice should be injected with 200µl of complexes totaling 5mg/kg of siRNA.  To monitor 
luciferase expression and the siRNA biodistribution (cy3 emission) mice must be injected 
intraveinously with 150 mg/kg of d-Luciferin (Xenogen Corporation, Alameda, CA) 
approximately 10 min before imaging.  For imaging, the mice must be anaesthetised with 
isofluorane (2.5%). Mice should be imaged at approximately 6, 12, 24, 36 and 48 hrs 
postinjection using Living Image software with XFO-6 fluorescence option and a 
bandpass filter program (Xenogen Corporation, Alameda, CA).  
 
6.2.3 In vivo Efficacy Study of p(TETA/CBA)-g-PEG-c(RGDfC) for  
HIF-1! siRNA Delivery to Primary Tumors 
 Respective gene carrier formulations should be complexed with 50ug of HIF-1! 
siRNA at the preferred w/w ratios identified in the biodistribution study. Buffer and 
naked siRNA controls should also be used.  Repeated injections should be performed 
intravenously every three days once the average tumor volumes reach approximately 
100mm3.  Tumor volume should be measured each time animals are injected in order to 
derive a tumor growth/inhibition curve.  Animals should be sacrificed when the buffer 
control animals are sacrificed due to excessive tumor size or complications. Tumors and 
other organs (lung, liver, kidney, spleen, blood, heart, stomach, ovary) should be excised 
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immediately and flash frozen in liquid nitrogen. The capillary density of the tumors 
should be evaluated and HIF-1! protein expression should be determined using an 
ELISA kit.  
 In addition, the potential immune response of the injected formulations should be 
studied.  To do so, blood samples should be taken at 6 and 12 hrs postinjection from the 
treated mice and evaluated for cytokine production using an appropriate ELISA kit. 
Relevant cytokines to be evaluated are: IFN-!, IFN-", IFN-#, IL-2 and IL-6.  Buffer-only 
animals should be used for comparison and mice treated with polyinosinic:polycytidylic 
acid poly(I):(C) should serve as positive controls.  
 Further work with these gene delivery reagents may include the use of 
conventional chemotherapy in conjunction with therapeutic nucleic acid such as HIF-1! 
siRNA.  Chemical modification of the polycation with chemotherapeutic agents is 
plausible if physiological release of the agent is achieved in order to maintain the 
therapeutic activity.  Examples for triggered physiological release are mentioned at the 
beginning of section 6.2.  Using a combined therapy with the targeted carrier, 
p(TETA/CBA)-g-PEG-c(RGDfC), may lend a synergistic anticancer effect and can 
reduce the off-target cytotoxicity of the chemotherapeutic agent.  If nonspecific 
cytotoxicity is reduced and synergistic anti-tumor effects are achieved, promising clinical 
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POL(ETHYLENE GLYCOL) MIXTURES  
FOR THERAPEUTIC SIRNA  




 The systemic delivery of pDNA with 75% p(TETA/CBA/PEG)/25% 
p(TETA/CBA) at 0.5 w/w ratio denoted here as 75% p(TETA/CBA/PEG), and the 100% 
p(TETA/CBA/PEG) at 3 w/w denoted herein as 100% p(TETA/CBA/PEG) formulations 
provided the greatest tumor accumulation of pDNA among the tested formulations 
(Section 4.4.3).  Most notably, the 75% p(TETA/CBA/PEG) formulation exhibited 
passive tumor accumulation and provided nearly 10-fold higher copy number/mg tissue 
in the tumor than the other major organs.  On the other hand, 100% p(TETA/CBA/PEG) 
showed comparable pDNA accumulation in the major organs when compared to the 
tumor, however showed approximately 5-fold higher copy number/mg tissue than the 
75% p(TETA/CBA/PEG) formulation. These nucleic acid carrier formulations are 
comprised of a polycationic unit and a hydrophilic, neutrally charged poly(ethylene 
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glycol) (PEG) chain.  Often the covalent incorporation of PEG to polycationic carriers 
can mask their surface charge and provide a steric barrier to avoid undesireable, non-
specific interaction with serum proteins that can lead to opsonization and removal of the 
delivery vehicle from the blood stream by the reticuloendothelial system (RES) (1-4).  If 
RES uptake of polyplexes is avoided, passive tumor accumulation and putative 
therapeutic efficacy may be improved because delivery carrier circulation times are 
lengthened.  Improved passive tumor accumulation of macromolecules and nucleic acid 
carriers is a product of the Enhanced Permeability and Retention Effect (EPR), which is 
commonly observed following systemic administration. However, the extent to which the 
EPR effect can be exploited by drug/nucleic acid delivery reagents depends on carrier 
characteristics, largely on individual tumor types that possess different 
pathophysiological characteristics, which affect tumor vascularization, or angiogenesis 
(5).   Delivery vehicles with a negative surface charge and small particle sizes have been 
shown to preferentially accumulate in tumors compared to positively charged carriers 
with a large size (6).  
 As mentioned above, 75% p(TETA/CBA/PEG) complexed with pDNA showed 
passive tumor accumulation and it possesses a net-negative surface charge.  Conversely, 
100% p(TETA/CBA/PEG) possesses a net-positive surface charge and demonstrated no 
preference in tumor accumulation compared to nondiseased organs.  Each formulation 
produced similar complex size when used with pDNA. Provided with these results, we 
sought to study the ability of p(TETA/CBA/PEG) formulations to complex with siRNA 
and evaluate their potential efficacy in vivo for the delivery of therapeutically useful 
siRNA against a gene target known to promote tumor growth and vascularization.  This 
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gene target is Hypoxia Inducible Factor-1! (HIF-1!) and many inhibitors of this protein 
have been used clinically to mitigate cancer progression (7, 8).  Complexation studies of 
the polymer formulations with siRNA provided similar particle sizes and surface charge 
to the results obtained using them in conjunction with pDNA.  Furthermore, when used in 
vivo for the delivery of HIF-1! siRNA to tumor bearing mice, they provide promising 
results when tumor growth inhibition and median animal survival is assessed. 
 
A.2 Materials and Methods 
A.2.1 Materials 
 Triethylenetetramine (TETA), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC), N-hydroxysulfosuccinimide (sulfo-NHS) and HPLC grade 
methanol were purchased from Sigma-Aldrich (St. Louis, MO).  N,N’-Cystamine-bis-
acrylamide (CBA) was purchased from Polysciences, Inc. (Warrington, PA). 
Ultrafiltration devices and regenerated cellulose membranes (10 kDa) were supplied by 
Millipore Corporation (Billerico, MA).  The siRNA sequences were purchased from 
Integrated DNA Technologies (IDT) (San Diego, CA).   
 
A.2.2 p(TETA/CBA) Synthesis 
 Synthesis of p(TETA/CBA) was performed as described in section 4.3.2. at 30°C 
for 12 hrs, at which time excess TETA was added to the reaction mixture and the reaction 
was allowed to run for an additional 24 hrs to ensure that the reaction had been 
terminated. The pH was subsequently adjusted to 7.0 and the polymer was purified by 
ultrafiltration using a 10kDa regenerated cellulose membrane.  p(TETA/CBA) was 
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obtained by lyophilization. Composition of the polymer was monitored using1H NMR 
(400 MHz, D2O). p(TETA/CBA) ! 2.61 (COCH2CH2NH, 4H), 2.72 (NHCH2CH2S-S, 
4H), 2.90-3.21 (COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-S, 4H). 
 
A.2.3 p(TETA/CBA/PEG) Synthesis 
 The synthesis of p(TETA/CBA/PEG) is described as a one-pot synthesis in section 
4.3.3 that began with  the original polymerization reaction conditions described for 
p(TETA/CBA) at 30°C.  However, following 10 hrs reaction time, amine-reactive 
methoxy PEG-NHS (mPEG-NHS) was added to the reaction mixture and allowed to react 
for an additional 2 hrs before the addition of excess TETA (100%).  The reaction was 
allowed to proceed for an additional 24 hrs before the pH was lowered to 7.0 and the 
polymer was purified using ultrafiltration (10 kDa) The composition of 
p(TETA/CBA/PEG) was monitored using 1H NMR (400 MHz, D20). 
p(TETA/CBA/PEG); ! 2.61 (COCH2CH2NH, 4H), 2.72 (NHCH2CH2S-S, 4H), 2.90-
3.21 (COCH2CH2NHCH2CH2,16H), 3.41 (NHCH2CH2S-S, 4H), 3.45-3.7 (CH2CH20, 
4H). 
 
A.2.4 Polymer Characteristics 
 Absolute molecular weight analysis for p(TETA/CBA) and p(TETA/CBA/PEG) 
was performed using AKTA/FPLC (Amersham Pharmacia Biotech Inc.) coupled to a 
light-scattering detector and using the polymer refractive index increment (dn/dc) for 
each sample. A Superose 6 110/300 GL column was used for polymer sample separation. 
Poly[N-(2-hydroxypropyl)methacrylamide] (poly(HPMA)) standards were injected onto 
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the column prior to experimental sample analysis in order to ensure the column was clean 
and functional. Experimental and standard polymer samples were dissolved in degassed 
and filtered (0.2 µm (Nylon, Alltech)) 0.3 M NaOAc, pH 4.4 with 30% (v/v) acetonitrile 
eluent buffer. The flow rate was set to 0.4 mL/min. 
 
A.2.5 Polyplex Formation 
 In all cases polyplex was formed with a known amount of siRNA and a 
corresponding and desired amount of polymer suspended in HEPES buffer (20 mM, pH 
7.4, 20% glucose).  The two solutions were combined, lightly vortexed and allowed to 
equilibrate for 30 min. When mixtures of two different polymers were used to form 
polyplex, a known amount of siRNA was brought up in solution and a corresponding and 
desired concentration of p(TETA/CBA) and p(TETA/CBA/PEG) were prepared by 
mixing the appropriate species at specified ratios before being added to the siRNA 
solution and lightly vortexed.  The resulting complexes were and allowed to equilibrate 
for 30 min. at room temperature. 
      
A.2.6 Light Scattering and "-Potential Measurements 
 The surface charge and polymer/pDNA particle (polyplex) diameters were 
measured at 25°C using a Zetasizer 2000 instrument  (DTS5001 cell) and a dynamic light 
scattering (DLS) unit on a Malvern 4700 system, respectively. Polyplexes were prepared 
by adding equal volume polymer solution (200µl) at increasing concentrations in HEPES 
buffer (20 mM, pH 7.4, 5% glucose) to a desired concentration of 40µg siRNA in HEPES 
buffer (200µl).  Polyplexes were allowed to equilibrate for 30 min and were subsequently 
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diluted in filtered milliQ water to a final 2 mL volume.   
 
A.2.7 In Vivo Tumor Regression and Survival 
 Human non-small cell lung carcinoma cells (A549) suspended in 100µl sterile PBS 
were subcutaneously injected (1 x 106 cells) into the right flank of 6-week old, BALB/c 
nude female mice.  Tumors were allowed to form over 2 weeks or until they reached an 
average tumor volume around 80 mm3. Outliers were discarded to maintain this average.   
Once sufficient tumors formed, animals were randomly assigned to groups of 5 and were 
injected systemically with sterile HEPES buffer (20 mM, pH 7.4, 20% glucose), or the 
following polyplex formulations also prepared in sterile HEPES buffer: 75% 
p(TETA/CBA/PEG)/25% p(TETA/CBA) complexed with HIF-1! siRNA  at 0.5 w/w 
(75% p(TETA/CBA/PEG)/siHIF), 100% p(TETA/CBA/PEG) complexed with HIF-
1alpha siRNA at 3 w/w (100% p(TETA/CBA/PEG)/siHIF), 75% 
p(TETA/CBA/PEG)/25% p(TETA/CBA) complexed with scrambled siRNA  at 0.5 w/w 
(75% p(TETA/CBA/PEG)/scRNA), 100% p(TETA/CBA/PEG) complexed with 
scrambled siRNA at 3 w/w (100% p(TETA/CBA/PEG)/scRNA). Treatments were 
administered every three days for each group. Mice treated with formulated siRNA 
received a total siRNA dose of 55ug, which is approximately 2.5mg/kg.  Tumor volume 
was measured on each injection day prior to treatment using digital calipers.  The siRNA 
seqyuences used are as follows: The siRNA sequences specific for HIF-1" mRNA: 5’-
TAGUUGGGUCUGUAUAGGUG-3’and 5’-TCACCUAUACAGACCCAACU-3’.  The 
scrambled siRNA sequences: 5’-TUUUAAGGGCGCAAUGCGCA-3’ and 5’-
TTGCGCATTGCGCCCTTAAA-3’.  Animal survival was also assessed during these 
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studies to generate a survival curve for analysis. Due to Institutional Animal Care and 
Use Committee (IACUC) standards, the animals were sacrificed when tumor ulcerations 
reached a standard surface area equal to 1mm2 or when the individual tumor volume 
exceeded 1500mm3.  No animal death associated with treatment was observed.  Animals 
were checked everyday for survival and the onset of tumor ulceration. 
 
A.2.8 Statistical Analysis 
 The statistical analysis for tumor growth inhibition was performed by comparing 
the AUEC for each treatment, which is reported as mean ± SD (n = 4-5), using a one-way 
ANOVA in conjunction with a Tukey’s post-hoc test. A p < 0.05 was considered 
statistically significant.  The animal survival curve was analyzed using a built-in survival 
analysis using GraphPad Prism 5 Software that ran a log-rank (Mantel-Cox) test and a 
log-rank test for trend reporting Chi square values (n = 4-5). 
 
A.3 Results 
A.3.1 Physiochemical Characterization 
 Because complexation of polycationic gene carriers with pDNA may be different 
than it is with siRNA, we tested the ability of the aforementioned and relevant 
p(TETA/CBA/PEG) formulation to complex with siRNA.  These formulations were 75% 
p(TETA/CBA/PEG), and the 100% p(TETA/CBA/PEG) at polymer/siRNA w/w ratios 
equal to 0.5 and 3, respectively.  For simplicity, these formulations are referred to as 75% 
p(TETA/CBA/PEG) and 100% p(TETA/CBA/PEG), that is 75% p(TETA/CBA/PEG) is 
always complexed with siRNA at 0.5 w/w and 100% p(TETA/CBA/PEG) at 3 w/w.  The 
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intensity-based mean particle size for 75% p(TETA/CBA/PEG) and 100% 
p(TETA/CBA/PEG) were similar to those observed using pDNA.  Particle sizes were 
maintained at approximately 100nm in diameter with little standard deviation (Figure 
A.1).   The surface charge of the complexes formed between the formulations and siRNA 
were also similar to those observed using pDNA (Figure A.1).  Based on the similarity of 
pDNA and siRNA complex physiochemical characteristics alone, we believe these two 
gene carrier formulations complexed with siRNA will possess similar in vivo 
biodistribution characteristics to those seen with pDNA.  A biodistribution study using 
the relevant formulations and siRNA should be performed to unequivocally assert this 
putative similarity. Nonetheless, the therapeutic efficacy of siRNA against HIF-1! 
(siHIF) using these carrier formulations was studied.   
 
A.3.2 In Vivo Tumor Regression and Survival 
 Human lung carcinoma cells were injected into female BALB/c nude mice and 
allowed to grow sufficient tumors over approximately 2 weeks.  Once sufficient tumors 
formed, therapeutically active siHIF or scrambled siRNA (scRNA), serving as a negative 
control, was complexed with 75% p(TETA/CBA/PEG) and 100% p(TETA/CBA/PEG) 
and administered to the mice two times per week.  Buffer only injections also served as a 
control.  Following 18-20 days of treatment, The 75% p(TETA/CBA/PEG)/siHIF treated 
group had average tumor volumes that were 55% smaller than 75% 
p(TETA/CBA/PEG)/scRNA and also smaller than the buffer only group (Figure A.2).  
This result indicates that the carrier-mediated delivery of siHIF is therapeutic and tumor 
delivery of the siRNA payload occurs using the 75% p(TETA/CBA/PEG) formulation. 
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The 100% p(TETA/CBA/PEG)/siHIF treatment group exhibited nearly 30% reduction in 
tumor volume compared to 100% p(TETA/CBA/PEG)/scRNA also suggesting carrier 
activity and target specific siHIF therapeutic activity (Figure A.2).  These results suggest 
a promising trend toward efficacy for 75% p(TETA/CBA/PEG)/siHIF and 100% 
p(TETA/CBA/PEG)/siHIF, however no statistical significance between treatment groups 
was found.  A power analysis performed using StatMate 3.0 software (Graphpad Inc.) 
indicates that nine animals per treatment group are required to achieve significant tumor 
growth inhibition with a 95% confidence limit and assuming a standard deviation in 
tumor volume equal to 100mm3.  Thus, a repeated study using more animals has potential 
to provide significance.  
 Animal survival curves were generated from the tumor regression studies. As 
described above, animals were sacrificed for tumor ulceration or when the tumor volume 
exceeded 1500 mm3.  Interestingly, tumor ulceration was not size dependent, thus large 
and small tumors were susceptible to tumor ulceration. Also noteworthy, animals treated 
with 75% p(TETA/CBA/PEG)/siHIF and 100% p(TETA/CBA/PEG)/siHIF appeared to 
exhibit more tumor ulceration than the other groups (data not shown).  This character 
may be due to tumor necrosis imposed by effective delivery and treatment with siHIF, 
however, this is not confirmed and additional studies are required to ascertain this 
postulation.  Nonetheless, 75% p(TETA/CBA/PEG)/siHIF and 100% 
p(TETA/CBA/PEG)/siHIF treated animals did demonstrate a significant survival trend 
compared to  the 75% p(TETA/CBA/PEG)/scRNA and 100% 
p(TETA/CBA/PEG)/scRNA negative control groups (Figure A.2).  This significance was 
determined using the logrank test for trend with a Chi square equal to 6.649 and a p value 
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less than 0.0099. Median survival times for 75% p(TETA/CBA/PEG)/scRNA and 100% 
p(TETA/CBA/PEG)/scRNA negative control groups ranged between 17 and 21 days, 
respectively.   Conversely, the 75% p(TETA/CBA/PEG)/siHIF group had a median 
survival equal to 52 days (Figure A.2).  As with the tumor growth inhibition studies, 
these results are promising with respect for 75% p(TETA/CBA/PEG)/siHIF and 100% 
p(TETA/CBA/PEG)/siHIF therapeutic efficacy and  appears to be target specific for HIF-
1!, as scRNA demonstrated no significant trend.  However, a repeated study using more 




 The results presented here coincide strongly with those obtained using the 75% 
p(TETA/CBA/PEG) and 100% p(TETA/CBA/PEG) formulations for pDNA 
complexation and in vivo biodistribution.  Based on physiochemical characteristics and 
the biodistribution patterns alone, it is likely that the significant survival and tumor 
growth inhibition trend observed for 75% p(TETA/CBA/PEG) may be due to an 
increased ability to penetrate the tumor environment due to its negative charge.  This 
reason may be 2-fold.  First, by having a negative surface charge, the carrier is less likely 
to interact with serum proteins that are often positively charged and thus less likely to be 
removed from circulation by the RES system, which allows for passive tumor 
accumulation.  Secondly, the tumor environment is often overcome with negatively-
charged cell-surface glycosaminoglycans (GAGs), which have been shown to limit 
particle diffusion of positively charged carriers into the tumor and/or may cause complex 
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destabilization which will result in reduced efficacy (9-12).  Multiple nanoparticle 
delivery systems that exhibit small size and a negative charge have demonstrated 
increased tumor accumulation compared to other organs and to highly positively charged 
carriers (6).  Carriers with a low positive surface charge and small particle size are also 
preferred because they have limited interaction with serum proteins and cell surfaces.  
The significant trend in animal survival using 75% p(TETA/CBA/PEG)/siHIF also 
suggests increased efficacy by tumor penetration of these nucleic acid delivery reagent 
compared to the positively charged formulation, 100% p(TETA/CBA/PEG). 
 
A.5 Conclusion 
 The results from the biodistribution study presented in Chapter 4.4.3 showed that 
when 75% p(TETA/CBA/PEG) and the 100% p(TETA/CBA/PEG) were used to deliver 
pDNA systemically, they showed the greatest degree of tumor accumulation compared to 
the other formulations.  Specifically, the 75% p(TETA/CBA/PEG) formulation showed 
passive tumor accumulation and provided nearly 10-fold higher copy number/mg tissue 
in the tumor than the other major organs.  The 100% p(TETA/CBA/PEG) formulation 
showed comparable pDNA accumulation in the major organs when compared to the 
tumor, however showed approximately 5-fold higher copy number/mg tissue than the 
75% p(TETA/CBA/PEG) formulation.  These formulations were tested for their ability to 
interact and form complex with therapeutically relevant siRNA specific for HIF-1alpha, a 
target gene known to promote tumor growth and vascularization.  Complexation studies 
of the polymer formulations with siRNA provided similar particle sizes and surface 
charge to the results obtained using them to complex with pDNA.  Furthermore, when 
 184 
used in vivo for the delivery of siHIF to tumor bearing mice, the treatments provided 
promising results with respect to tumor growth inhibition and median survival times, 
which appear to be target specific for HIF-1alpha.  These results provide a promising 






















Figure A.1. a) dynamic light scattering (DLS) was performed to evaluate complexation of 
75% p(TETA/CBA/PEG) and 100% p(TETA/CBA/PEG) with siRNA.  b) "-Potential 
measurements to determine mean surface charge of 75% p(TETA/CBA/PEG) and 100% 













Figure A.2.  Efficacy studies using 75% p(TETA/CBA/PEG) and 100% 
p(TETA/CBA/PEG) for siHIF-! and scRNA negative controls. a) Tumor volume over 
time.  Treatments were given every 3 days following tumor volume measurement each 
time. b) Survival curve generated from the same experiment.  Respective treatments are 
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